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Abstract 
The EURL ECVAM status report provides an update on the progress made in the development, validation and regulatory 
acceptance of alternative methods and approaches and their dissemination since the last report published in June 2014. It 
is informing on ongoing research and development activities, validation studies, peer reviews, recommendations, 
strategies and regulatory/international acceptance of alternative methods and approaches and dissemination activities.    
R&D activities within large European or International consortia continued in toxicity areas where 3Rs solutions are more 
difficult to find due to the underlying complexity of the area. 
On the other hand, toxicity areas where promising non-animal approaches have been developed, their validation and 
regulatory acceptance/international adoption could be progressed. Particular emphasis was given to the best and most 
intelligent combination and integration of these different non-animal approaches to ultimately obtain the required 
information without resorting to animal testing. 
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Executive Summary 
The EURL ECVAM status report provides an update on the development, validation and 
regulatory acceptance of alternative methods and approaches and their dissemination 
since the last report published in June 2014.  
All the areas in which EURL ECVAM is active are described in this report. This includes 
activities focusing on finding 3Rs (Replacement, Reduction and Refinement) solutions for 
human health-(related) effects, for environmental toxicity, for the safety and efficacy 
testing of vaccines, activities on knowledge-sharing and structuring, dissemination and on 
stakeholder engagement. For environmental effects, R&D projects aiming at improving fish 
toxicity testing by reducing or avoiding the use of fish are supported. Similarly projects are 
proposed at regulatory/international level to standardise in vitro methods to determine in 
vitro fish intrinsic hepatic clearance rates with an aim to enhance the reliability of 
Bioconcentration Factor (BCF) models, and projects which address the use of solvents in 
aquatic toxicity tests on fish with a view to reducing the number of fish in current OECD 
Test Guidelines and Guidance Documents. 
 
Concerning human health related R&D projects, EURL ECVAM continued to be very active in 
the SEURAT-1 project, a major European research consortium established to evaluate the 
safety of chemicals considering repeated exposure in humans without using animals. 
Besides the cross cluster proof-of-concept activities in SEURAT-1, the individual projects 
(Detective, Notox, HeMiBio, COSMOS, Scr&Tox and Toxbank) yielded important milestones 
in the development of alternative approaches based on e.g. the development of pluripotent 
stem cells into specific types of cells that could be used in microbioreactors (developed 
within the HeMiBio project) and computer technology (explored within the COSMOS project). 
These results will be presented at the final SEURAT-1 symposium at the end of 2015. 
  
In the framework of the OECD programme on the development of Adverse Outcome 
Pathways (AOP), EURL ECVAM has developed AOPs relevant to neurotoxicity, toxicity via 
disruption of the endocrine system and liver toxicity. An adverse outcome pathway is a 
conceptual framework constructed from knowledge that relates exposure of a type of toxic 
substance to subsequent molecular and cellular changes that result in illness or injury to 
an individual or population. This knowledge-based framework helps to guide the 
development of mechanistically relevant methods and models and their best integration to 
ultimately predict the adverse outcome of interest without the need to resort to animal 
tests. Most of these AOPs were introduced into the AOP Knowledge Base-Wiki, developed 
by JRC/EURL ECVAM in collaboration with the US Environmental Protection Agency (EPA), 
and are currently undergoing an OECD external review process. In addition, JRC/EURL 
ECVAM contributed to the development of guidance on the principles and best practices for 
constructing AOPs and AOP networks.  
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EURL ECVAM strategies in the areas of acute systemic toxicity, aquatic toxicity and 
bioconcentration/bioaccumulation testing as well as toxicokinetics were published in 2014 
and 2015, respectively. A EURL ECVAM strategy to replace, reduce and refine the use of 
animals in the assessment of (developmental) neurotoxicity is currently in preparation. 
These strategies address the different regulatory needs in the respective fields, review the 
progress made on alternative approaches, identify gaps and opportunities with regard to 
the development and validation of alternative approaches and outline actions that should 
be taken to achieve an impact on the 3Rs. 
 
Thirty test submissions were evaluated by EURL ECVAM during the period covering this 
report, fifteen entered via the standard EURL ECVAM test submission process and another 
fifteen submissions were a result of a call for submission of in vitro human hepatic 
metabolic clearance methods. For the very few promising test submissions addressing 
toxicity areas that are not covered by AOP or Integrated Approaches to Testing and 
Assessment (IATA) frameworks, EURL ECVAM consulted its network of regulators for the 
preliminary assessment of regulatory relevance (PARERE).  
 
EU-NETVAL, EURL ECVAM's network of validation laboratories has been established and the 
validation of an Androgen Receptor Transactivation Assay (ARTA) is currently ongoing in 
three selected EU-NETVAL test facilities as first pilot project. The generation of 
experimental data using this method will support the development of an OECD 
performance-based test guideline and associated performance standards for ARTAs for the 
detection of compounds with (anti)androgenic potential. The next task of EU-NETVAL will 
be to assist EURL ECVAM in harmonising and standardising human hepatic metabolic 
clearance methods to increase the reliability of this class of in vitro assays to be used in 
regulatory decisions.  
 
The ECVAM Scientific Advisory Committee (ESAC) peer reviewed the EURL ECVAM-
coordinated validation studies on the human cell line activation test (h-CLAT), the 
EpiOcular™ Eye Irritation Test and the human-based CYP induction assays. In addition, it 
reviewed the external (to EURL ECVAM) Performance Standards-based validation study on 
the epiCS® test method for skin irritation testing. 
EURL ECVAM Recommendations on the h-CLAT for skin sensitisation testing and on the 
Zebrafish Embryo Toxicity Test (ZFET) for acute aquatic toxicity testing were published. Two 
additional recommendations on the EpiOcular™ Eye Irritation Test and on the human-based 
CYP induction assays are currently being prepared. 
At OECD level, EURL ECVAM is active in various programmes. Within the OECD Test 
Guideline programme, EURL ECVAM is leading or co-leading ten projects on the 
development of new test guidelines or guidance documents. Over recent years, the 
development of IATA has become a first priority in the search for alternative solutions to 
animal safety testing. In that context, EURL ECVAM is leading, within the OECD Task Force 
on Hazard Assessment, the development of two guidance documents (GD) that focus on 
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the reporting of IATA and on individual information sources used within IATA for skin 
sensitisation, with an aim to promote the consistent reporting of IATA within OECD member 
countries. 
EURL ECVAM is also co-chairing with the US EPA the OECD Extended Advisory Group on 
Molecular Screening and Toxicogenomics and its AOP Development Programme. 
Furthermore, it supports the development of consistent assessment approaches for 
combined exposure to chemical mixtures at international level within the OECD project on 
combined exposure that is led by the OECD Task Force on Hazard Assessment in 
collaboration with the OECD Task Force on Exposure Assessment. 
At international level, EURL ECVAM is also collaborating with VICH1 in the framework of 
development of VICH Guidelines on vaccines, with ICH2 on ICH guidelines, with the WHO3 
International Programme on Chemical Safety (IPCS) and with its international partners 
within the International Cooperation on Alternative Test Methods (ICATM).  
At EU level and in the context of REACH, EURL ECVAM continued to actively support the 
regulatory acceptance of alternative approaches through updates of REACH Annexes for 
reflecting scientific progress in the areas of skin corrosion/irritation, serious eye 
damage/eye irritation, skin sensitisation and acute systemic toxicity and updates of REACH 
Guidance on Information Requirements and Chemical Safety Assessment for skin 
corrosion/irritation, serious eye damage/eye irritation, respiratory irritation and for skin and 
respiratory sensitisation. EURL ECVAM also contributed to a series of free webinars 
focusing on alternative methods and testing strategies that can be used to meet REACH 
requirements, organised by the PETA International Science Consortium, Ltd., and Chemical 
Watch. 
EURL ECVAM's dissemination activities range from well-established EURL ECVAM 
databases such as the EURL ECVAM’s DataBase service on ALternative Methods to animal 
experimentation (DB-ALM), the QSAR Model Database and the EURL ECVAM Search Guide 
to the revision of the Tracking System for Alternative Test Methods towards Regulatory 
acceptance (TSAR),  the chemical information portal ChemAgora, the Reference Chemicals 
List for Validating Alternative Methods CheList and the EURL ECVAM Genotoxicity and 
Carcinogenicity Database of Ames Positive Chemicals. 
  
EURL ECVAM furthermore increased its engagement with regulators from the EU Member 
States and EU agencies (ECHA4, EMA5, EFSA6) via PARERE; with all EU industry associations 
                                              
1 International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary 
Medicinal Products 
2 International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals 
for Human Use 
3 World Health Organisation 
4 European Chemicals Agency 
5 European Medicines Agency 
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dealing with chemicals, pharmaceuticals and cosmetics, non-governmental organisations 
and academia via its ECVAM Stakeholder Forum (ESTAF) and the EPAA7, and the 3Rs 
community as a whole, for a sustained investment, commitment and support of all actors 
in the field of alternative approaches. 
  
                                                                                                                                            
6 European Food Safety Authority 
7 European Partnership for Alternative Approaches to animal testing  
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1. Introduction 
The EURL ECVAM status report describes primarily, but not exclusively, all the activities 
that EURL ECVAM has undertaken or has been involved in since the publication of the last 
report in June 2014. It covers the period May 2014 to September 2015 and reports on 
research and development, and validation activities as well as on activities which promote 
the regulatory acceptance and use of alternative approaches and their dissemination. It is 
intended to inform interested parties and serve multiple purposes, including providing input 
to the annual Commission report on the progress made in the development, validation and 
regulatory acceptance of alternative methods/approaches prepared in the framework of 
Regulation 1223/2009 on cosmetic products. 
2. Research and Development Activities on Alternative Methods 
2.1. SEURAT-1: 2015 - the final year of the largest European project on 
alternative methods 
SEURAT-1 is a major European research consortium established to evaluate the safety of 
chemicals considering repeated exposure in humans without using animals. It is a public-
private partnership co-financed by the European Commission's FP7 Health Programme and 
Cosmetics Europe. SEURAT-1 consists of six individual research projects and one 
coordination action (COACH), and combines the research efforts of over 70 European 
universities, public research institutes and companies. 
The SEURAT vision is to fundamentally change the way we assess the safety of chemicals, 
by superseding traditional animal experiments with a predictive toxicology that is based on 
a comprehensive understanding of how chemicals can cause adverse effects in humans. 
The SEURAT strategy is to adopt a toxicological mode-of-action framework to describe how 
any substance may adversely affect human health, and to use this knowledge to develop 
complementary theoretical, computational and experimental (in vitro) models that predict 
quantitative points of departure needed for safety assessment. One of the SEURAT-1 
objectives is to demonstrate a multiple level proof-of-concept (theoretical, methodological, 
and application) for repeated dose systemic toxicity, but in principle also applicable to 
other endpoints.  
Firstly, a theoretical Adverse Outcome Pathway (AOP) describing the key events of the 
biological process initiated by a chemical stressor is developed (Level 1). Secondly, a 
testing strategy for toxicity prediction, based on AOP knowledge relevant to the toxicity to 
be predicted is needed (Level 2). Typically a combination of in vitro, in silico and in chemico 
data is required to trigger selected key events. Finally, the results of testing strategies in 
combination with already existing data (physical chemical information, animal or human in 
vivo data or other) and biokinetic modelling, could provide sufficient evidence to support 
chemical safety assessment (Level 3). 
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For Level 1, several AOPs were developed within SEURAT-1, primarily with relevance to 
hepatotoxicity. The pathway description from protein alkylation to liver fibrosis has been 
revised, extended, and modified. In October 2014, an expert workshop was organised to 
discuss and analyse the AOP on liver fibrosis, and to identify and prioritise data gaps for 
further research. Collaboration for the confirmation and elucidation was agreed and further 
studies for measuring relevant key events (KEs) and possibly their quantitative 
relationships to up- and down-stream KEs were discussed.  
The updated AOP has gone through internal OECD review and will be submitted to another 
review by external experts. 
The applicability of this AOP to liver fibrosis for Nanoparticles has been investigated and 
described. A scientific paper titled "The Adverse Outcome Pathway approach in 
nanotoxicology" has been submitted for publication. 
On Level 2, there are currently eight case studies with different toxicity prediction goals 
that are close to finalisation. On Level 3, there are three case studies, for which chemicals 
safety assessments are carried out based on (1) an ab initio approach (no animal data 
available on the chemical itself or similar chemicals), (2) read-across from data-rich source 
substances to the substance to be assessed using strengthening arguments from 
alternative data, and (3) accepting a Threshold of Toxicological Concern (TTC) to be good 
enough based on improved substance characterisation using computational models. All 
three case studies apply a conceptual framework for chemicals safety assessment 
developed within SEURAT-1.  
Besides the cross cluster proof-of-concept activities, the individual projects are finalising 
their deliverables. At the SEURAT-1 fifth annual meeting in Barcelona on 21-22 January 
2015, the project coordinators reported major achievements and progress since the last 
annual meeting and explained how to successfully conclude the activities by the end of 
2015.  DETECTIVE reported identification of novel biomarkers for kidney, liver and heart. 
They also showed that differentiated human-skin derived cells can acquire hepatic 
properties, e.g. they demonstrate steatotic functions when exposed to a chemical known to 
cause fatty liver, and therefore they are suitable to use for in vitro hepatotoxicity testing. 
All cell systems tested within DETECTIVE were found to have a toxicological memory in 
their genetic profile after exposure to chemical stressors. NOTOX demonstrated the results 
of a multi-scale model for steatosis prediction including repeated dose 3D in vitro models, 
using HepaRG, in combination with computational biokinetic modelling mimicking human 
exposure. The COSMOS DataBase, with a record of more than 80.000 cosmetic relevant 
substances, is now publicly available and is further complemented with a TTC (Threshold 
for Toxicological Concerns) database, 'COSMOS space' with representations of the chemical 
space of cosmetic ingredients and easy-to-use biokinetic models in the open source 
software KNIME (Konstanz Information Miner). COSMOS also developed several profilers 
that can be applied to characterise chemicals, for example binding potential to specific 
proteins or skin penetration coefficients. SCR&Tox has finalised protocols for 
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differentiations of human pluripotent stem cells into keratinocytes, neurones, cardiocytes 
and hepatocytes, and in addition established technologies for large scale production and 
banking.  HeMiBio12 presented results from a unique model predicting fibrosis composed 
of 3D co-cultured liver cell lines in a flow over bioreactor with implemented electronic 
sensors for detection of read-outs. ToxBank13 reported good progress in collecting 
resulting data from the SEURAT-1 projects as well as the proof-of-concept case studies. 
The main achievement of each project and the results of the proof-of-concept case studies 
will be presented at the final SEURAT-1 symposium planned in Brussels on the 4th of 
December 2015.  
2.1.1. Cosmetics Europe Contract 
A collaborative arrangement between the JRC and Cosmetics Europe aims to supplement 
the work programme of the SEURAT-1 cluster. This research initiative, although motivated 
by the Cosmetic industry, is also relevant to other industrial sectors (e.g. industrial 
chemicals, pharmaceuticals).  
The aims of this project are (a) to facilitate cluster interaction and to demonstrate proof-
of-concept at three different levels, namely 1) defining mode-of-action (MoA), 2) predicting 
toxicity, and 3) supporting safety assessment decisions, to supplement the computational 
modelling activities of the cluster and to generate large reference datasets to support the 
establishment of toxicological MoA. In brief, the following work was carried out by EURL 
ECVAM: 
 A case study was designed to predict repeated dose liver toxicity by developing a MoA-
based classification model that was aimed at distinguishing between hepatotoxicants 
and non-hepatotoxicants. Hepatotoxicity was mainly related to three major liver 
adverse outcomes associated with repeated dose exposure: cholestasis, fibrosis and 
steatosis. Concentration-response data sets for 90 reference chemicals relevant to the 
three hepatotoxicity MoA mentioned above were generated using a well characterised 
in vitro liver system (HepaRG cells). A repeated dose exposure scenario and high-
throughput screening (using a 96-well plate format) was employed. Mitochondrial 
damage, reactive oxygen species formation (indicator of oxidative stress), formation of 
neutral lipid droplets (indicator of chemically induced steatosis), apoptosis and cell 
count (indicator of cell viability), were the selected key events studied. The read-outs 
were performed using high content imaging. The lowest concentration at which the 
effect was observed (i.e. the first significant effect level in vitro) was determined. The 
project showed that the MoA knowledge is fundamental to define the prediction goal of 
a testing strategy, to support the identification of the biological events to be measured, 
to select the most suitable in vitro cell model and to guide the entire design of the 
study by improving the selection of chemicals, the definition of exposure protocol and 
the strategy for data analysis.  
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 A human Physiologically Based Kinetic (PBK) model that simulates the in vivo kinetics 
of caffeine was developed and coupled with a Physiologically Based Dynamic (PBD) 
model that simulated the dynamics of caffeine-induced effects on liver cells. The PBD 
model used elements of our previously developed Virtual Cell based (VCB) model, which 
simulates the fate and effects of chemicals in cell cultures (Zaldivar et al., 2010, 2011, 
2012). The resulting PBK/D modelling was implemented in the KNIME workflow and 
several consumer exposure scenarios, based on the expected use of three caffeine-
containing cosmetic products, were explored. This project showed how in silico models 
describing the kinetics and dynamics of chemicals in cell cultures and the human body 
can be applied in risk assessment to translate in vitro toxicity data into predictions of 
human toxicity under defined consumer exposure scenarios (in vitro to in vivo 
extrapolation; IVIVE) (Gajewska et al., 2015). 
 Different modelling approaches, including physiologically-based toxicokinetics (PBTK) 
and quantitative structure-activity (QSAR) modelling were used to illustrate how they 
could be employed in the risk assessment process for cosmetic substances. The various 
theoretical models were built, applied, and integrated in order to develop an approach 
for assessing systemic exposure or internal dose (dermal bioavailability including 
metabolism) upon topical (dermal) use of cosmetic products and to investigate whether 
dermal threshold values could be set for humans. The work focused on two cosmetics-
relevant chemicals, coumarin and caffeine, for which dermal and oral repeat dose 
toxicity data were available. The results showed that assessment of dermal 
bioavailability, expressed as area under the curve (AUC) and using integration of PBTK 
modelling for whole body kinetics and QSAR modelling for dermal penetration is 
possible, albeit with unknown uncertainties linked to assumptions in the models. In 
addition, extrapolation from external oral to dermal threshold values is practically 
impossible and, consequently, not a generally feasible approach. Differences between 
various human dermal exposure scenarios can have significant effects on the 
qualitative aspects of the concentration-time curve (the form) as well as on the more 
quantitative aspects of the curve, expressed as AUC and Cmax. Therefore, it is more 
realistic and feasible to compare the effects of oral and dermal exposure scenarios by 
using internal threshold values and an internal margin of safety approach (Gajewska et 
al., 2014). 
2.1.2. DETECTIVE (Detection of endpoints and biomarkers of repeated dose toxicity 
using in vitro systems) 
The DETECTIVE project8 aims at the identification and evaluation of in vitro biomarkers for 
repeated dose toxicity testing. To obtain these biomarkers, human cell models 
representative of the liver, kidney and heart are exposed to model compounds, as selected 
by the golden compound working group of SEURAT-19.  The effects are then assessed at 
                                              
8 http://www.detect-iv-e.eu 
9 http://www.toxbank.net/compound-wiki 
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the –omics (which deliver data on the entire cellular situation at the molecular level) and 
the functional levels (which give more insight into the effects of toxicants on specific cell 
functions of interest). The project is also exploring whether repeated dose effects on 
epigenetics and microRNA (miRNA) expression expand our understanding of toxic modes of 
action. Relevant, specific, sensitive and predictive biomarkers will be selected based on 
integrative statistical analysis, systematic verification and correlation with in vivo data. A 
comprehensive overview of the results obtained until now in the project can be found in 
the Annual reports of the SEURAT-1 Research Initiative10 (SEURAT-1, 2011; 2012; 2013; 
2014). Some highlights from the project include: 
 The establishment of an adverse outcome pathway framework for drug-induced 
cholestasis (Vinken et al., 2013). 
 The development of a panel of fluorescent reporter cell lines that allows the 
quantitative assessment of cellular stress responses in cells after chemical 
exposure in relation to organellar perturbations (Wink et al., 2014). 
 A publicly available toxicotranscriptomics directory11 which provides information for 
all genes whether they are up- or down-regulated by chemicals and, if yes, by 
which compounds. The directory, which also contains information about 
stereotypical stress response, liver disease-associated genes, unstable baseline 
genes, and biological function, offers a basis for a rational choice of candidate 
genes for biomarker evaluation studies and represents an easy to use source of 
background information on chemically influenced genes (Grinberg et al., 2014). 
2.1.3. SCR&Tox (Stem Cells for Relevant Efficient Extended and Normalized 
Toxicology) 
The Scr&Tox project developed a variety of test systems derived from human pluripotent 
stem cell lines as they may be expanded indefinitely and triggered to differentiate into any 
cell type. The protocols for cell differentiation of human embryonic and induced pluripotent 
stem cells (iPSCs) towards 5 different lineages (liver, heart, CNS, epidermis and muscles) 
have been established and applied to in vitro toxicity testing using a variety of functional 
cell specific assays.  Recently, the genetically engineered induced pluripotent stem cell line 
expressing a reporter for activity of the Nrf2 transcription factor, as a marker of cell 
responses to oxidants, was created. This cell line will be differentiated into keratinocytes 
(2D and 3D epidermis) and neural cells to evaluate the relevance of Nrf2 activation as a 
general “toxicity” pathway for toxicity testing. 
                                              
10 http://www.seurat-1.eu  
11 http://wiki.toxbank.net/toxicogenomics-map/ 
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2.1.4. COSMOS (Integrated in silico models for the prediction of human repeated dose 
toxicity of COSMetics to Optimise Safety) Project 
2.1.4.1. COSMOS Project Background 
EURL ECVAM is a partner in the COSMOS project12 which is developing publicly available 
computational workflows based on the integrated use of open-access and open-source 
models for the prediction of repeated dose toxicity (Anzali et al., 2012). The work includes: 
a) the establishment of an inventory of cosmetic substances (including identifiers and 
chemical structures) and a repeat dose toxicity database (including oral and dermal data); 
b) the development of novel ways of establishing thresholds of toxicological concern (TTC); 
c) the development of innovative toxicity prediction strategies based on molecular and 
QSAR modelling; d) the development of a multi-scale modelling approach to predict target 
organ concentrations and to extrapolate from in vitro to in vivo exposure scenarios; and e) 
the integration of databases and modelling tools to provide publicly accessible 
computational workflows for use in the safety assessment of cosmetics. 
2.1.4.2 COSMOS Database 
The COSMOS database is a freely accessible comprehensive and reliable resource for 
repeated dose toxicity data, including subacute, subchronic, and chronic studies as well as 
carcinogenicity studies (Rathman et al., 2013). It is also linked to high quality and validated 
chemical structures to facilitate modelling. A COSMOS webinar entitled "COSMOS DB: A 
New Database of Toxicological Information to Support Knowledge Discovery", hosted by 
the American Society for Cellular and Computational Toxicology (ASCCT), is accessible from 
Youtube13:  
2.1.4.3 Threshold of Toxicological Concern  
The Threshold of Toxicological Concern (TTC) work was carried out with the support of two 
International Life Sciences Institute (ILSI) (Europe) expert groups. The main developments 
were the establishment of a COSMOS TTC dataset containing peer-reviewed NO(A)EL values, 
and the development of the oral-to-dermal extrapolation approach to investigate whether 
the TTC approach can be applied to dermal exposure scenarios.  This work was presented in 
a webinar entitled "Threshold of Toxicological Concern – an approach for safety 
assessment and its applicability to cosmetics-related chemicals" on 24 July 2014. The 
webinar is accessible from the ASCCT14:  
2.1.4.4. Modelling of Key Events Leading to Liver Steatosis  
Several computational approaches have been applied and integrated to develop an in silico 
strategy for the evaluation of potential activation of nuclear receptors (in particular, the 
Liver X Receptor [LXR] and the Peroxisome Proliferator-Activated Receptor γ [PPARγ] 
involved in the development of liver steatosis). These methodologies include: molecular 
                                              
12 http://www.cosmostox.eu/ 
13 https://www.youtube.com/watch?v=oLD0mHxNz6c&feature=youtu.be 
14 http://www.ascctox.org/meetings.cfm 
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modelling, QSAR (quantitative structure-activity relationship) and structural alerts. The use 
of molecular modelling approaches as a means of supporting the AOP framework for 
toxicity prediction is one of the Level 2 SEURAT-1 case studies (Al Sharif et al., 2014; 
Tsakovska et al., 2014).  
2.1.4.5 Toxicokinetic Modelling  
Physiologically-based kinetic (PBK) models can be used to predict in vivo toxicokinetics (e.g. 
time-course of blood or tissue concentrations of a chemical) based on in vitro 
measurements of the underlying processes of absorption, distribution, metabolism and 
excretion (in vitro to in vivo extrapolation; IVIVE), as well as to extrapolate existing animal 
blood time-courses of a chemical for one exposure route to another exposure route (route-
to-route extrapolation; RtR), e.g. oral-to-dermal extrapolation. During 2014-2015, PBK 
models have been developed for selected compounds (Gajewska et al., 2014a, 2014b, 
2015). In addition, the Virtual Cell Based Assay (VCBA), developed by the JRC to model the 
fate and toxicity of chemicals in in vitro assays, was extended to include a mitochondrial 
compartment. Furthermore, VCBA models were made publicly accessible by 
implementation as KNIME workflows. In a multi-scale modelling approach, PBK models can 
be coupled with VCBA models to enable realistic estimates of in vivo effects from in vitro 
toxicity data. This work was presented on 13 April 2015 during an ASCCT-hosted webinar 
entitled "Automated in silico tools for in vitro to in vivo extrapolation". The webinar is 
accessible from Youtube15:  
2.1.4.6 Computational Tools  
A number of KNIME workflows have been developed to support in silico modelling, 
including: i) analysis of chemical space using Principal Component Analysis (PCA) on 
molecular descriptors and functional groups; ii) evaluation of nuclear receptor binding 
potential, based on structural alerts and QSAR approaches; iii) prediction of skin and 
gastrointestinal absorption; and iv) biokinetic modelling (VCBA and PBK models for selected 
chemicals).  
These computational workflows can be accessed via the KNIME WebPortal16, following 
registration through COSMOS Space17. COSMOS Space is a platform for the sharing of 
predictive toxicology resources (e.g. data sets, models, workflows, documentation). In 
addition to linking with KNIME workflows developed by the COSMOS project, COSMOS 
Space also provides a link to the COSMOS database. 
                                              
15 https://www.youtube.com/watch?v=vJc1UEbuWdE&feature=youtu.be 
16 (http://knimewebportal.cosmostox.eu) 
17 http://cosmosspace.cosmostox.eu) 
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2.2. CALEIDOS Project 
EURL ECVAM played an advisory role in the CALEIDOS (Chemical Assessment according to 
Legislation Enhancing the In silico Documentation and Safe use) project18. This was a DG 
Environment-funded project under the Life+ programme (January 2013-June 2015). The 
project explored the regulatory applicability of non-testing methods (QSAR and read-
across) to REACH substances. Using data on REACH-registered chemicals, the predictive 
performances of QSAR models (mostly freely available, but also some commercial models) 
were evaluated and compared for the following endpoints: Ames mutagenicity, rodent 
carcinogenicity, developmental toxicity (rats and rabbits), logP (relevant for waiving of 
bioaccumulation testing and the screening level assessment of bioaccumulation), and 
bioconcentration in fish (BCF). 
The project has also provided a freely available software tool called Toxread which 
currently facilitates read-across for mutagenicity and BCF predictions. 
2.3. Fish Toxicity R&D Projects 
Three R&D projects related to fish toxicity, which are of specific interest to EURL ECVAM, 
are described below. 
2.3.1. Use of a Fish Cell Line-Based Cytotoxicity Assay for Acute Fish Toxicity Testing 
As a follow-up of the CEllSens19 project (Tanneberger et al. [2013]), a ring trial evaluating 
the transferability and within-laboratory reproducibility of the RTgill-W1 (rainbow trout gill 
cell line) cytotoxicity assay has been organised by EAWAG (K. Schirmer; CEFIC LRI project 
ECO8.3-NC3Rs-EAWAG20). Results should become available during 2015.  
In addition, the method had been submitted to EURL ECVAM in early 2014 and the test 
submitter had been invited to provide a full submission (see 3.1).  
2.3.2. Development of AOPs for Chronic Fish Toxicity Testing  
Several research groups are working on the identification and description of potential AOPs 
relevant to chronic fish toxicity, which is currently assessed with fish early life-stage (FELS) 
test (OECD TG 210; OECD 2013a). A CEFIC LRI-funded project (LRI-ECO20-UA21) aims at 
mapping FELS-relevant AOPs and developing an in vitro toolbox and zebrafish embryo 
based assays to test for AOP-specific events and responses predictive for FELS chronic 
toxicity. The report of a recent ILSI Health and Environmental Sciences Institute (HESI) 
workshop (Villeneuve et al., 2014) discusses AOPs relevant to FELS toxicity and how they 
could be discovered and annotated.  
                                              
18 http://www.caleidos-life.eu/ 
19 http://cefic-lri.org/projects/eco8-development-of-a-strategy-to-predict-acute-fish-lethality-using-fish-cell-
lines-and-fish-embryos/ 
20 http://cefic-lri.org/projects/eco8-3-nc3rs-eawag-round-robin-test-of-the-rtgill-w1-cell-line-assay-to-study-
its-robustness-in-establishment-and-inter-laboratory-comparability/ 
21 http://cefic-lri.org/projects/lri-eco20-ua-development-of-an-alternative-testing-strategy-for-the-fish-early-
life-stage-test-for-predicting-chronic-toxicity/ 
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At a recent AOP workshop22, co-organised and co-sponsored by the JRC, AOPs related to 
fish chronic toxicity with a focus on fish growth were discussed and the outcome was 
published (Groh et al., 2015a; Groh et al., 2015b). 
2.3.3. Threshold of Toxicological Concern in Aquatic Toxicity Assessment 
The Threshold of Toxicological Concern (TTC) approach is based on the premise that there 
is a general exposure limit for chemicals below which no significant risk to human health 
or the environment is expected. It is well established for assessing human safety of 
substances present in low levels in food and feed (Kroes et al., 2004; EFSA 2012).  
The potential usefulness of the TTC approach for various applications in environmental 
toxicity and risk assessment has been explored and reported by several groups (de Wolf et 
al., 2005; Gross et al., 2010; Williams et al., 2011; Gutsell et al., 2015).  
An international collaboration under the ILSI HESI has been established to address 
challenges related to developing and applying useful ecotoxicological threshold of concern 
(eco-TTC) concepts. EURL ECVAM is contributing to this initiative.  
2.4. Activities within EPAA  
The European Partnership for Alternative Approaches to Animal Testing23 (EPAA) is a 
collaboration between the European Commission, European trade associations and 
companies from seven industry sectors. 
The partners are committed to pooling knowledge and resources to accelerate the 
development, validation and acceptance of alternative approaches to animal use in 
regulatory testing. The overall aim is the replacement, reduction and refinement (3Rs) of 
animal use in regulatory testing. JRC, represented by EURL ECVAM, is one of the 
Commission services that are members of the EPAA. 
2.4.1. Stem Cells  
The development of alternatives to replace animal-based safety testing requires the 
development of suitable in vitro systems possessing physiological relevance. Induced 
Pluripotent Stem Cells (iPSC), derived from human adult tissues, can be manipulated to 
produce all cell types and offer great potential as a pivotal alternative to animal use in 
safety testing. The development of iPSC and establishment of physiological relevance in 
safety testing requires a multidisciplinary, international approach to combine the expertise 
in academic, industry and regulatory groups. 
In 2014, the stem cells working group of EPAA together with collaborating groups and 
building on previous workshops and expert meetings, developed the 'Research Prospectus', 
                                              
22 https://aopkb.org/saop/workshops/somma.html 
23 The European Partnership for Alternative Approaches to Animal Testing (EPAA) is a public-private 
collaboration; see also: http://ec.europa.eu/growth/sectors/chemicals/epaa/index_en.htm 
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a document which defines specific research needs and priorities for the development of 
iPSC as a central and accepted test system for alternative methods in safety assessments. 
It also proposes possible topics for calls under the Horizon 2020 Work Programme. The 
document was discussed with and welcomed by the European Commission (DG RTD). 
In succession of the first International Stem Cells Forum that was initiated by EPAA in 
2013, a second Forum took place in September 2014, jointly organized by EPAA and the 
British Centre for Drug Safety Science (CDSS24). The event gathered 25 invited experts 
from Europe and US and focused on benchmarking of stem cell assays in safety 
assessment across international consortia. Hepatotoxicity was at the forefront of 
discussions. Participants from industry, academia, regulators (US National Institutes of 
Health, European Medicines Agency), EURL ECVAM and civil society agreed that reinforced 
collaboration at international level could accelerate the development of reliable stem-cells 
based alternative methods. A paper summarising the conclusions of the event was 
published in the peer-reviewed journal Stem Cells and Development (Suter-Dick L et al., 
2015). 
2.4.2. Toxicokinetics - Exposure Prediction tool 
A new project funded by EPAA started in June 2014 which aims at the further development 
of an existing bioinformatics tool to convert external exposure data to internal exposure in 
humans and vice versa. The tool uses human absorption, distribution, metabolism and 
excretion (ADME) characteristics that may have been obtained using QSARs as well as in 
vitro approaches. The outcome of the project will be an open source web application 
programmed in R syntax25. It will serve the needs of in vitro as well as in vivo toxicologists, 
risk assessors and mathematical modellers for the purpose of quantitative in vitro to in 
vivo as well as in vivo to in vitro dose metric extrapolation. It is based on a physiologically 
based toxicokinetic (PBTK) model structure. Once finalised, the tool will not only be freely 
accessible in all its modules, but also downloadable to the user's PC. This avoids the need 
for uploading proprietary information to the web and thus assures the confidentiality of 
the user's data.  
The beta-release of the tool is expected for the end of 2016 and a second project phase, 
which will generate the final open-access version, is under consideration at EPAA. EURL 
ECVAM participates in the technical advisory team to this project. 
2.4.3. EPAA Science Awards/Prizes  
The EPAA Awards are granted to young scientists (3Rs Science Prize) or laboratory 
technicians (3Rs Technician Prize) whose work has brought an outstanding contribution to 
                                              
24 https://www.liv.ac.uk/drug-safety/  
25 https://www.r-project.org/ 
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the development and implementation of alternatives to animal testing. Both Science and 
Laboratory technician prizes are awarded biannually. 
In 2014, the EPAA granted the 3Rs Science Prize to a scientist from the University of 
Tampere/FICAM for her outstanding research that helped to develop a novel in vitro 
human-based vascular network model. By making use of cell co‐cultures, the model is 
meant to be used for angio‐/vasculogenesis testing, resulting in a tissue‐like system. The 
Prize winner presented her work to the participants of the EPAA Annual Conference in 
November 2014. 
3. Test Method Submissions  
In total, 13 test submissions were sent to EURL ECVAM for evaluation during the period 
covered by this report, of which eight were pre-submissions, reporting information in the 
Test Pre-Submission Form (TPF), and five were full submissions, reporting information in 
the Test Submission Template (TST), usually complemented by annexes. In addition, two 
full submissions that had been received in late 2013, i.e. the Yeast Androgen Screening 
Test (YAS) and the Ocular Irritection Test were also reviewed by EURL ECVAM in 2014. 
Thus, in total, EURL ECVAM assessed 15 test submissions during this period. 
Noteworthy, all seven full submissions were reporting information and data on external 
validation studies submitted to EURL ECVAM in view of peer review by the ECVAM Scientific 
Advisory Committee (ESAC) and an EURL ECVAM recommendation.  
For each test submission, an assessment report was prepared, an assessment meeting was 
held and reply letters were drafted according to the internal JRC quality procedure.  
Besides the assessment of the test submissions received, EURL ECVAM also reviewed a 
validation project plan of a test that had been submitted in 2011 (SENS-IS) and further to 
the definition of the EURL ECVAM strategy on toxicokinetics, also replied for a second time 
to a test method developer of a skin penetration method submitted in 2012 (Skin PAMPA). 
In addition, EURL ECVAM consulted its network of regulators PARERE (Preliminary 
Assessment of Regulatory Relevance Network) on the regulatory relevance of a test 
method that had been initially submitted in 2009 (GreenScreen HC) and for which an 
updated full submission was received in 2014 and launched the PARERE consultation 
process on a test method for teratogenicity testing (devTox qp).  
In addition to the standard EURL ECVAM test submission process via the EURL ECVAM 
website, EURL ECVAM also launched a call for in vitro human hepatic metabolic clearance 
methods (HHMC) in March 2014 that resulted in the submission of 15 HHMC methods. 
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3.1. Test Method Submission Related to Acute Fish Toxicity   
RTgill-W1 test method 
EURL ECVAM assessed the pre-submission on the RTgill-W1 cell line assay received in 
March 2014. The method uses the fish cell line RTgill-W1 derived from rainbow trout gills 
(Tanneberger et al., 2013). Cells are exposed for 24 h to a series of test chemical 
concentrations. Cytotoxic effects (EC50 values) are determined by measuring the cell 
viability using three fluorescent dyes (AlamarBlue for cellular metabolic activity, 5-
carboxyfluorescein diacetate acetoxymethyl ester for cell membrane integrity and Neutral 
Red for lysosomal membrane integrity testing). Cell viability of the exposed cells is 
expressed in % of the control cells. The lowest EC50 values are used for predicting acute 
fish toxicity. Based on the outcome of the assessment, EURL ECVAM invited the test 
submitter to provide a full test submission as soon as more data on the within and 
between laboratory reproducibility become available (see 2.3.1). 
3.2. Test Method Submissions Related to Genotoxicity 
3.2.1. Green Screen HCTM (GSHC) Assay 
A full test submission was received in May 2013 on a method intended to predict the in 
vivo genotoxic potential of chemicals: the Green Screen HCTM (GSHC) assay. The GSHC is a 
microplate format genotoxicity plus cytotoxicity screening assay which uses the DNA 
damage-inducible "Growth Arrest and DNA Damage 45 alpha" (GADD45a) - Green 
Fluorescent Protein (GFP) reporter gene, expressed in the p53-competent human 
lymphoblastoid TK6 cell line (Hastwell et al., 2006; Jagger et al., 2009).  
Upon treatment with a DNA damaging agent, GADD45a is highly induced, mostly in a p53-
dependent manner. When GADD45a transcription is increased over its constitutive level, 
cells accumulate GFP, the fluorescence of which can be measured as a proportional 
assessment of genome damage and genotoxic stress.  
This test method underwent an external (non EURL ECVAM-coordinated) validation study 
and all available information/data were submitted to EURL ECVAM for a retrospective 
validation in view of ESAC peer review.  Based on the information provided, the method 
appeared to be mechanistically and biologically relevant in relation to genotoxicity. A 
standardised protocol is publicly available in the EURL ECVAM DB-ALM since July 2012 
(http://ecvam-dbalm.jrc.ec.europa.eu/). The data provided in this submission were 
convincing enough to support the use of the test method as a screening tool in early 
phases of compound discovery and development. However, due to the properties of the 
method as a general indicator of genotoxicity the actual role of the GreenScreen HCTM 
assay within current regulatory testing approaches needed to be further elucidated.  In 
light of this, and before considering peer review by ESAC, in June 2014, EURL ECVAM 
launched a consultation with the PARERE (Preliminary Assessment of Regulatory 
Relevance) network of regulators. EURL ECVAM considered a number of scenarios, some of 
which might have had an added value to current genotoxicity testing practices. Scenario 1: 
24 
 
GreenScreen as a substitute to the Ames test in ICH S2 (R1) Option 2; Scenario 2: 
GreenScreen as an alternative to the in vitro battery; Scenario 3: GreenScreen as an 
alternative to one of the currently used in vitro tests; Scenario 4: GreenScreen as an 
additional test to the current in vitro battery. PARERE members were asked to give 
feedback on the following matters: relevance of the method for regulatory testing of 
genotoxicity, relevance in respect of different sectors, evaluation of the four different 
scenarios, and other scenarios in which the use of such a method could be envisaged. 
In agreement with the main conclusion drafted by EURL ECVAM in the Assessment Report 
on the Full Test Submission, the GreenScreen HC™ assay has been considered by PARERE 
as a suitable method to identify the genotoxic potential of substances, e.g. as a screening 
tool at early phase of drug discovery and development. However, the impossibility of 
deriving specific information on the mechanism(s) leading to the observed genotoxic 
effects (endpoints: mutations, structural and numerical chromosomal aberrations) upon 
treatment with any type of substances appears to be one of the main reasons for 
questioning its regulatory relevance.  
PARERE highlighted that the lack of this endpoint information could lead to an increase of 
in vivo experiments instead because of the lack of guidance on the specific test to be 
performed in animals when needed/required.  However, the GreenScreen HC™ assay was 
considered to be potentially useful as an additional test in a weight of evidence strategy to 
follow up, on a case-by-case basis, and to clarify the relevance of positive results from the 
standard in vitro battery. In the future, the GreenScreen HC™ assay could make an 
important contribution to satisfying regulatory information requirements across many 
sectors, if it was incorporated into a suitable Integrated Approach to Testing and 
Assessment (IATA) for genotoxicity. The assay may reflect a mechanistic key event in a 
possible Adverse Outcome Pathway for carcinogenicity and, as such, it could be considered 
useful to provide sensitive dose-response information that might be meaningful within an 
IATA aimed at estimating point(s) of departure (e.g. no-effect level) useful for risk 
assessment. 
3.2.2. ɣH2AX In cell western (ICW) test method 
A test pre-submission on a new in vitro method intended for testing genotoxicity, the 
ɣH2Ax in Cell western (ICW) assay, was received in late May 2014. The assay was 
presented as a 96-well plate format capable of detecting simultaneously the cytotoxic and 
genotoxic potential of compounds in different proliferating and metabolic competent cell 
lines (human or rodent).  
The test aims at assessing ɣH2AX histone phosphorylation as a consequence of global 
genotoxic insult. The method relies on the strong correlation between the ɣH2AX histone 
and DNA damage, DNA double strand breaks (DSBs), and the ɣH2AX histone recognition as 
a suitable pre-cancerous biomarker in vivo. The test uses the 'in cell western technique' 
which is an immunohistochemistry in situ (in the well) test coupled with infra-red 
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fluorescence detection, determining the change in phosphorylation of ɣH2AX histone levels 
(genotoxicity) and DNA content (cytotoxicity) compared to control cells. 
Based on the information provided, EURL ECVAM considered the method biologically and 
mechanistically relevant in relation to genotoxicity. However, the assay , in its current form, 
needs further development with regard to method definition, optimisation and 
standardisation (accuracy values, etc.) before entering into a formal validation process. 
Moreover, its impact on the 3Rs, its role within the current regulatory context and its 
applicability domain need to be further explored. A final response was delivered to the 
submitter in October 2014. 
3.3. Test Method Submission Aiming to Address Various Endpoints 
Light Up Cell System (LUCS) 
The pre-submission of the Light Up Cell System (LUCS) was received in 2014. It was 
submitted to EURL ECVAM to replace and close a previous submission received in 2011, 
the Dequenching After Photobleaching (DAP) assay. The submitter claimed that the LUCS 
would be able to address acute toxicity and genotoxicity, to replace 3T3 NRU in its 
applications, including phototoxicity, and to be applied for skin corrosion and irritation. The 
submitter based this assertion on the possibility to use the assay in any cell types, from 
prokaryotes (e.g. Escherichia coli) to eukaryotes (e.g. human, plant or fish cells), given that 
the cell type used would determine the potential application of the assay. The LUCS test 
method measures nucleic acid alteration (e.g. DNA damage) in living cells through 
fluorescence readout following their treatment with a toxic substance. The underlying 
mechanism is the alteration of nucleic acids (DNA and/or RNA) by Reactive Oxygen Species 
(ROS) which trigger the observed variations of fluorescence in the cells.  
 For the human acute oral systemic toxicity, the performance of the assay was not 
evident from the data shown. Additionally, it was not obvious what advantages the 
LUCS offered in comparison to other in vitro assays, e.g. the 3T3 neutral red uptake 
(3T3 NRU) cytotoxicity assay for predicting official acute oral toxicity categories.  
 For the genotoxicity area, the LUCS has limited applicability as it does not directly 
measure damage to DNA or RNA, because ROS formation is only one of the 
mechanisms involved in DNA damage. The assay does not provide information on 
the extent of the damage either. The induction of permanent transmissible changes 
in the amount or structure of the genetic material is a regulatory requirement 
across sectors, which is not addressed by the LUCS. The test method was therefore 
not considered to be tailored for the genotoxicity assessment.  
 Finally, there was not enough evidence to judge the relevance of the test method 
for its potential applications in phototoxicity or skin irritation/corrosion.  
Overall, the test method was not prioritised since the intended purpose (effect of interest), 
applications and its possible regulatory relevance were unclear. 
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3.4. Test Method Submission Related to Respiratory 
Permeability/Penetration (Toxicokinetics) 
MucilAirTM  
A pre-submission on an in vitro cell model of the human airway epithelium for the trans-
epithelial permeability assessment (MucilAirTM) was received in 2014. This method provides 
Papp (apparent permeability) values for the upper airways. Some shortcomings were 
identified during the evaluation process. For instance, it was not evident which human 
model (bronchial or nasal) was used to generate the results presented and which model 
would be preferred in specific circumstances. Furthermore, clear purpose and scope for the 
use (regulatory or non-regulatory, quantitative for PBTK modelling or categorisation when 
used within testing strategies) was lacking. Various validation approaches for assessing the 
reliability and relevance of in vitro ADME/TK methods are under consideration at EURL 
ECVAM and described in the EURL ECVAM Strategy for Achieving 3Rs Impact in the 
Assessment of Toxicokinetics and Systemic Toxicity 26 . In addition to the current 
development of standards in the area of metabolic clearance and stability (see 3.10), EURL 
ECVAM intends to address the area of absorption which will involve, among other tasks, the 
identification of representative methods which could be used to support the development 
of standards. In the light of all these facts the test method did not progress at that stage 
but may be reconsidered in the wider context of ADME/toxicokinetics and development of 
standards. 
3.5. Test method submission related to Endocrine Disruption 
 Yeast Androgen Screening (YAS) test 
The YAS assay is a screening assay for measuring endocrine disruption.  It uses yeast cells 
that are transformed with a human androgen receptor and a lacZ reporter gene, and, 
measures the response towards chemicals with (anti) androgenic potential.  The method 
was submitted to EURL ECVAM at the end of 2013 to be considered for an ESAC peer 
review.  A full validation study had been carried out with 4 laboratories.  The submission 
dossier was assessed by EURL ECVAM in early 2014 and feedback was requested from the 
submitter for some critical procedural aspects prior to continuing the evaluation.  This 
assay may have potential to be annexed to a future Performance Based Test Guideline 
(PBTG) for Androgen Receptor Transactivation Assays (ARTAs).   
3.6. Test Method Submission Related to Teratogenicity  
DevTox qp  
EURL ECVAM has received a pre-submission on a teratogenicity test method in September 
2014. The assay is based on the measurement of changes in the ornithine/cystine ratio 
(metabolic biomarkers) present in the media after exposure of undifferentiated human 
induced pluripotent stem (iPS) cells to a chemical. Based on the obtained results, the test 
                                              
26 https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-publishes-its-strategy-in-the-area-of-toxicokinetics 
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developer suggests that any perturbation in this metabolite ratio past the established 
threshold will have the potential to cause developmental toxicity. The submitter claims that 
these two biomarkers provide predictive information on teratogenicity in humans. 
The assay is currently used to assess developmental toxicity risk potential in discovery and 
preclinical development programs for prioritisation of the development of new compounds 
using a human embryonic stem cell version of the assay (not iPS cells). Further to EURL 
ECVAM's assessment, the submitter provided clarifications on some critical issues. 
However, since the usefulness of the test method in the current regulatory context 
regarding developmental toxicity mediated by teratogenicity remains unclear, EURL ECVAM 
launched a consultation with its network of regulators (PARERE) which is currently on-
going. 
3.7. Test Method Submissions Related to Skin Sensitisation 
3.7.1. The Genomic Allergen Detection (GARD) test method 
The Genomic Allergen Detection (GARD) test method (Johansson et al., 2011, 2013), a 
transcriptomics-based in vitro assay proposed to discriminate between skin sensitising and 
non-sensitising chemicals on the basis of the expression level of mRNA transcripts for a 
panel of 200 genes in MUTZ-3 cells, was resubmitted to EURL ECVAM in the first quarter of 
2015. Since the initial submission in 2013, the test method has undergone additional 
refinement including modifications to the prediction model. Following the evaluation of the 
test submission EURL ECVAM concluded that, although the test method appears to be of 
relevance for the assessment of the skin sensitisation potential of substances, additional 
data need to be generated with the latest versions of the protocol and the prediction 
model before the test method can be considered for progression into the next phases of 
the validation process. 
3.7.2. U-SENSTM (former MUSST) 
The U-SENSTM (former MUSST) which distinguishes sensitisers from non-sensitisers on the 
basis of CD86 membrane protein enhanced expression in U937 cells, includes an addition 
to the prediction model, consisting of a score derived from six rules that allows classifying 
a chemical, which would have been considered inconclusive on the basis of the original 
prediction model, as a sensitiser or non-sensitiser (Piroird et al., 2015).  The U-SENSTM 
assay underwent an external validation study conducted in two phases. The results of the 
first phase were submitted to EURL ECVAM in 2013 and were judged to be insufficient to 
enter the EURL ECVAM peer review process at that time. A revised submission was received 
in the last quarter of 2014. This second submission is complemented with additional 
results generated during the second phase of the validation study. The evaluation of the 
full submission performed by EURL ECVAM indicated that the information provided in the 
submission would qualify the test method to enter the peer-review process upon the 
clarification of a few aspects of the submission by the test developer.  
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3.7.3. SENS-IS 
The SENS-IS assay (Cottrez et al., 2015) is a gene expression-based test method proposed 
to discriminate between sensitisers, non-sensitisers and irritants by analysing the 
expression of a panel of 65 genes grouped in one gene set for irritancy (IRR) and two 
(SENS-IS and ARE) for sensitisation. A test substance is classified as sensitiser on the basis 
of the number of overexpressed genes (compared to solvent control) measured by qRT-PCR 
in Episkin tissues (SkinEthic, France). In addition, the test method allows the classification 
of sensitisers into potency categories on the basis of the concentration of chemical needed 
to induce a positive response. Subsequent to the submission of the SENS-IS method to 
EURL ECVAM, the test submitter communicated the intention to undertake an external 
validation study on the method. During the first quarter of 2014, EURL ECVAM provided 
advice and comments on the submitted SENS-IS Pre-validation Study Plan. In addition, 
since the test developer applied for a patent that broadly covers the test method, EURL 
ECVAM suggested exploring the impact of this patent on the development of similar tests, 
since this would have consequences on the possible future development of an OECD Test 
Guideline on the SENS-IS assay. 
3.7.4. LuSens 
The LuSens is an in vitro test method designed to discriminate between skin sensitising 
and non-sensitising chemicals. The test method is based on the same concepts as the 
OECD adopted KeratinoSens™ (TG 442D) by quantifying luciferase gene induction as a 
measure of the activation of the Keap1-Nrf2-antioxidant/electrophile response element 
(ARE)-dependant pathway in a genetically modified keratinocyte cell-line (Bauch et al., 
2012). The Lu-Sens underwent an external catch-up validation study based on the 
performance standards for in vitro skin sensitisation ARE-NrF2 luciferase test methods 
(OECD, 2015) and the results were submitted to EURL ECVAM during the first quarter of 
2015. In the light of the results of the catch-up study, EURL ECVAM considers the method 
would qualify to progress into the peer-review process once the test submitter provides the 
clarifications requested on some aspects of the submission.  
3.8. Test Method Submissions Related to Skin Irritation 
3.8.1. Background to the Skin Irritation Test Submissions 
All formal test submissions received in the period covered by this report concern RhE-
based test methods. The submissions seek formal evaluation and validation by EURL 
ECVAM in reference to the Performance Standards (PS) for in vitro skin irritation testing 
(EURL ECVAM 2009; OECD TG 439, 2010). This includes requests for the evaluation of 
similarity of test methods prior to the execution of external PS-based validation studies as 
well as finished studies conducted in reference to the PS.  
3.8.2. OS-REp: Open Source Reconstructed Epidermis model 
In May 2014, EURL ECVAM received a full submission on the OS-REp test method 
validation study that had been conducted externally by the test submitter in reference to 
the ECVAM/OECD Performance Standards for skin irritation testing (OECD TG 439). 
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3.8.2.1. Background to the OS-Rep 
The background of this test method has been described in detail in the previous EURL 
ECVAM status report. Briefly, the OS-REp assay is a 3-dimensional Reconstructed human 
Epidermis (RhE) model consisting of normal primary human epidermal keratinocytes that, 
at air-liquid interface, undergo keratinization (Pruniéras et al., 1983). From this point of 
view, it is a typical RhE "me-too" method. Importantly, the OS-REp model is not exclusively 
produced and distributed by a commercial entity but follows the "open source" principle: 
due to the fact that all the information on constructing the skin equivalents is available, 
tissues can be produced by any interested end user/laboratory. However, it is understood 
that a company intends to commercially market the OS-REp tissue kits using their 
automated tissue production line ("skin factory"; see previous EURL ECVAM status report, 
2014). 
 
The protocol for tissue construction is based on the RhE model developed by Poumay and 
colleagues (Poumay et al., 2004) who demonstrated that a RhE tissue model can be 
constructed using keratinocytes from adult skin collected as a result of plastic surgery 
(abdominoplasty) from consenting patients and, importantly, by following publicly available 
procedures and commercially available reagents (media, growth factors, etc.) without the 
need of procedures/reagents protected by IPRs. Thus, this "open source" protocol enables 
any researcher to reconstruct, in his/her laboratory, RhE models for investigations of 
epidermal biology, dermatology and toxicology at a low cost while being in full control of 
the production process and avoiding any problems due to commercial availability or 
shipment. Poumay et al. demonstrated that the RhE model can also be used for predictive 
toxicity. In particular, the authors were able to distinguish a pure skin irritant from an 
irritant with skin sensitising properties on the basis of the pattern of inflammatory 
mediators released by the tissue (Interleukin 1alpha vs Interleukin 8; measured 20h post-
incubation). This indicates that this test system appropriately models key aspects of the 
biology of human epidermis and epidermal physiology in response to xenobiotic insult. The 
idea of a RhE model that comes without commercial restrictions, originally put forward by 
Poumay, has been taken up by the test submitter and some changes to the original tissue 
production protocol have been introduced. The changes were intended to improve the 
quality of the RhE model. The resulting RhE model was termed "Open Source Reconstructed 
Epidermis" = OS-Rep, alluding to the open source concept of availability of information on 
processes and source materials (as in the software world). Changes with respect to the 
Poumay model include: 
1) the use of ascorbic acid 2-phosphate sesquimagnesium salt instead of ascorbic acid 
(vitamin C) due to its longer shelf-life time in warm cell culture medium. Vitamin C 
significantly improves the barrier characteristics of the reconstructed tissue (Ponec et al., 
1997; Pasonen-Seppanen et al., 2001). 
2) the exclusive use of juvenile foreskin (=male skin) instead of tissue from plastic surgery 
of the abdomen, presumably from male and female donors. Thus, with regards to the 
gender source of skin tissues for keratinocyte isolation, the OS-REp RhE is based on male 
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keratinocytes only. Based on the keratinocyte source and near identical SOPs, this method 
and others (e.g. SkinEthic, epiCS) can be termed "EpiDerm-like", in contrast to EpiSkin which 
uses only mammary skin tissue (=female skin). 
3.8.2.2. PS-based validation study  
Previously, the test submitter had organised a validation study (submitted to EURL ECVAM 
in 2012) that had shown problems with respect to within-laboratory reproducibility (WLR), 
between-laboratory reproducibility (BLR) and the specificity. Following discussions and 
suggestions for improving the performance of the method, the submitter had organised a 
second study, submitted to EURL ECVAM in 2014. This study had been designed in view of 
demonstrating the equivalence of the OS-REp model to the validated reference methods 
underlying the Performance Standards associated OECD TG 439 and, at the same time, 
assessing the feasibility of the open source principle: tissue production was conducted 
under "open source" conditions at the three participating laboratories. The kits produced in 
the laboratories were then used for assessing the performance of the method with respect 
to the 20 reference chemicals in terms of WLR, BLR and sensitivity and specificity.  
EURL ECVAM evaluated the dossier and study in view of assessing:  
1) The sufficiency of biological and procedural similarity of the OS-REp test method in 
relation to the PS specifications based on the validated reference methods. Sufficient 
similarity is a prerequisite for a test method to qualify for the lean validation procedure via 
Performance Standards (using a small set of pre-defined test chemicals). The evaluation 
confirmed that the OS-REp method is in full compliance with the PS specifications. 
2) Adequacy of the two SOPs relating (i) to the construction of the skin model in the user 
laboratory and (ii) to the execution of the Skin Irritation Test (SIT) for assessing the skin 
irritation potential of chemicals. Both SOPs were found appropriate and sufficiently 
detailed. The overall success of the study demonstrates that the tissue construction SOP 
appears appropriate. However, the study conditions can be considered favourable with 
regard to successful tissue constructions as extensive training had been organised for all 
participating laboratories. It remains to be seen how successful transfer of the tissue 
construction can be ensured under realistic conditions of use of the method (i.e. open 
source). 
3) Compliance check of the validation study data with the target values of the PS relating 
to WLR (at least 90% concordant predictions of three valid runs per chemical), BLR (at 
least 80% concordant predictions among laboratories based on the mean of viability of the 
three runs in each lab) and PC based on assessing the individual laboratory predictions 
(optimally n=60 = 3 labs x 20 RCs) obtained by the mean viability of the runs generated. 
Specificity should be at least 70%, sensitivity at least 80%). This step involves cross 
checking the reported values by re-calculating the figures based on the rules set-out in the 
PS.  
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Although the study was found to be of very high quality and complied with the PS criteria 
with respect to BLR and predictive capacity (sensitivity, specificity), the performance for 
WLR were, in two laboratories (85% in one lab and 80% in a second lab) below the criteria 
as specified in the PS (≥90%). It would need to be demonstrated that the WLR levels that 
have been repeatedly shown to be attainable by other methods can also be reached using 
the OS-REp method which relies on tissue constructions at individual sites. This is 
necessary for eventual inclusion in an internationally recognised test guideline (e.g. OECD 
439). EURL ECVAM has provided extensive advice to the submitter with respect to potential 
factors that could have caused problems with regard to WLR.  
3.8.3. Sterlab Reconstructed human Epidermis 
In October 2014, EURL ECVAM received a pre-submission of the Sterlab Skin Irritation Test 
(SIT). After evaluation by EURL ECVAM, the submitter was invited to submit a full 
submission which arrived at EURL ECVAM in June 2015. The full submission included 
results of a PS-based validation study that had been conducted in three different 
laboratories with the twenty reference chemicals of the PS. No other additional chemicals 
were tested. The Sterlab RhE SIT was submitted in view of its possible inclusion in OECD TG 
439. The dossier is currently under evaluation at EURL ECVAM where the assessment of 
similarity and compliance with PS requirements is carried out.  
3.8.4. Ashland Reconstructed human Epidermis 
In May 2015, EURL ECVAM received a pre-submission of the Ashland Skin Irritation Test 
(SIT). This test is based on Reconstructed human Epidermis (RhE) tissues. EURL ECVAM 
currently assesses the pre-submission  
3.9. Test Method Submissions Related to Eye Irritation  
3.9.1. Ocular Irritection® 
The in vitro macromolecular test method Ocular Irritection® represents a refinement of the 
former Eytex® method (Kelly, 1989; Gordon, 1992) following recommendations made by 
Balls et al., (1995). It predicts the ocular hazard effects of chemicals based on the premise 
that corneal opacity may result from the disruptive effects ocular irritants may have on the 
highly organized structure of corneal proteins and carbohydrates. This assay mimics the 
biochemical phenomena of corneal protein denaturation and disruption caused by irritant 
chemicals acting on the cornea. One of the components of the test method is a 
macromolecular reagent composed of a mixture of proteins, glycoproteins, carbohydrates, 
lipids and low molecular weight components. The constituents of the macromolecular 
reagent combine with each other to form a complex macromolecular matrix that mimics 
the highly ordered structure of the transparent cornea. It is believed that irritant chemicals 
produce a turbidity of the macromolecular reagent by promoting protein denaturation, 
protein unfold and change in conformation, which then results in the disruption and 
disaggregation of the highly organised macromolecular reagent matrix. This mechanism is 
believed to mimic the disruptive effects ocular irritants can have on the highly organised 
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structure of corneal proteins and carbohydrates, which result in corneal cloudiness/opacity 
in the in vivo Draize eye test. 
The Ocular Irritection® underwent an external prospective and retrospective validation study 
to assess its scientific validity to identify chemicals not requiring classification for serious 
eye damage/eye irritation (No Category) and chemicals inducing serious eye damage 
(Category 1), according to the United Nations Globally Harmonized System of Classification 
and Labelling of Chemicals (UN GHS) (UN, 2013) and the European Union Regulation on 
Classification, Labelling and Packaging of chemicals (EU CLP) (EC, 2008), in the framework 
of a Bottom-Up/Top-Down test strategy (Scott et al., 2010). In December 2013, after 
completion of the validation study, EURL ECVAM received a full submission on the Ocular 
Irritection® test method. After careful evaluation, EURL ECVAM concluded that the test 
method appears to have promise to identify chemicals not requiring UN GHS/EU CLP 
classification for serious eye damage/eye irritation (e.g. as an initial step of a bottom-up 
testing strategy) and chemicals inducing serious eye damage (e.g. as an initial step of a 
top-down testing strategy) since its performance seems to be comparable to that of other 
validated test methods and also because it is a highly cost-effective assay as compared to 
other methods. However, EURL ECVAM’s evaluation uncovered a number of shortcomings in 
the method definition and in the information provided concerning its performance and, in 
August 2014, the test submitter was requested to address and clarify these issues in a 
revised submission. Upon request of the test submitter, a meeting between EURL ECVAM 
and the Validation Management Group of the Ocular Irritection® validation study was 
organised in October 2014 to discuss the various points raised by EURL ECVAM in its 
assessment report. The submission was then updated with additional (non-testing) 
information and biostatistical analyses as requested by EURL ECVAM and the full revised 
submission was provided to EURL ECVAM in April 2015. EURL ECVAM currently evaluates 
this revised submission. If considered complete and ready to enter peer-review, it will be 
submitted to ESAC. Peer-review of the Ocular Irritection® test method by ESAC is expected 
to occur in Q4 2015 – Q1 2016. 
3.9.2. Cornea Cell Reprogramming (CORNiPSC) 
The Cornea Cell Reprogramming (CORNiPSC) test method was submitted to EURL ECVAM 
for the eye irritation endpoint. For this purpose, the test developer devised a differentiation 
protocol of induced pluripotent human stem cells to yield cells differentiated into human 
corneal epithelial cell lines (Shalom-Feuerstein et al., 2012). For the measuring of eye 
irritation effects, the test method uses cell viability as an endpoint measurement. The test 
method would represent another cell-based test method for eye irritation testing, if proven 
to be scientifically valid, it could also have an impact on 3Rs. Since the test method is 
based on cell culture, it is expected that only water-soluble chemicals could be tested. This 
test method is in a pre-submission stage. Further refinement of the testing protocol in the 
light of the addressed key endpoint, will show whether this test method could be used as 
an initial step of an integrated testing strategy, following either a "bottom-up" or a "top-
down" approach. 
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3.10. Test Method Submissions Related to Human Hepatic Metabolic 
Clearance  
As part of wider efforts to develop harmonised standards for in vitro ADME methods EURL 
ECVAM has launched a public web survey asking for submission of in vitro human hepatic 
metabolic clearance methods (HHMC) in March 2014. To reach the scientific community, 
the survey was advertised in international scientific journals and it was disseminated 
through EURL ECVAM's networks, such as the European Union Network of Laboratories for 
the Validation of Alternative Methods (EU-NETVAL), DataBase on ALternative Methods (DB-
ALM), Preliminary Assessment of Regulatory Relevance (PARERE), ECVAM Stakeholder 
Forum (ESTAF), International Cooperation on Alternative Test Methods (ICATM) and through 
the European Society for In vitro Toxicology (ESTIV).  
 
Nine test facilities submitted 15 HHMC methods that aim to measure in vitro the rate at 
which a test chemical is metabolised by a human liver based test system. HHMC methods 
are currently used for the prediction of in vivo hepatic metabolic clearance of 
pharmaceuticals, and their relevance to chemical testing can be initially demonstrated by 
employing a test system that shows strong resemblance of in vivo human liver. Three 
protocols were submitted using human liver microsomes as a test system. Liver 
microsomes consist of vesicles of hepatocyte endoplasmatic reticulum and thus contain 
almost only CYP and Uridine 5'-diphospho-glucuronosyltransferase (UGT) enzymes. One 
protocol was submitted using S9 fractions. This test system contains both microsomal and 
cytosolic fractions. However, it has low enzymatic activity. Ten protocols were submitted 
using human cryopreserved hepatocytes as a test system. Human hepatocytes possess the 
full spectrum of metabolising enzymes, co-factors and cell membrane receptors. In seven 
of these ten protocols human hepatocytes were applied in suspension, in two protocols 
hepatocytes were applied in adherent monolayer form and in one protocol, up-regulated 
hepatocytes were applied in adherent monolayer form. Finally, one experimental protocol 
using human liver slices as a test system was submitted.  
 
Following the evaluation of the submitted methods EURL ECVAM decided to use the three 
most highly ranked protocols.  These protocols employ cryopreserved human hepatocytes 
in suspension and they will be used to develop a EURL ECVAM in vitro hepatic metabolic 
clearance standard operating procedure of a representative HHMC method. This method 
will aim to predict the in vivo intrinsic hepatic metabolic clearance of fast to medium 
cleared chemicals.  
4. Validation of Alternative Methods  
This section refers to validation studies which are either carried out by EURL ECVAM or for 
which EURL ECVAM has been consulted. It is not an exhaustive list of all possible validation 
studies carried out around the world. Nonetheless, EURL ECVAM is aware of external (to 
EURL ECVAM) validation studies that are carried out by companies/industry on methods 
which are meant to be submitted to EURL ECVAM for peer review. These studies are 
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mentioned under chapter 3 (Test Submissions) and chapter 4.6 (EURL ECVAM Scientific 
Advisory Committee Activities). The validation studies undertaken with EURL ECVAM's 
international partners in the framework of the International Cooperation on Alternative 
Methods (ICATM) are described under chapter 7 (International Cooperation on Alternative 
Test Methods). 
4.1. AR Calux 
The AR CALUX assay makes use of osteosarcoma cells, stably transfected with a human 
androgen receptor, which express luminescence when presented with chemicals that have 
(anti)androgenic potential.  The method was submitted by the Dutch company 
BioDetectionSystems for an EURL ECVAM coordinated validation study.  After a positive 
evaluation, EURL ECVAM carried out an experimental assessment of the method, followed 
by a GLP study in order to refine the assay and establish transfer criteria.  Three members 
of the 2014 established European Union Network for the Validation of Alternative Methods 
(EU-NETVAL) were chosen to participate in the validation study.  A Validation Management 
Group to provide oversight on the study has been established too.  EURL ECVAM provided 
training on the method for the 3 participating test facilities at the JRC Ispra premises early 
2015, and the transfer phase of the method is currently being carried out. This assay, and 
other similar ones currently under validation by other validation bodies or by industry, has 
potential to be annexed to a future Performance Based Test Guideline (PBTG) for Androgen 
Receptor Transactivation Assays (ARTAs). In fact, a project to develop a PBTG and related 
Performance Standards on ARTAs (under the lead of the European Commission represented 
by JRC-EURL ECVAM) was inserted in the OECD work plan in 2013. At the present time, 
three ARTAs will be considered for the development of this PBTG:  the AR-CALUX, the AR 
STTA using the AR-EcoScreen cell line (led by Japan) and the ARTA using the 22Rv1/MMTV 
cell line (the validation study led by Korea is currently ongoing).  EURL ECVAM participates 
in the latter study as a member of the VMG, providing support with the chemicals selection 
and study design.  
4.2. Micronucleus Test and Comet assay in Reconstructed Skin Models for 
genotoxicity testing 
The validation of methods for genotoxicity testing in reconstructed human 3D skin models, 
coordinated by Cosmetics Europe, is still ongoing (Aardema et al., 2010; Reus et al., 2013). 
For the micronucleus test in 3D epidermis model, a slightly modified version of the former 
protocol is under evaluation; while for the comet assay in full-thickness skin models the 
between-laboratory reproducibility and predictive capacity is assessed with further 
chemicals.  
4.3. Hen's Egg test for Micronucleus Induction (HET-MN) for genotoxicity 
testing 
The hen's egg test for micronucleus induction (HET-MN; Wolf et al., 2008) has also been 
proposed as a follow-up test method for in vitro positives. The HET-MN combines the use 
of the commonly accepted genetic endpoint “formation of micronuclei” with the well-
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characterised and complex model of the incubated hen's egg, which enables metabolic 
activation, elimination and excretion of xenobiotics, including those that are mutagens or 
pro-mutagens. The predictive capacity of the assay is currently being evaluated by a 
German consortium (Greywe et al., 2012). 
4.4. Ongoing Validation Studies for Vaccine Quality Control – EDQM 
Biological Standardisation Programme 
Most of the validation studies on alternative methods for vaccine quality control are 
carried out within the framework of the Biological Standardisation Programme (BSP) of the 
European Directorate for the Quality of Medicines & HealthCare (EDQM; Council of Europe) 
and co-sponsored by the European Commission.  
Several validation studies are currently ongoing which assess alternative methods for the 
safety and potency testing of human and veterinary vaccines (e.g. a serological assay for 
the potency testing of whole-cell pertussis vaccines; alternative method to the histamine 
sensitization test (HIST) for acellular pertussis vaccines; a multi-dose serological assay for 
rabies vaccine for veterinary use; in vitro methods for the testing of Clostridium septicum 
vaccines) or are planned for 2015 and beyond (e.g. ELISAs for tetanus/diphtheria vaccines, 
the BINACLE assay for in vitro detection of toxicity in tetanus vaccines).  
More information on the BSP, its background and work programme is available at 
https://www.edqm.eu/en/BSP-Work-Programme-609.html. 
Two projects are of particular interest since they are close to finalisation and the methods 
assessed are considered ready for product-specific validation at manufacturer level. 
Results of the above mentioned study on alternative methods to the HIST have been 
reviewed and discussed by regulators and manufacturers at a recent international 
workshop "In search of acceptable alternatives to the murine histamine sensitization test 
(HIST): What is possible and practical?"27. Participants concluded that the "indirect CHO-cell 
based assay" is a suitable alternative for replacement of HIST. As described by Isbrucker et 
al., (2014), this assay had been identified as most promising in a collaborative study 
involving a wider range of cell-based assays and biochemical methods. 
The second project, in vitro methods for the testing of Clostridium septicum vaccines has 
been launched within an EPAA project and more details are given under 5.12.5 (EPAA 
projects).  
4.5. EU NETVAL 
EURL ECVAM has established a network of highly qualified laboratories (EU-NETVAL) to (1) 
respond to some of the provisions of Directive 2010/63/EU, (2) generate in vitro method 
information that is reliable, relevant and based on current best quality and scientific 
                                              
27 https://www.nc3rs.org.uk/events/search-acceptable-alternatives-murine-histamine-sensitization-test-what-
possible-and 
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practices, (3) increase the European Commission's validation capacity of in vitro methods 
and (4)  provide a laboratory network knowledgeable on the routine implementation of 
good in vitro method practices (Coecke et al., 2014) for regulatory use in human safety 
assessment. The first pilot project of selected EU-NETVAL test facilities is the generation of 
experimental data using the in vitro AR-CALUX method to support the development of an 
OECD performance-based test guideline and associated performance standards for 
Androgen Receptor Transactivation Assays (ARTA) for the detection of compounds with 
(anti)androgenic potential (see 4.1). Future tasks for EU-NETVAL will be the generation of 
high quality data based on current best scientific practices for in vitro methods targeting 
one of EURL ECVAM's priority areas, e.g. toxicokinetics (see 8.3). To actively trigger test 
submissions for these priority areas, EURL ECVAM identifies in vitro methods using test 
submission e-survey tools as a parallel process to the traditional test submission 
procedure. The whole process is managed by EURL ECVAM and its collaborating ad-hoc 
expert teams who analyse the information retrieved from these surveys and ultimately 
define internationally accepted harmonised in vitro method standards. EURL ECVAM is in 
the planning phase of involving EU-NETVAL in harmonising and standardising human 
hepatic metabolic clearance methods to increase reliability of this class of in vitro assays 
to use in regulatory decisions (see 3.10).  
4.6. EURL ECVAM Scientific Advisory Committee (ESAC) Activities 
4.6.1. ESAC Peer Review on the epiCS® Test Method for Skin Irritation Testing 
From April 2014 to October 2014, ESAC reviewed the Performance Standards-based 
validation study on the epiCS® test method for skin irritation testing. The epiCS® test 
method is based on Reconstructed human Epidermis (RhE) and sufficiently similar with 
regard to the essential test method components to validated reference methods (e.g. 
Episkin and EpiDerm, OECD TG 439, see ECVAM status report 2014). The study was 
conducted by the test method supplier (CellSystems, Germany) and submitted to EURL 
ECVAM for evaluation and ESAC peer review. In agreement with the Performance 
Standards, the study addressed within and between laboratory reproducibility and 
predictive capacity on the basis of the 20 Reference Chemicals. Like most methods 
covered by TG 439, the epiCS® test method (initially trademarked and evaluated as 
EST1000) was developed to discriminate between irritant (Category 2) and non-classified 
chemicals in order to allow classification of chemicals according to the United Nations 
Globally Harmonized System (GHS) either as "Category 2" or "no Category" respectively. 
 
The study was conducted in two phases. In 2011, data from a completed ring trial had 
been submitted to EURL ECVAM. While the study data met the predictive capacity target 
values (sensitivity = 93%, specificity = 73%), within laboratory reproducibility was not 
acceptable in the three laboratories involved (in particular in the naïve laboratory) and 
between laboratory reproducibility was slightly below the target. The submitter identified 
poor proficiency (no training phase had been conducted) and lack of stringency of SOP 
execution (in particular washing/rinsing) as likely main reasons for poor reproducibility. 
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Additionally, issues with shipment were identified in the case of the overseas laboratory. 
After improved training of the participating laboratories, all 20 chemicals were tested 
again in the naïve laboratory to assess whether proficiency indeed had caused within 
laboratory reproducibility issues. Moreover, the other two laboratories also re-tested those 
chemicals that had shown non-concordant predictions in view of generating supplementary 
information on the plausibility of the problems identified and effectiveness of the 
measures taken to address the problems (these were 6 and 7 chemicals, respectively). This 
data set showed that the measures significantly improved WLR in all three laboratories. In 
the case of the naïve laboratory, where all 20 reference chemicals had been tested de 
novo, WLR now met the acceptance value. The study was submitted in 2013 to EURL 
ECVAM and forwarded by EURL ECVAM to ESAC for scientific peer review in 2014. 
 
ESAC reviewed the study design and data sets submitted in 2011 and in 2013 and, in an 
interim report, concluded that the study showed acceptable values for BLR, specificity, 
sensitivity and overall accuracy. However, only the naïve laboratory satisfied the 
performance values relating WLR when re-testing all 20 reference chemicals in 2013. The 
two other laboratories only met performance values when grouping data from the 2011 
testing with data from the re-testing in 2013. Although these were generated under 
slightly different conditions with regard to exactitude of SOP execution, ESAC was of the 
opinion that this was not an a priori reason to reject such grouping which can indeed be a 
valid approach in agreement with the modular approach, in particular with respect to use 
of retrospective data. Although ESAC was of the opinion that all data together tended to 
support that performance values for WLR can be attained, ESAC was concerned that 
grouping the data from de facto two validation trials may introduce bias towards more 
positive results, since the remaining 14 and 13 chemicals had not been re-tested and 
hence had not been subjected to the possibility of generating results of lesser quality (e.g. 
more non-concordant or invalid runs/run sequences). ESAC recommended that for a final 
robust characterisation of WLR supporting regulatory use of the test method, also the 
remaining 13 and, respectively, 14 reference chemicals would need to be re-tested in the 
two participating laboratories. The submitter is currently (summer 2015) generating these 
missing data and the dossier is expected to go into final ESAC peer review in autumn 2015. 
4.6.2. ESAC Peer Review on the hCLAT Test Method for Skin Sensitisation 
From September 2013 to March 2014 ESAC reviewed the EURL ECVAM-led validation 
study which had assessed mainly the transferability and reproducibility (within and 
between laboratories) of the h-CLAT test method (primary objective of the study) in view 
of its possible future use as part of a non-animal testing strategy for skin sensitization. 
The study had also been designed to provide preliminary information on a) the predictive 
capacity of the test method and b) its potential use for contributing to sub-categorisation 
of sensitising chemicals. Overall, ESAC agreed with the conclusions drawn by the Validation 
Management Group that oversaw the study. The ESAC however disagreed with the VMG 
conclusion concerning the interpretation of the results on Within Laboratory Reproducibility 
(WLR) which was found to be  on average 80% WLR over the four participating laboratories 
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and thus not meeting the expectation of the VMG (85%). ESAC expressed concern that 
there may be inherent characteristics or critical aspects of the h-CLAT test method, which 
could be sources of variability that may impact on the usefulness of the data even when 
generated in the context of an integrated approach. Furthermore, while agreeing that the 
study generated promising results, ESAC concluded that predictive capacity, applicability 
domain and limitations of the test method were not yet fully defined and would require 
further characterisation through empirical testing and/or the evaluation of existing 
information. 
4.6.3. ESAC Peer Review on the Human-based CYP induction assays 
From April 2014 to October 2014 ESAC reviewed the EURL-ECVAM coordinated validation 
study on cytochrome P450 induction (CYP1A2, CYP2B6, CYP2C9, and CYP3A4) in human 
cryopreserved primary hepatocytes and the human cryopreserved HepaRG cell line. The 
main study objective was to assess the transferability, reproducibility (within and between 
laboratories) and predictive capacity of the two in vitro test systems employed. Predictive 
capacity was assessed using exclusively human reference data. Availability of robust 
human in vivo CYP induction data was one of the criteria in chemical selection and this 
limited the test chemicals to pharmaceuticals. Chemicals were tested over a wide range of 
concentrations covering clinical human dose-response. Chemicals with animal data only 
were avoided because they are not comparable to the human situation due to the well 
described metabolic interspecies differences. 
The ESAC concluded that the study had appropriately addressed test definition, within 
laboratory reproducibility, transferability, and between laboratory reproducibility. However, 
ESAC was of the opinion that the assessment of predictive capacity had been only partially 
fulfilled and concluded that the data as generated during the study were not fully 
sufficient to conclude on the readiness of the test for regulatory use supporting chemical 
safety assessments. In particular, ESAC recommended that additional CYP induction studies 
be conducted with rodent hepatocytes to investigate both applicability domain and 
predictive power for substances that have "drug-like" properties (i.e. 
persistence/bioaccumulation, highly lipophilic compounds, rapid metabolism, and poor 
water solubility). Notwithstanding this recommendation, ESAC agreed that CYP induction 
assays based on human cells may have a potential role in chemical safety assessments, 
e.g. as markers of possible receptor activation or as an adjunct test to interpret other 
toxicological information. According to ESAC, the human cell-based assay has also 
potential use for evaluating the human relevance of animal test results, whether in vivo or 
in vitro. ESAC further concluded that the study data were in good agreement with other 
existing information regarding hepatocyte assays and provided a proof of principle: that 
EURL ECVAM study had demonstrated that reliable hepatocyte assays for other important 
purposes, including identification of metabolites and quantification of metabolic clearance, 
are feasible. ESAC encouraged EURL ECVAM to continue conducting studies with human 
hepatic models to develop methods for characterization of other kinetic data, including 
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clearance, metabolic profiling, and inhibition. In this context, ESAC emphasized the 
importance of developing in vitro to in vivo extrapolation methods. 
4.6.4. ESAC Peer Review on the EpiOcular™ Eye Irritation Test (EIT) 
From March to October 2014, ESAC reviewed the EURL ECVAM eye irritation validation 
study (EIVS). The EIVS originally addressed two test methods, the SkinEthic™ HCE assay 
reconstructed cornea based on a human corneal cell line and the EpiOcular™ EIT assay 
using reconstructed tissue based on keratinocytes from male foreskin. During the study it 
became apparent that the SkinEthic™ HCE would require optimisation and further 
validation, which could not be completed within the time-frame of the EIVS. The ESAC 
review hence focused primarily on the EpiOcular™ EIT. ESAC concluded that the study 
addressing the potential usefulness of the EpiOcular™ EIT for use within a test strategy to 
assess eye irritation of chemicals was well planned and executed. Reproducibility, 
transferability and predictive capacity had been assessed in three laboratories testing 105 
chemicals plus an additional 8 solids to assess an optimised version for testing of solids. 
The chemicals represented a wide range of irritancy scores, chemical categories and use 
classes. While ESAC agreed with the bulk of conclusions of the study results as presented 
by the VMG, ESAC disagreed with the approach chosen to calculate the predictive capacity 
based on the individual test runs generated in all participating laboratories. According to 
ESAC, this approach over-estimated the sample size, produced overly narrow confidence 
limits, and resulted in a seemingly high degree of certainty with respect to the point 
estimates of sensitivity and specificity. ESAC recommended that, in case single runs are 
used for analysing predictive capacity, other statistical methods such as bootstrapping 
should be used. ESAC concluded that the study had satisfied the requirements regarding 
transferability, reproducibility and predictive capacity, supporting the use of the EpiOcular™ 
EIT within a test strategy to determine the eye irritation potential of chemicals, specifically 
to detect non-irritants as part of a Top-Down or Bottom-Up approach. Despite this positive 
appraisal, ESAC pointed out that confidence in the test method would be further increased 
if supplementary studies confirm that the test method correctly classifies a small but 
representative sample of labelled products or mixtures as defined by REACH and from 
various sectorial use classes. 
4.7. EURL ECVAM Recommendations 
4.7.1. EURL ECVAM Recommendation on the Zebrafish Embryo Toxicity Test (ZFET) 
for Acute Aquatic Toxicity Testing 
Acute fish toxicity testing is an important component of the environmental hazard 
assessment of chemicals. For many years, (zebra-)fish embryo-based methods have been 
proposed as alternatives to the acute fish toxicity test carried out with juvenile or adult fish 
(e.g. Schulte and Nagel 1994; Nagel 2002; Braunbeck et al., 2005; Scholz et al., 2008; 
Lammer et al., 2009).   
The Zebrafish Embryo Acute Toxicity Test Method (ZFET) is based on the use of newly 
fertilised eggs from zebrafish (Danio rerio). It is a short-term exposure test (96 h) and 
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determines the concentration that is lethal to 50% of the zebrafish embryos (LC50) as an 
indication of acute fish toxicity. Observation of one of the following apical endpoints 
indicates the death of the embryo: coagulation of the embryo, lack of somite formation, 
non-detachment of the tail and lack of heartbeat.  
On behalf of the OECD, EURL ECVAM coordinated during 2008-2012 the validation of the 
ZFET to evaluate its reproducibility in support of the development of an OECD Test 
Guideline (OECD 2011, 2012; Busquet et al., 2014). In parallel to this study, Belanger and 
colleagues continued to collect acute fish embryo toxicity and acute fish toxicity data to 
assess the predictive capacity and applicability of the ZFET and submitted their report to 
EURL ECVAM in July 2012 (Belanger et al., 2012; 2013). Following independent scientific 
peer review by ESAC of both studies and having considered input from regulators, 
stakeholders, international partners and the general public, EURL ECVAM concluded (EURL 
ECVAM, 2014) that the ZFET - being available as OECD TG 236 since 2013 (OECD, 2013b) 
- is transferable and reproducible within and between laboratories and can provide 
information on acute fish toxicity comparable to that derived from standard tests (e.g. 
OECD TG 203; OECD 1992). Therefore, it should be used for generating information on 
acute fish toxicity, where appropriate taking into consideration the various regulatory 
frameworks and regions as well as its potential limitations.  
The use of the ZFET will result in an overall reduction in the numbers of juvenile and adult 
fish required for aquatic toxicity testing. Notably, since Directive 2010/63/EU (EU 2010) on 
the protection of animals used for scientific purposes covers larval forms of non-human 
vertebrate animals once they are independently feeding, the ZFET as used in OECD TG 236 
is outside the directive's scope: zebrafish start to feed independently not before 5 days 
post-fertilisation and the method uses zebrafish embryos only up to 4 days (= 96 h) post-
fertilisation. 
Prospective users of the method should consult EURL ECVAM’s DataBase for ALternative 
Methods (DB-ALM) to access the detailed ZFET protocol (see DB-ALM Protocol no. 140 at 
the address: http://ecvam-dbalm.jrc.ec.europa.eu.  
The EURL ECVAM Recommendation on the Zebrafish Embryo Acute Toxicity Test for Acute 
Aquatic Toxicity Testing was published in July 2014 (EURL ECVAM, 2014). 
4.7.2. EURL ECVAM Recommendation on the human Cell Line Activation Test (h-
CLAT) for Skin Sensitisation Testing  
The human Cell Line Activation Test (h-CLAT) for skin sensitisation testing was developed 
by Kao Corporation and Shiseido (Japan). With a view to facilitating its use as a component 
of integrated approaches to assessing the skin sensitisation potential of chemicals, EURL 
ECVAM coordinated a validation study to assess the reliability of the h-CLAT method and to 
gain some preliminary insight into its predictive capacity. On completion of the study, EURL 
ECVAM requested ESAC to conduct a scientific peer review of the validation study report 
and the resulting ESAC opinion was delivered in May 2014 (see 4.6.2). Having considered 
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the ESAC opinion and inputs from regulators, stakeholders, international partners and the 
general public and taking into consideration all existing published information on the 
method, in February 2015, EURL ECVAM published its recommendation on the h-CLAT 
indicating that the test method is transferable to laboratories sufficiently experienced in 
cell culture techniques and flow cytometry analysis. Considering the within and between-
laboratories reproducibility and the preliminary predictive capacity of the method as 
assessed with the chemicals tested in the validation study and in published studies, EURL 
ECVAM concluded that the test method should prove valuable as part of Integrated 
Approaches to Testing and Assessment (IATA) together with complementary information 
(e.g. in chemico or other in vitro data, QSAR or read-across predictions). The ESAC peer 
review of the h-CLAT study included valuable expert discussion of various statistical 
approaches to assess within and between laboratory reproducibility. As a follow-up, EURL 
ECVAM proposed to re-analyse the data from the validation study with a view to exploring 
the merits of various statistical methods for describing the reproducibility of a test method 
that produces a classification-based prediction. EURL ECVAM undertook this statistical 
analysis and produced a report that was submitted to the OECD in support of the 
development of a Test Guideline on the h-CLAT. 
EURL ECVAM recommendations on the EpiOcular™ Eye Irritation Test (see 4.6.4) and on the 
human-based CYP induction assays (see 4.6.3) are currently being prepared. 
5. Promoting the Regulatory Acceptance of Alternative Methods and 
Approaches  
5.1. PARERE (Preliminary Assessment of Regulatory Relevance) and 
ESTAF (ECVAM Stakeholder Forum) Annual Meetings 
EURL ECVAM organises annual meetings with the Preliminary Assessment for Regulatory 
Relevance network (PARERE) and the EURL ECVAM Stakeholder Forum (ESTAF). In 2014, the 
meetings took place on 5th and 6th June. 
5.1.1. PARERE Meeting 
At the PARERE meeting on 5th June 2014, the participants gave an overview on the 
establishment of the PARERE network in their respective countries, including the 
involvement of national bodies/agencies/experts, as well as a brief description of its 
functioning and difficulties encountered. 
In relation to the tasks that PARERE should carry out, the following was agreed:  
1. Provide upstream input on potential regulatory relevance and suitability of 
proposed alternative approaches and identify approaches that deserve attention; 
2. Highlight 3Rs priority areas within the regulatory domain and provide feedback on 
draft EURL ECVAM strategy documents; 
3. Comment on draft EURL ECVAM Recommendations; 
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4. Identify regulatory experts that could participate in specific EURL ECVAM project 
groups (e.g. supporting validation studies, peer-review working groups); 
5. Support and facilitate the work of the EU Network of laboratories for the validation 
of alternative methods (EU-NETVAL) within Member States; and 
6. Contribute to the promotion, dissemination and communication of alternative 
approaches within Member States. 
In the framework of task 1 above, EURL ECVAM consulted PARERE on the regulatory 
relevance of a test method for the prediction of the in vivo genotoxic potential of 
chemicals (GreenScreen™HC), which had been initially submitted in 2009 and for which an 
updated full submission was received in 2014 (see 3.2.1). In addition, the PARERE 
consultation process on a test method for teratogenicity testing (DevTox qp) was launched. 
5.1.2. Joint PARERE-ESTAF meeting 
Following the PARERE meeting (see above), a joint meeting of PARERE and ESTAF members 
was held on 5th and 6th June 2014.  EURL ECVAM gave updates on its activities in relation 
to alternative approaches; explained modifications of its validation workflow; and informed 
PARERE on the establishment of the European Union Network for the Validation of 
Alternative Methods (EU-NETVAL).  EURL ECVAM presented strategies in the following three 
areas: 
 Toxicokinetics; 
 Acute systemic toxicity; and 
 Fish toxicity and bioaccumulation. 
PARERE and ESTAF members commented on these draft strategies by written procedure 
after the meeting and the strategies were published by ECVAM28. 
Finally, participants provided their views on a number of topics including the efficiency of 
the review process of ESAC, the usefulness of EURL ECVAM Recommendations outside the 
context of OECD Test Guidelines and the possibilities of a test submitter to comment on a 
validation study report and the draft EURL ECVAM Recommendation in relation to their test 
method. In addition, the participants were asked to provide their views about 
considerations to implement a fully transparent model of test submissions, i.e. making 
public all details of a test method submitted to EURL ECVAM. 
5.2. OECD Test Guideline Programme (TGP) 
At the 27th meeting of the Working Group of National Coordinators of the OECD TGP held 
at the OECD headquarters in Paris on 14th to 17th April 2015, six new Test Guidelines were 
approved of which four were based on in vitro methods, i.e. the Short-Time Exposure test 
(eye hazard potential), a test method based on reconstructed Human Corneal Epidermis 
(eye hazard potential) and the Estrogen-Receptor Binding Assay (endocrine disruption). In 
                                              
28 https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers 
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the context of a broader revision and update of genotoxicity OECD Test Guidelines, the 
mouse lymphoma assay and TK6 test (using TK gene locus), originally contained in TG 476, 
were moved to the new TG 490 based on revision of acceptance criteria and data 
interpretation.  Now, two distinct TGs for in vitro mammalian cell gene mutation tests are 
available: TG 476 – using hprt and xprt genes; TG 490 – using tk gene. 
 
In addition, ten Test Guidelines were updated (TG 404, TG 430, TG 431, TG 435, TG 439 on 
in vitro and in vivo skin irritation and/or corrosion; TG 478 and TG 483 on in vivo 
genotoxicity, TG 455 on Estrogen-receptor transactivation (endocrine disruption), TG 421 
and TG 422 on screening for reproductive toxicity (updated with endocrine-related 
endpoints).  
 
A series of supporting documents were approved as well. More information on the OECD 
TG programme can be found on the OECD website of the Test Guideline Programme29. 
 
The following chapters exclusively focus on TGs for which the EC (through JRC-EURL 
ECVAM) had the lead or co-lead or carried out validation studies. Beside those, EURL 
ECVAM participated in, or co-chaired, numerous OECD expert groups and commented on 
several draft TGs and GDs led by other OECD Member Countries.  
5.2.1. OECD Test Guidelines on Skin Sensitisation 
5.2.1.1. Adopted Test Guidelines 
In March 2015, TG 442C on the Direct Peptide Reactivity Assay (DPRA) and TG 442D on the 
ARE-Nrf2 Luciferase Test Method, KeratinoSens™ were adopted by the OECD. These 
represent the first two test guidelines describing non-animal test methods for skin 
sensitisation. The DPRA assay is an in chemico assay that addresses protein reactivity, the 
molecular initiating event (Key event 1) of the skin sensitisation adverse outcome pathway 
(AOP), by quantifying the reactivity of test chemicals towards synthetic peptides containing 
either lysine or cysteine. The KeratinoSens™ test method focuses on the second key event 
of the AOP, the inflammatory response and gene expression in keratinocytes associated 
with the antioxidant/electrophile response element (ARE)-dependent pathways. Both test 
methods underwent EURL ECVAM validation and/or peer review. The issuing of the EURL 
ECVAM recommendation on the DPRA in 2013 and the one on the KeratinoSens™ in 2014 
formed the basis for the development of OECD test guidelines. Both methods are proposed 
in the test guidelines for supporting the discrimination between skin sensitisers (i.e., UN 
GHS category 1) and non-sensitisers within Integrated Approaches to Testing and 
Assessment (IATA). 
                                              
29 http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicalsandrelateddocuments.htm 
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5.2.1.2. Draft OECD Test Guideline on h-CLAT 
At OECD, EC-EURL ECVAM is co-leading together with Japan the development of a third 
test guideline on an in vitro method for skin sensitisation validated by EURL ECVAM. The 
method in question is the human Cell Line Activation Test (h-CLAT) which is addressing the 
process of dendritic cells activation, the third key event within the skin sensitisation AOP. A 
draft test guideline was submitted to OECD in 2014 and underwent revisions following the 
first commenting round. In addition EURL ECVAM submitted to the OECD a report on the 
reanalysis of the validation study data where the reproducibility of the method was 
reconsidered by looking at all possible combinations of the nine conducted runs per 
chemical, rather than the sequential analysis initially performed. At the 27th WNT meeting, 
it was agreed that the reanalysis has been useful to address some of the issues raised by 
the WNT comments and there was general support to move the TG towards approval once 
the remaining minor issues have been discussed and solved. A second commenting round 
took place shortly after the 27th WNT meeting and an OECD meeting of the expert group on 
skin sensitisation will be held in October 2015 to address the comments received with a 
view of moving the TG forward for written approval by the WNT. 
5.2.1.3. New OECD Project Proposals for developing Test Guidelines on in vitro 
methods for skin sensitisation testing 
U-SENS™  
Further to the evaluation of an industry-led validation study and submission of the 
information to EURL ECVAM (see 3.7.2), a project proposal for the development of a Test 
Guideline on the U-SENS™ test method was submitted by France to the OECD and included 
in the OECD work program in 2015. 
IL-8 Luc assay 
A project proposal was made by Japan for developing a Test Guideline on the IL-8 assay 
(see 7.2) and included in the OECD work program in 2015. The test method was evaluated 
in a JaCVAM-coordinated validation study which was finalised in September 2014. The 
independent peer review by JaCVAM of the validation study started in February 2015 and 
is currently being finalised.. 
5.2.2. OECD Test Guideline on reconstructed Human Corneal Epidermis for the 
detection of chemicals not requiring classification for serious eye damage/eye irritation  
Based on the outcome of the EURL ECVAM/Cosmetics Europe validation study (see EURL 
ECVAM status report 2014), the EC (through JRC-EURL ECVAM) submitted a new draft TG 
on the EpiOcular™ EIT for the identification of chemicals not requiring classification for 
serious eye damage/eye irritation to the OECD in July 2014. After a first commenting 
round, a meeting of the expert group was convened at the OECD headquarters in Paris in 
November 2014 to discuss and address the comments from experts and the WNT on the 
first version of the TG. Following this meeting, a revised draft TG and associated 
Performance Standards (PS) were prepared by EURL ECVAM and circulated to the WNT and 
the OECD expert group on eye irritation for commenting in December 2014. The revised 
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documents were finally submitted to the OECD for approval in February 2015 and were 
adopted by the OECD WNT in 2015. The TG (no. 492) and PS were published by the OECD 
in July 2015. TG 492 was published in Section 4 (Heath Effects) of the OECD Test 
Guidelines and the PS in the Series on Testing and Assessment. 
5.2.3. OECD Guidance Documents on SHE and Bhas 42 CTA 
Cell transformation assays provide a way to detect, in cultured cells in vitro, those 
phenotypic alterations that have been considered alterations associated with cells 
exhibiting neoplastic potential in vivo. A draft TG on the cell transformation assay (CTA) in 
SHE cells had been submitted for adoption at the 26th WNT meeting in 2014. As there was 
no consensus to approve the revised TG due to a minority of Member Countries who were 
against it, it was agreed to make the SHE CTA test method available in a guidance 
document (GD). This GD has been published as No. 214 in the Series on Testing and 
Assessment in May 2015. As in the case of the SHE CTA, the WNT also decided that the 
draft TG on the other version of the CTA, based on BHAS 42 cells, should also become a 
GD. The draft GD underwent several commenting rounds and the revised version will be 
sent to the WNT for a final review before approval and declassification by the Joint 
Meeting. 
GDs are not covered by Mutual Acceptance of Data (MAD), but they will allow test method 
users to perform the test methods in a standardised manner.  This will hopefully lead to 
the generation of new data of good quality, which will in the future be useful for the 
revision of the status of the assays. 
In April 2014, the WNT recognised that the CTA is insufficient to completely address non-
genotoxic carcinogens and that a more comprehensive battery of tests addressing non-
genotoxic mechanisms was needed. This discussion raised the need for an IATA approach 
to properly address the issue of non-genotoxic carcinogenicity and discuss where the CTA, 
together with other relevant assays, could fit. A new project proposal by the UK for the 
development of an IATA for non-genotoxic carcinogens was approved at the 27th WNT. The 
project will provide a thought starter that examines what non-genotoxic carcinogens are, 
the current regulatory difficulties encountered with respect to them and how an IATA could 
be explored and ultimately developed in the second stage of the project to assist 
regulators in their assessments of non-genotoxic carcinogenicity. 
5.2.4. Draft OECD Performance-based Test Guideline on CYP induction 
Further to the EURL ECVAM-coordinated validation study on human-based CYP induction 
assays (reported in the EURL ECVAM status report 2014) and the subsequent ESAC peer 
review (see 4.6.3.), the EC (JRC-EURL ECVAM) developed and submitted a draft 
Performance-based test guideline (PBTG) on "human cytochrome P450 (CYP) activity n-fold 
induction" to the OECD in July 2014. The comments raised by the WNT in this new area of 
in vitro biotransformation assays were reviewed and addressed in an OECD expert group 
meeting on biotransformation assays in May 2015.  
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The submitted PBTG was considered to fit well within the new OECD concept for advancing 
test methods dealing with complex endpoints. The information generated by the human 
CYP activity n-fold induction in vitro test method may be included in integrated approaches 
to testing and assessment when attempting to assign a test chemical to a particular 
Adverse Outcome Pathway. CYP induction can be identified as a molecular initiating event 
(AOP-dependent; e.g. cholestasis and CYP3A4 up regulation) or may be of relevance 
because induction may alter key metabolic pathways by perturbing the biotransformation 
pathways catalysed by the induced CYP enzyme (AOP-independent). 
The expert group recognised the usefulness of the submitted PBTG not only to assess 
potential CYP induction of test chemicals but also of chemicals in mixtures which are likely 
to significantly change metabolic pathways, i.e. change the biotransformation rates of 
individually co-occurring substances and their metabolites with potential consequences for 
their toxicity. 
Based on the results generated during the validation project, the expert group considered 
the human cytochrome P450 (CYP) activity n-fold induction in vitro test method robust and 
reliable and supported the submitted PBTG. However, to better explain the context of use 
of this type of PBTG or of a new TG, an explanatory background document that will 
accompany the PBTG, will be drafted. All the experts at the meeting agreed to contribute to 
this document for progressing the PBTG. 
In general, the approach adopted by EURL ECVAM for the development of standards for 
ADME in vitro methods aimed at human risk assessment was appreciated. The 
development of other PBTGs covering in vitro methods on human hepatic metabolic 
clearance, but also on protein binding and oral/dermal and inhalation barrier routes useful 
for the assessment of bioavailability of compounds, is encouraged. 
5.2.5. Development of an OECD TG "In vitro Fish Hepatic Metabolism" 
In April 2014, the OECD WNT approved a project (under the lead of USA and the European 
Commission represented by JRC - EURL ECVAM) on the development of a new OECD TG on 
In vitro Fish Hepatic Metabolism. The project aims at standardising two in vitro methods 
using rainbow trout S9 fraction (Johanning et al., 2012) or cryopreserved rainbow trout 
hepatocytes (Fay et al., 2014) to determine in vitro fish intrinsic hepatic clearance rates.  
A multi-laboratory ring trial to assess the reliability, transferability, and predictive value of 
the two in vitro methods started in late 2014 and will provide results in 2015. It builds on 
work carried out within the framework of the ILSI HESI project "Bioaccumulation". ILSI HESI, 
will coordinate the ring trial and the outcome will serve as basis for developing the OECD 
TG. 
The bioconcentration potential of a chemical is important information that is required in 
many pieces of chemical legislation. It is used for hazard classification and for the 
assessment of persistent, bioaccumulative and toxic (PBT) substances. The 
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Bioconcentration Factor (BCF) is either predicted or measured (typically in fish, but if 
necessary, also in invertebrates). 
The fish intrinsic hepatic clearance rate derived with in vitro methods can be extrapolated 
to a whole-body metabolism rate constant. Inclusion of measured biotransformation rates 
enhances the reliability of BCF models (Nichols et al., 2013; Laue et al., 2014).  
5.2.6. New OECD Project Proposals in Fish Toxicity 
Control fish 
Following up on discussions initiated by the International Council on Animal Protection in 
OECD Programmes (ICAPO) at the 25th WNT meeting in 2013, the European Commission 
(JRC - EURL ECVAM) and ICAPO submitted a project proposal to OECD addressing the use 
of solvents in aquatic toxicity tests on fish. When solvents are used, e.g. for the testing of 
poorly soluble chemicals, OECD test guidelines require two control groups, i.e. a water 
control and a solvent control. Part 1 of the project aims at minimising the use of solvents 
and updating OECD Guidance Document 23 on Aquatic Toxicity Testing of Difficult 
Substances and Mixtures (OECD, 2000) with advanced methodology for media preparation 
and exposure systems. Part 2 of the project aims at determining whether it is possible to 
use only one control, the solvent control, when solvents are used in aquatic toxicity tests on 
fish. A retrospective review of existing data generated according to OECD test guidelines in 
the presence of a solvent will be used to determine if the use of only one control would 
impact the outcome of the study. It is anticipated that a Detailed Review Paper (DRP) will 
be prepared. The project was approved in 2015 and included in the OECD work plan. 
5.2.7. New OECD Project Proposal for a Guidance document on an IATA for serious eye 
damage/eye irritation 
The EC (JRC-EURL ECVAM) and the United States Environmental Protection Agency (US 
EPA) jointly submitted a new project proposal for the development of a Guidance 
Document on an IATA for serious eye damage/eye irritation (see 5.3.3.1) to the OECD in 
November 2014. This new project proposal was discussed and approved by the OECD WNT 
at its 27th meeting in 2015. 
5.3. Integrated Approaches to Testing and Assessment (IATA) 
developments 
5.3.1. General background on IATA 
IATA can be defined as a framework used for hazard identification, hazard characterisation 
and/or safety assessment of a chemical or group of chemicals, which strategically 
integrate and weight all relevant existing data and guide the targeted generation of new 
data where required to inform regulatory decision-making regarding potential hazard 
and/or risk. At the OECD level, IATA projects are run either under the OECD Test Guideline 
Programme or the OECD Task Force on Hazard Assessment.  
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5.3.2 Guidance Document on the Reporting of IATA 
EURL ECVAM is leading at the OECD the development of two guidance documents (GD), 
one on the reporting of IATA and one on the reporting of structured approaches to data 
integration and individual information sources used within IATA for skin sensitisation. The 
overall purpose of these GDs is to promote the consistent reporting of IATA within OECD 
member countries. The first guidance document delivers a set of principles for describing 
and evaluating IATA to facilitate their consideration in regulatory decision-making. In 
addition, the GD provides templates for reporting: a) structured approaches to data 
integration and b) individual information sources used within IATA so that the same 
documentation format for describing and evaluating IATA and its elements is used to the 
extent possible. 
These templates were used by an ad-hoc expert group for developing the second guidance 
document in which a number of structured approaches to data integration are presented. 
These can constitute, or be part of IATA for skin sensitisation hazard and potency 
prediction, based on the adverse outcome pathway as a conceptual framework. Among the 
case studies, the approach developed by EURL ECVAM is also presented.  
This document does not intend to seek for endorsement of any specific approaches 
provided in the case studies, but rather to provide a perspective of how individual 
information sources and structured approaches to data integration used within IATA for 
skin sensitisation should be reported in a harmonised way and to illustrate what forms 
these may take, whether they are statistically derived, or qualitative in nature, and serve 
different purposes (i.e. hazard versus potency prediction). A harmonised approach in 
reporting is critical to ensure consistency in the use of IATA-derived 
predictions/assessments for regulatory decisions and to promote mutual acceptance of 
such assessments. 
The two GDs are currently under review by the OECD Hazard Assessment Task Force 
(HATF). 
5.3.3. IATA Development in the OECD Test Guideline Programme 
EURL ECVAM co-leads and contributed to two IATAs which were developed in the OECD 
Test Guideline Programme: the IATA on Serious Eye Damage/Eye Irritation and the IATA on 
Skin Irritation/Corrosion.  
5.3.3.1. Development of an OECD Guidance Document on an Integrated Approach to 
Testing and Assessment (IATA) on Serious Eye Damage/Eye Irritation 
Assessments of serious eye damage and eye irritation hazards are basic information 
requirements in international regulations for the safety of chemicals, pesticides, and 
medicines including classification and labelling, packing and their transport. Under some 
regulations (e.g., EU Cosmetics Regulation, REACH) this information is required to be 
generated without the use of animal tests. Since 2002, the OECD TG 405 on in vivo "acute 
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eye irritation/corrosion" contains a supplement describing a sequential testing and 
evaluation strategy (OECD, 2002). This strategy recommends that, prior to undertaking the 
described in vivo test, a weight-of-evidence analysis be performed on all existing relevant 
data and that, where sufficient data are not available, new data need to be developed 
through application of a sequential testing strategy, starting first with alternative methods, 
in order to avoid unnecessary testing in laboratory animals. Steps 5 and 6 of this 
sequential testing and evaluation strategy call for validated and accepted in vitro or ex vivo 
test methods for "eye corrosion" and "eye irritation", respectively, before the use of the in 
vivo OECD TG 404 (on acute skin irritation/corrosion) and the in vivo TG 405 (on acute "eye 
irritation/corrosion") in steps 8 and 9, respectively, with the purpose of minimising animal 
use. However, this strategy does not foresee the use of negative results from validated 
and accepted in vitro assays, requiring confirmatory in vivo testing in such cases. Since 
publication of the supplement in 2002, several in vitro methods for serious eye 
damage/eye irritation have been developed, validated and accepted by the OECD. 
Depending on country requirements and the results obtained with the OECD accepted 
methods (i.e., BCOP, ICE, FL, EpiOcular™ EIT and STE), they may, in many cases, satisfy all 
information requirements for serious eye damage/eye irritation. In addition, non-standards 
methods (i.e., not yet validated and/or accepted by OECD) may provide further information 
(e.g., persistence vs. reversibility of effects) that could contribute to the full replacement of 
the in vivo Draize eye test. Although the suitability of such data for regulatory purposes 
needs to be judged case by case, they should be considered before conducting animal 
studies. For these reasons, guidance in relation to the use and generation of data for 
serious eye damage/eye irritation requires update in view of amending the possible use 
and usefulness of individual test methods and in order to avoid contradiction between the 
provisions of individual OECD TGs on in vitro methods and the provisions of the OECD TG 
405 supplement.  
The EC (JRC-EURL ECVAM) and the US EPA thus proposed to develop a Guidance Document 
on IATA for serious eye damage/eye irritation that should provide guidance on how to use 
the various types of alternative methods available and how to best combine them to reach 
a scientifically sound conclusion in an effective way, at the same time minimising animal 
testing to the extent possible. The project has three main objectives: 
1. To propose an IATA considering the scientific and technical progresses in the 
development, validation and acceptance of alternative methods to assess serious 
eye damage/eye irritation, in view of replacing the "testing and evaluation strategy" 
provided in the supplement to OECD TG 405, which was developed in 2002. 
2. To provide a clear and consistent description of each of the individual information 
sources that are relevant for the assessment of serious eye damage/eye irritation 
in the context of an IATA in terms of their key performance characteristics 
(reproducibility and predictive capacity) and their usefulness and limitations. 
3. To provide guidance on how to best use and combine relevant information in the 
context of the IATA for regulatory decision making on the serious eye damage or 
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eye irritation hazard potential of test chemicals (including decisions on the need for 
further testing when the existing information is not sufficient to reach a sound 
decision). 
A first draft of the document should be available for discussion at a meeting of the OECD 
Expert Group on eye irritation planned for November 2015 at the OECD headquarters. The 
final document is expected to be submitted for approval by the OECD WNT in April 2017. 
5.3.3.2. Guidance Document on an Integrated Approach to Testing and Assessment for 
skin corrosion/irritation hazard identification 
In July 2014, the OECD published the guidance document on an "integrated approach on 
testing and assessment" (IATA) for skin corrosion and irritation hazard identification (series 
on testing and assessment No. 203) (OECD, 2014). This represents an important milestone 
in the area of skin corrosion/irritation assessment. The document was developed by the 
OECD expert group for skin corrosion and irritation with substantial contribution from EURL 
ECVAM experts. Building on the Integrated Testing Strategy (ITS) for skin corrosion/irritation 
assessment which had been developed in 2006/2007 in the context of implementation of 
the REACH legislation, the OECD IATA outlines a strategic and scientifically based workflow 
to assess the hazard of a wide spectrum of chemicals in view of concluding on their 
classification and labelling (C&L) as well as choosing appropriate packing groups for 
transport. Like the original REACH ITS, the OECD IATA provides a step-by-step approach 
that is organised in three fundamental blocks: (1) gathering of existing information and 
conduct of weight of evidence of individual data sources; (2) weight of evidence of all 
collected information and, if necessary, an analogue approach; (3) new testing using first 
non-animal test methods and employing a strategic approach based on whether the 
substance is likely to be hazardous (either irritant or corrosive) or whether it is more likely 
to be non-hazardous. Animal testing is only foreseen as a last resort. While preserving this 
fundamental approach, additional data sources have been added also taking into account 
progress that has been made with respect to the capacity of alternative methods to 
provide additional C&L information. For instance, the IATA now supports subcategorisation 
of corrosive substances in subcategory 1A and a combination of subcategories 1B and 1C. 
As a novelty, it makes provision for using information from non-guideline methods, in 
particular where such methods can provide additional information that may be needed 
depending on country requirements. This includes for instance information on Category 3 
("mild" irritants) or full subcategorisation of skin corrosives (that is resolving subcategories 
1B versus 1C). Thus, with these flexible instruments, the IATA allows to completely replace 
the traditional Draize rabbit test for skin corrosion / irritation (OECD Test Guideline 404) for 
a wide spectrum of chemicals/use classes. 
While the IATA is a big step forward, there is still considerable room for improvement in 
the area of skin corrosion/irritation. We outline the most important in the following: 
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Importantly, while the current IATA provides solutions for classification and labelling needs 
of all global areas, it does so by resorting to non-guideline test methods or protocols, often 
relying on one single alternative method. This is far from ideal. It is therefore 
recommended that also other test method developers invest in improving their methods / 
protocols in view of providing data on corrosion subcategorisation and also on Category 3 
predictions. Recently, progress with regard to improving the prediction model of some of 
the RhE based corrosion models have been made, allowing more accurate 
subcategorisation predictions (Desprez et al., 2015).  
Moreover, it should be noted that the skin irritation methods are all based on the very 
upstream readout of tissue trauma (a key event in dermal inflammation, see provisional 
AOP for skin irritation in Worth et al., 2014, but do not exploit more mechanistic 
parameters such as inflammatory mediators or other stress indicators. 
Finally, when improving prediction models for categorical predictions, it would be advisable 
to reflect on the introduction of the prediction "inconclusive" for chemicals that fall within 
defined margins close to the cut-off of the prediction model (further details in Griesinger 
et al., 2015) since the categories of C&L are entirely arbitrary and put on a continuum of 
effect from non-irritant to irritant. A more scientific approach would be to process 
borderline predictions (falling within said margins) by expert judgement to decide on the 
final classification or non-classification.  
5.4. OECD Good Laboratory Practices Programme: EURL ECVAM Good 
In Vitro Method Practice (GIVIMP) Project 
In vitro methods, often based on the use of human cells and tissues, are submitted to 
international validation bodies. Well-designed, robust, reliable in vitro methods that can be 
run in a routine environment for generating data sets are becoming more and more 
instrumental for supporting regulatory decisions. Therefore, a project on an international 
Guidance Document on good in vitro method practices (GIVIMP) for the development and 
implementation of in vitro methods for regulatory use in human safety assessment was 
launched by EURL ECVAM. This project has recently been included in the OECD Test 
Guideline work programme.  The major goal of these efforts consists of reducing the 
uncertainties in in vitro based predictions and therefore increasing the acceptance of the in 
vitro estimated safety measures by regulatory agencies.  The GIVIMP guidance is meant to 
gather expert input from regulators of European and international authorities such as the 
European Food Safety Authority, the European Medicines Agency, the European Chemicals 
Agency, the US Food and Drug Administration as well as from the European Union Network 
of Laboratories for the Validation of Alternative Methods (EU-NETVAL), from ECVAM's 
Stakeholder Forum, from the EU and OECD Working Group on Good Laboratory Practices, 
from European 3Rs Centres, from EURL ECVAM's Preliminary Assessment of Regulatory 
Relevance (PARERE) network, from scientists from large industries and small and medium-
sized enterprises and from international scientists with expertise in kinetics, stem cells, cell 
biology, GLP and in vitro methods. The purpose of the GIVIMP guidance is taking into 
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account all necessary good scientific, technical and quality practices, to ensure that the 
overall process from in vitro method development to in vitro method implementation for 
regulatory use becomes more efficient and effective. An experimental project will be 
undertaken as a first GIVIMP-based pilot project aiming at harmonising and standardising 
human hepatic metabolic clearance methods to increase reliability of this class of in vitro 
assays to use in regulatory decisions. 
5.5. Support to OECD Policies: Chemical Mixtures and Combined 
Exposure 
Humans and the environment are continuously exposed to a multitude of substances via 
different routes of exposure. The toxicological risk of mixtures, relates both to intentional 
mixtures (e.g. known compositions, such as personal care products, food additives and 
pesticides) and unintentional ones (e.g. the combination of dozens to hundreds of 
substances in surface water, drinking water or air). For the latter, the assessment is much 
more challenging because (a) the compositions are various and complex, (b) many of the 
substances are unidentified and toxicity data are lacking. The current risk assessment 
approach of chemicals, for regulatory purposes, does not generally take into account this 
complex situation of exposure to multiple substances and mainly relies on the assessment 
of individual substances. Moreover, although the current EU regulations identify different 
types of mixtures, there is no harmonised methodological approach to their assessment.  
This gap in the EU regulatory assessment framework has recently gained more attention, 
following a 2012 Commission Communication on the Combined Effects of Chemicals (EC, 
2012). The communication required further work to be accomplished in order to reach a 
consistent approach to the assessment of priority mixtures across the different relevant 
pieces of EU legislation.  
Thus, one of the objectives of recent EURL ECVAM work has been to gain a clear up-to-
date overview on the current regulatory requirements and available guidance, as well as to 
collate information on the application of different approaches in current risk assessments. 
To this end, more than 20 different pieces of EU legislation (food and non-food related 
such as REACH, plant protection products, biocides, medicines, cosmetics, food 
contaminants, food and feed additives etc.) were reviewed as well as guidance documents 
from the EU and international bodies (Kienzler et al., 2014). Furthermore, an expert survey 
was performed to gather information on current practices and expert views.  
In conclusion, while many pieces of EU legislation are in place to protect humans and the 
environment against adverse effects of chemicals including mixtures, in many cases it 
remains unclear how this is to be carried out and only few explicitly consider (real life) 
exposure to mixtures. In cases where mixtures are considered, the assessment is 
frequently limited to some well-known components. Several mathematical models and 
approaches have been developed to assess the toxicity of mixtures, but their routine 
application is hampered by considerable information gaps. 
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To further investigate this question, and as international harmonisation is essential in this 
context, EURL ECVAM plays an active role in the OECD project on combined exposure (led 
by the OECD Task Force on Hazard Assessment in collaboration with the Task Force on 
Exposure Assessment) and supports the development of consistent assessment 
approaches for combined exposure to chemical mixtures at international level. 
5.6. Contributions to the OECD Adverse Outcome Pathway development 
Programme 
In 2012, the OECD launched a new programme on the development of Adverse Outcome 
Pathways30 (AOP). AOPs are structured, mechanistically-based descriptions of chemically-
induced toxicity. They portray existing knowledge concerning the linkage between two 
anchor points, the Molecular Initiating Event (MIE), and an Adverse Outcome (AO), 
connected by a chain of Key Events (KE) and the relationships between them (KER). AOPs 
are typically represented sequentially, moving from one KE to another, as compensatory 
mechanisms and feedback loops are overcome. These KEs are a limited number of 
measurable and toxicologically relevant events that are essential for the progress to the 
AO. An AOP is not required to provide a comprehensive molecular description of every 
aspect of the biology, focusing instead on the critical steps in the pathway.  
While there are a large number of cellular and molecular processes known to be critical for 
proper development and function of the different systems in the body, there are relatively 
few examples of a comprehensive understanding of how these processes are perturbed 
following a chemical exposure leading to an adverse outcome. AOPs have the potential to 
become a powerful tool to support alternative methods for chemical risk assessment which 
may be predictive of the adverse outcome in vivo without the need to actually 
demonstrate the adverse outcome.  
EURL ECVAM has undertaken the following AOPs projects relevant to neurotoxicity (see 
8.4), toxicity via disruption of the endocrine system and liver toxicity (see 2.1). For five of 
the seven projects, the AOPs have been entered into the AOP KB (see 6.9) and are currently 
undergoing an OECD external review process:  
 
1. Binding of inhibitor to the Complex I of mitochondrial ETC leads to motor deficit of 
Parkinson's disease (PD)" (in collaboration with EFSA); 
2. Inhibition of Na+/I- symporter (NIS) decreases thyroid hormone synthesis leading 
to  learning and memory deficit  in children; 
3. Binding of agonists to N-methyl-D-aspartate receptor (NMDAR) in adult brain 
causes excitotoxicity that mediates neuronal cell death, contributing to reduction (or 
loss) of cognitive function; 
                                              
30 http://www.oecd.org/chemicalsafety/testing/adverse-outcome-pathways-molecular-screening-and-
toxicogenomics.htm 
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4. Binding of antagonist to N-methyl-D-aspartate (NMDA) receptors during brain 
development (synaptogenesis) induces impairment of learning and memory 
abilities; 
5. PPARα activation leading to impaired fertility upon utero exposure in males; 
6. PPARγ activation leading to impaired fertility in adult females; and 
7. Protein Alkylation leading to Liver Fibrosis.  
A workshop held in 2014, co-sponsored and co-organised by the JRC-EURL ECVAM, 
contributed to the development of guidance on the principles and best practices for 
constructing AOPs and AOP networks (Villeneuve et al., 2014a; Villeneuve et al., 2014b).  
5.7. Data Reporting Template for Intermediate Effects: OHT201 
The basic information most current animal tests deliver is how much of a chemical 
substance has to be applied to a test animal to trigger an adverse effect like cancer, 
reproductive toxicity, other effects, or simply death. However, animal tests often fail to 
answer the fundamental question of how a chemical actually acts in the body when it 
leads to an adverse outcome? 
With an answer to this question, science will be able to develop predictive models to 
foresee the toxicity of a chemical, derived from observations in (non-animal) test systems 
that happen on molecular, cellular or organ level and long before the actual negative 
outcome manifests itself in a living organism. Once researchers can capture these 
observations in a coherent, widely accepted data format (comparable and compatible to 
the data formats already used today), the results can be used by modellers to build and 
calibrate their predictive systems, which in turn will be applied to yet untested chemicals 
without the need to go back to the laboratory. 
Such a new data format template has been developed and delivered by the JRC-EURL 
ECVAM, in collaboration with the OECD and ECHA. The template titled "OHT 201" has now 
been adopted by OECD as the new standard for reporting "Intermediate Effects", i.e. 
observations relevant in the explanation and ultimately prediction of toxicity. 
OHT 201 will have the following immediate impacts: 
 In the upcoming new version of IUCLID 6 (the ICT system used by industry to fulfil 
reporting obligations under more and more legislative programmes like e.g. REACH), 
OHT 201 will be part of the selectable reporting endpoints. A public version of 
IUCLID 6 is foreseen for early 2016. 
 The Adverse Outcome Pathway Knowledge Base (AOP-KB) module Intermediate 
Effects Database (IEDB, see 6.9.) will be implemented by the JRC-EURL ECVAM, 
using a dedicated IUCLID 6 instance that will be populated by stakeholders 
submitting filled-in OHT 201 templates (IUCLID export/import files). 
 With OHT 201 being implemented in IUCLID, the notion of Intermediate Effects (and 
implicitly AOPs and predictive toxicology) will get attention in the regulatory world. 
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This is a first step towards the ultimate goal of replacing animal-test-centred 
Adverse Outcome observations with alternative-methods-centred Adverse Outcome 
Pathway considerations as the basis for risk assessment, also in the domain of 
regulatory decision making. 
5.8. Promoting Regulatory Acceptance in the Frame of EMA: JEG3Rs 
The European Medicines Agency (EMA) decided in 2010 to establish an expert group, JEG 
3Rs31, which should provide advice and recommendations to the Committee for Medicinal 
Products for Veterinary Use (CVMP) and Committee for Medicinal Products for Human Use 
(CHMP) on all matters relating to the use of animals and the application of the 3Rs in the 
testing of medicines for regulatory purposes. Members of the JEG 3Rs are European 
experts of the CVMP and CHMP working parties for which animal testing is relevant, other 
named 3Rs experts, and representatives from EDQM and the European Commission (e.g. 
EURL ECVAM). Over the recent years, JEG 3Rs focused on the following areas: a) 
compliance check of EMA guidelines with 3Rs principles and proposals for revision; b) the 
development of guidance relating to the acceptance of 3Rs testing approaches32, c) 3Rs 
issues related to batch release testing of vaccines, and d) supporting implementation of 
Directive 2010/63/EU. 
5.9. ICH Guideline for the Photosafety Evaluation of Pharmaceuticals 
In an effort to recommend international standards for photosafety assessment, and to 
harmonise such assessments supporting human clinical trials and marketing authorisations 
for pharmaceuticals, the International Conference on Harmonisation (ICH) has adopted the 
ICH harmonised tripartite guideline S10 for photosafety evaluation of pharmaceuticals (ICH 
2013), which has entered the implementation phase at the regulatory bodies of the 
European Union (2014), Japan and USA (2015).  
According to the S10 guideline, the use of a validated in vitro method for the experimental 
evaluation of phototoxicity should be generally considered in order to reduce the use of 
animals, following the 3R principles. The S10 guideline provides recommendations for the 
experimental assessment of the phototoxic and photoallergenic potential of 
pharmaceuticals given via either the systemic routes or dermal routes and defines the 
applicability of in vitro testing and the conditions when results would trigger further 
phototoxicity testing in animals. 
Validated assays such as the 3T3 NRU-PT and the ROS assay (Onoue et al., 2013) could be 
used. The applicability of these methods has to be judged case-by-case depending on, for 
                                              
31 JEG 3Rs = The Joint Committee for Medicinal Products for Veterinary Use/Committee for Medicinal 
Products for Human Use Ad-hoc Expert Group on the Application of the 3Rs in Regulatory Testing of Medicinal 
Products 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/contacts/CVMP/people_listing_000094.jsp&mid=WC0b0
1ac05803a9d6d  
32 http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500174977.pdf 
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example, the solubility of the active pharmaceutical ingredient or any diluent or vehicle or 
the application of the relevant UVB dose. Because tissue distribution is usually not a 
concern for pharmaceuticals given via the dermal route, reconstructed human skin models 
can be used to determine the phototoxicity potential of clinical formulation. A negative 
result from a test with reconstructed human skin can serve as an indicator of low 
phototoxic potential of such clinical formulations. 
5.10. VICH Guidelines on Vaccines: VICH Guidelines on Harmonisation of 
Criteria for Waiving of Target Animal Batch Safety Testing of Vaccines for 
Veterinary Use 
The requirements on batch safety testing differ between the various geographic regions. 
For example, general safety tests for batch release of human and veterinary vaccines are 
no longer required in Europe and have been deleted from European Pharmacopoeia 
monographs several years ago (abnormal toxicity test; Schwanig et al., 1997) or recently 
(target animal batch safety test; EDQM 2012). Since these tests may still be required 
outside of Europe, European manufacturers may need to carry out these tests when 
exporting to third countries. 
Since 2008, EURL ECVAM has been working on behalf of EMA with VICH experts on the 
development of VICH GL50 "Harmonization of criteria to waive the target animal batch 
safety testing for inactivated vaccines for veterinary use" adopted in 2013 and in force 
since 1st March 2014.  
At present EURL ECVAM is working with experts from the three VICH33 regions (Europe, 
Japan, North America) on a comparable VICH guideline for live veterinary vaccines. After 
several commenting rounds, the guideline is expected to be ready for approval by the 
VICH34 Scientific Committee and public consultation. 
5.11. Promoting Regulatory Acceptance in the Context of REACH 
5.11.1. Update of REACH Annexes to Reflect Scientific Progress: Skin 
Corrosion/Irritation, Serious Eye Damage/Eye Irritation, Skin Sensitisation and Acute 
Systemic Toxicity 
In recent years, significant progress has been made in the development, validation and 
regulatory acceptance of alternative test methods for skin irritation/corrosion, serious eye 
damage/eye irritation, skin sensitisation and acute systemic toxicity. For skin corrosion and 
irritation, the regulatory accepted alternative methods now allow the generation of data 
that is adequate for classification and risk assessment for the vast majority of substances, 
so that in vivo testing is only required in exceptional cases. For serious eye damage/eye 
irritation, there is also a set of regulatory accepted alternative methods, which will in most 
                                              
33 International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary 
Medicinal Products; see http://vichsec.org  
34 http://www.vichsec.org/process/the-9-step-procedure.html 
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cases be sufficient to obtain information that is adequate for classification and risk 
assessment, either based on the results from a single test or from the combined results of 
two or more tests. For skin sensitisation, several in vitro test methods have been validated 
and some have already obtained regulatory acceptance. They are expected to be used in 
the context of IATA, and the decision on the skin sensitisation properties of the substance 
to be made based on the combined results from test methods and non-testing methods. 
These alternative methods may allow the assessment of the endpoint of skin sensitisation 
for many substances based on non-animal tests alone, without the need to resort to in vivo 
testing. 
In addition, several reviews and published data have indicated that substances 
demonstrated to be of low acute toxicity by the oral route are also of low toxicity by the 
dermal route (e.g. Creton et al., 2010; Seidle et al., 2011, Moore et al., 2013).  Building on 
this evidence, the Acute Toxicity Working Group of the EPAA has identified opportunities to 
waive animal testing requirements and, in particular, has developed recommendations to 
waive an acute dermal toxicity study for those substances which are non-toxic via the oral 
route. EURL ECVAM, by its direct participation in this EPAA acute toxicity project and data 
analysis, has contributed to drafting these recommendations which were then forwarded to 
the Commission. As a follow up, in November 2013, the Commission submitted these 
recommendations to the Competent Authorities for REACH and CLP (CARACAL) for 
consideration. After several commenting rounds, in July 2014, CARACAL agreed to amend 
REACH Annex VIII (point 8.5.3) so that substances that have not shown oral acute toxicity 
up to a limit dose of 2000 mg/kg body weight would not require dermal data35.  
At the end of May 2014, after informal discussions with DG ENV36 on the necessity to 
update the REACH Annexes, a request was made to EURL ECVAM to provide an update on 
the status of replacing in vivo testing for skin corrosion/irritation, serious eye damage/eye 
irritation and skin sensitisation with in vitro methods to help DG ENV in understanding if 
there would be any impact on the current wording in REACH Annexes and need for 
changes/amendments. Following these initial contacts, DG ENV initiated internal 
discussions on the need and feasibility to revise the Annexes and, in October 2014, a more 
in depth technical exchange was initiated with EURL ECVAM, which led to the drafting of a 
proposal to Member States to amend REACH Annexes VII and VIII concerning skin 
irritation/corrosion, serious eye damage/eye irritation and skin sensitisation. While the 
Standard Information Requirements (SIR) for skin irritation/corrosion and serious eye 
damage/eye irritation in REACH Annex VII is already based on in vitro tests, the SIR for 
these two endpoints on the Annex VIII level is an in vivo test. This requirement does not 
adequately reflect the state of science any more, as the available in vitro tests can deliver 
results that are adequate for classification and risk assessment. In accordance with Article 
13(2) of REACH, which requires the European Commission to amend the Annexes of REACH, 
                                              
35 http://www.piscltd.org.uk/wp-content/uploads/2014/09/20140714-110033_CA_61_2014-Acute-toxicity-
testing-proposal.pdf 
36 European Commission Directorate-General Environment 
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if relevant, so as to replace, reduce or refine animal testing, a proposal to amend Annexes 
VII and VIII was therefore put forward by the Commission to allow fulfilling the information 
requirement for these endpoints based on in vitro tests wherever they give information 
adequate for classification and risk assessment. In vivo testing for these endpoints should 
only be done as a last resort in cases where in vitro tests are not able to provide such 
information. For skin sensitisation, the SIR in Annex VII currently does not make any 
reference to in vitro tests, since such tests were not available at the time the Annexes were 
established. The Commission has therefore also proposed an amendment to Annex VII for 
skin sensitisation to explicitly allow the use of in vitro test methods as soon as they have 
reached regulatory acceptance at EU level. 
A proposal was presented to the Competent Authorities for REACH and CLP (CARACAL) at 
its 16th meeting on 10-11 November 2014 for discussion and comments. The CARACAL 
submitted written comments by the end of 2014, which were discussed at its 17th meeting 
on 26-27 March 2015. Following CARACAL consultation, the EC prepared a draft 
Commission Regulation where it proposes: 
− For skin irritation/corrosion and serious eye damage/eye irritation, to delete the 
standard information requirement for an in vivo study, which currently applies to 
substances manufactured or imported at or above 10 tonnes/year, and to replace it 
by a conditional requirement only applying to substances for which adequate data 
cannot be generated by in vitro testing. 
− For skin sensitisation, to introduce an explicit adaptation rule which allows waiving 
of the in vivo study (the current REACH standard information requirement for all 
substances subject to registration), if the information requirement can be fulfilled 
by using an alternative testing approach based on the Adverse Outcome Pathway 
(AOP) concept. 
− For acute systemic toxicity, to introduce an adaptation rule which allows waiving 
the in vivo study by the dermal route if the substance does not meet the criteria for 
classification as acutely toxic or STOT SE (Specific target organ toxicity – single 
exposure) by the oral route and no systemic effects have been observed in in vivo 
studies with dermal exposure or, in the absence of such in vivo studies, no systemic 
effects after dermal exposure are predicted on the basis of non-testing approaches. 
 
This draft Commission Regulation is currently undergoing Inter-Service Consultation and is 
intended to be submitted to the REACH Committee in October 2015. 
5.11.2. Update of REACH Guidance on Information Requirements and Chemical Safety 
Assessment for Skin Corrosion/Irritation, Serious Eye Damage/Eye Irritation and 
Respiratory Irritation 
Section R.7.2 (Skin- and eye irritation/corrosion and respiratory irritation) of Chapter R.7a 
(endpoint specific guidance) of the REACH Guidance on Information Requirements and 
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Chemical Safety Assessment recently underwent revision by ECHA (see 
http://echa.europa.eu/support/guidance/consultation-procedure/closed-reach). EURL ECVAM 
was invited by ECHA and nominated by DG ENV to participate in a Partner Expert Group 
(PEG) responsible for reviewing and commenting on ECHA's proposed update to this section 
of the Guidance.  
A PEG meeting was organised at ECHA in November 2014 to discuss the written feedback 
on the document provided by the PEG members and to further develop the content to 
ensure that the Guidance is acceptable to all interested parties. ECHA received a total of 
580 written comments on the document, of which 158 were provided by EURL ECVAM. Two 
hundred of the 580 comments were prioritised by ECHA for discussion during the meeting, 
of which 79 had been provided by EURL ECVAM.  
The great majority of EURL ECVAM's comments were accepted by the PEG members and 
ECHA. These aimed mostly at making sure that 1) the clarity of the document is increased 
by separating the information on skin corrosion/irritation, serious eye damage/eye irritation 
and respiratory tract corrosion/irritation into different chapters; 2) the update of the 
Guidance reflects the current status of development of the different new or revised EU 
Test Methods and/or OECD Test Guidelines for skin corrosion/irritation and serious eye 
damage/eye irritation; 3) the usability of in vitro methods as full replacement alternatives 
is permitted and encouraged where possible; 4) the information about the use of non-
testing data is further updated to be aligned with OECD Guidance Document No. 203 on an 
IATA for skin corrosion and irritation and the latest developments in the area of serious eye 
damage/eye irritation; 5) the testing and assessment strategies described in the document 
were revised to become less prescriptive in the order and extent to which the various 
relevant information sources may be considered. 
ECHA used the output of the PEG meeting as the basis for the consolidation of the 
document. The revised document was provided to the PEG in January 2015 for final proof-
reading with the possibility of submitting further comments. The consolidated draft 
document addressing the new PEG comments was subsequently submitted to the Member 
State Committee and the Risk Assessment Committee in February 2015 for consultation by 
written procedure. A final consultation with CARACAL was initiated in April 2015. The final 
updated Guidance was published by ECHA in July 201537. 
                                              
37 http://echa.europa.eu/documents/10162/13632/information_requirements_r7a_en.pdf. 
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5.11.3. Update of REACH Guidance on Information Requirements and Chemical Safety 
Assessment for Skin and Respiratory Sensitisation 
ECHA is currently revising Section R.7.3 (Skin and respiratory sensitisation) of the endpoint 
specific guidance (Chapter R.7a) of the REACH Guidance on Information Requirements and 
Chemical Safety Assessment38. 
EURL ECVAM was invited by ECHA and nominated by DG JRC to participate in a PEG 
responsible for reviewing and commenting on ECHA's proposed updates to this section of 
the Guidance. 
A PEG meeting is foreseen to take place at ECHA in October 2015 to discuss the comments 
received from the PEG members and to further consolidate the updated guidance.  
5.11.4. Collaboration with ECHA 
During 2014-2015, the collaboration between the JRC’s Institute for Health & Consumer 
Protection (IHCP) and ECHA continued on a number of fronts related to chemicals. Based 
on work carried out for ECHA under the terms of a Service Level Agreement, EURL ECVAM 
published a state-of-the art review of test methods and non-testing (computational) 
approaches that help promote the 3Rs in the safety assessment of chemicals (Worth et al., 
2014). The report reviews the current scientific status of alternatives to animal 
experiments, such as in vitro test methods and computational models, for a range of 
human health and ecotoxicological endpoints. It describes their availability and applicability 
based on knowledge of the underlying mechanisms of toxicological actions. In relation to 
human health, the following endpoints are covered: a) skin irritation and corrosion; b) 
serious eye damage and eye irritation; c) skin sensitisation; d) acute systemic toxicity; e) 
repeated dose toxicity; f) genotoxicity and mutagenicity; g) carcinogenicity; h) reproductive 
toxicity (including effects on development and fertility); i) endocrine disruption relevant to 
human health; and j) toxicokinetics. In relation to ecotoxicology, the report focuses on 
methods for acute and chronic fish toxicity. 
5.11.5. Chemical Watch and PETA International Science Consortium Webinars  
The PETA International Science Consortium, Ltd., and Chemical Watch organised a series of 
free webinars focusing on alternative methods and testing strategies that can be used to 
meet REACH requirements. The series ran from October 2014 to June 2015 and consisted 
of seven webinars, of which four included speakers from EURL ECVAM. The four scientists 
from EURL ECVAM provided stakeholders and the general public an opportunity to get 
updated information on alternative methods and testing strategies that could be used to 
meet REACH information requirements on aspects of toxicological hazard of registered 
chemicals.  
                                              
38 http://echa.europa.eu/support/guidance/consultation-procedure/ongoing-
reach;jsessionid=19E2316109FE4C3E2DE8D0C6006743A7.live2 
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The slides and records of these webinars can be downloaded from the following links: 
- http://www.piscltd.org.uk/reaching-alternatives-animal-testing/ 
- https://chemicalwatch.com/peta-webinars 
5.11.5.1. REACH Webinar on Fish Toxicity 
EURL ECVAM contributed to the webinar "(Zebra)fish Embryo Acute Toxicity Test to predict 
short term toxicity to fish (and beyond)". The webinar covered REACH data requirements for 
short term toxicity testing on fish, OECD acute fish toxicity test (OECD TG 203), the Fish 
Embryo Acute Toxicity (FET) Test (OECD 236) as a possible alternative to the acute fish 
toxicity test underpinned by the correlation between the OECD acute fish toxicity test and 
the fish embryo toxicity test, as well as potential future uses of fish embryos in a much 
wider array of environmental science and human health applications.  
5.11.5.2. REACH Webinar on Acute Systemic Toxicity 
The webinar on acute systemic toxicity focused on alternative approaches to mammalian 
acute systemic toxicity testing. During this webinar, aspects on the EURL ECVAM's strategy 
to replace, reduce and refine the use of animals in the assessment of acute mammalian 
systemic toxicity were presented and discussed. The importance of developing adverse 
outcome pathways (AOPs) and integrated approaches to testing and assessment (IATA) 
related to acute systemic toxicity was highlighted. Furthermore, improvements in the 
predictability of the 3T3 NRU assay, development of additional in vitro and in silico 
approaches, waiving acute toxicity testing based on e.g., repeated dose data, and 
refinement of in vivo studies, were discussed. This was followed by an overview of industry 
experiences in using alternative strategies to meet acute systemic toxicity testing 
requirements. 
5.11.5.3. REACH Webinar on Skin Sensitisation 
The skin sensitisation webinar focused on alternative methods and testing strategies to 
meet REACH requirements. In this webinar, the data requirements and in vivo classification 
for skin sensitisation were presented to define what is required to replace the animal test.  
An overview of the key mechanisms of skin sensitisation, based on the published adverse 
outcome pathway, and an illustration of the in chemico and in vitro methods that can be 
used to assess skin sensitisation with a specific focus on the validated methods was 
provided. Examples of how these non-animal methods can be combined in testing 
strategies/integrated approaches were given including how they perform for "real life" 
substances. Information on the ongoing OECD activity on the development of a guidance 
document for the reporting of IATA was also provided. 
5.11.5.4. REACH Webinar on Serious Eye Damage and Eye Irritation 
In the webinar on serious eye damage and eye irritation, the REACH data requirements, the 
EU CLP/UN GHS classification system, and the drivers of in vivo classification for serious 
eye damage and eye irritation were first discussed in order to define today's requirements 
to achieve full replacement of the regulatory animal test. The available in vitro methods 
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and how they can be used alone or in combination in testing strategies, such as the top-
down or bottom-up approaches, to meet REACH requirements were then described in detail. 
Information on the ongoing (i) update of the REACH Guidance on Information Requirements 
and Chemicals Safety Assessment, (ii) update of REACH Annexes VII and VIII, and (iii) 
development of an OECD Guidance Document on an IATA on serious eye damage/eye 
irritation were also provided. 
 
5.12. Activities of EPAA to Promote the Regulatory Acceptance of 
Alternative Methods 
The partnership runs a number of projects and organises or financially supports workshops 
and conferences which aim at promoting the regulatory acceptance of alternative methods 
and approaches. 
5.12.1. Waiving of Two-year Carcinogenicity Studies  
A review of carcinogenicity testing requirements in different regulatory environments 
(human and veterinary medicinal products, plant protection products and industrial 
chemicals) as the main outcome of an EPAA-supported workshop in February 2013 was 
published in 2014 (Annys et al., 2014). The report discusses the diversity of requirements 
for carcinogenicity testing across regulatory sectors, and how these studies may be refined 
to improve hazard evaluation and risk assessment while improving the implementation of 
the principles of 3Rs. 
Building on the outcome of this review, an EPAA activity was launched aiming at the 
collection of scientific evidence of 3- and 6-months (sub-)chronic studies as predictors of a 
negative outcome of carcinogenicity bioassays. The University of Wageningen collaborates 
with the Dutch Medicines Evaluation Board to compile and analyse a database on active 
pharmaceutical ingredients. The aim is to confirm and expand previous investigations by 
Sistare et al., (2011), identify opportunities for waiving the two-years carcinogenicity 
studies based on, in vitro genotoxicity testing, and the results of (sub-)chronic toxicity 
studies. A peer reviewed publication about the project and its outcome is expected for 
2016. 
5.12.2. Acute Toxicity  
In 2013, EPAA started to build a decision framework to replace animals in acute systemic 
toxicity testing and, whenever animal use cannot be avoided, replace mortality as principal 
endpoint by clinical signs predictive of mortality at higher dose levels (evident toxicity). The 
framework also envisages the use of in vitro cytotoxicity assays, grouping of chemicals, 
read-across, QSARs and data from in vivo dose range-finding studies to satisfy regulatory 
requirements for acute systemic toxicity (e.g. REACH). Currently, a data mining exercise 
focused on the oral and dermal route is underway, which aims at enabling identification of 
clinical signs predictive of mortality. The work is being carried out in collaboration with the 
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UK's National Centre for the Replacement, Refinement and Reduction of Animals in 
Research (NC3Rs) and the UK Chemicals Regulation Directorate. Furthermore, in the 
context of the REACH Regulation and the assessment of acute systemic toxicity for 
chemicals subject to the 2018 registration deadline, the project team is consulting ECHA in 
order to ensure that the outcomes of the EPAA project are relevant to the update of ECHA 
guidance on acute toxicity and classification of chemicals that the Agency is planning to 
publish in 2016. 
A summary of the activities of the project team can be found in the EPAA Activity Report of 
201439 and additional details in the presentation of Tom Holmes at the 10th EPAA Annual 
Conference40, both available from the EPAA website. 
In addition, the Acute Toxicity Working Group of the EPAA has developed recommendations 
to waive an acute dermal toxicity study for those substances which are non-toxic via the 
oral route. The recommendations were included in a proposal to amend the REACH Annex 
VIII, which is currently in the adoption process (for more details see section 5.11.1). 
 
5.12.3. Optimised Evaluation of Skin Sensitisation  
The third in a series of workshops on skin sensitisation, co-organised by EPAA, CEFIC-LRI 
and Cosmetics Europe, was hosted by ECHA in April 2015. The workshop aimed at 
facilitating exchange of information on the current status of alternatives for skin 
sensitisation testing and assessment among experts from EU member state regulatory 
agencies, industry, ECHA, OECD, EURL ECVAM and NGOs. Progress in the area has been 
made since the previous workshop held in 2013 with the adoption at OECD level of two 
Test Guidelines (TG) on non-animal testing methods (TG 442C: DPRA  and TG 442D, ARE-
Nrf2 Luciferase Test Method, KeratinoSens™) and a third draft TG on the human Cell Line 
Activation Test (h-CLAT) in the approval process. Presentations on case studies 
demonstrating how data from in silico, in chemico and in vitro methods can be integrated 
for the purpose of hazard identification and/or potency sub-categorisation set the scene 
for the workshop discussion. The feasibility of using such approaches in regulatory decision 
making including their use in a weight-of-evidence approach for fulfilling requirements 
under the 2018 REACH registration deadline was considered. The workshop participants 
debated a number of key issues including: how to balance sufficient harmonisation of such 
approaches for regulatory use whilst guaranteeing a certain level of flexibility to 
accommodate new methods and methodologies, the level of uncertainties associated with 
the final prediction that would be tolerated in hazard assessment and to what extent the 
potency of a sensitiser can be predicted by non-animal methods bearing in mind the 
limitations associated with the benchmark in vivo potency data. It was generally 
recognised that, despite these challenges, a simple stepwise approach to testing and 
                                              
39 https://circabc.europa.eu/sd/a/b71c4155-48fd-47b0-9d5a-3343c75cba6e/ar-2014.pdf 
40 http://ec.europa.eu/growth/sectors/chemicals/epaa/2014_en.htm 
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assessment involving the use of the validated methods can already be used for substances 
falling within the applicability of the test methods/approach. 
5.12.4. Harmonisation on Biologicals  
The EPAA project aims at progressing harmonisation of requirements for batch testing of 
vaccines and other biological products at a global level. Due to evident differences in the 
current regional requirements, manufacturers may need to carry out animal tests which 
are no longer required in Europe, if they want to market their products outside of Europe. 
EURL ECVAM is a member of the project team. 
In a first step, during 2013-2014, key requirements and differences in the various regions 
were mapped and possible areas for harmonisation defined. A workshop was held on 15 to 
16 September 2015 with regulatory bodies and manufacturers discussing findings and 
possible ways forward.  
5.12.5. The Vaccines Consistency Approach 
In order to facilitate the introduction of the consistency approach for the quality control of 
established human and veterinary vaccines, EPAA has initiated a project aiming at 
developing and validating non-animal methods with the support of stakeholders from 
academia, regulators, Official Medicines Control Laboratories (OMCLs), EDQM, European 
Commission and vaccine manufacturers. The project's Technical Committee agreed on four 
priority vaccines/vaccine groups (diphtheria/tetanus/acellular pertussis vaccines; human 
rabies vaccines; veterinary rabies vaccines; clostridial vaccines) and established expert 
working groups to explore ways to implement the consistency approach.   
During 2013-2014, two collaborative studies have been carried out. The clostridial 
vaccines group evaluated cell culture based methods to replace the Minimum Lethal Dose 
and Total Combining Power assays required for in-process control of Clostridium septicum 
vaccines. This study is carried out in collaboration with the EDQM BSP. The results were 
discussed at a workshop on 15-16 September 2015 and recommendations will be given on 
adaptations of the methods to other clostridial vaccines.  
The human rabies vaccines group organised a study aiming at identification of the most 
suitable ELISA for quantitation of glycoprotein-G in rabies vaccines for human use. The 
overall goal is replacement of the current in vivo test for potency testing of rabies 
vaccines. The European Commission (via EURL ECVAM) is providing funding for carrying out 
independent statistical data analysis. A workshop took place on 10-11 May 2015 to 
discuss the findings and make recommendations on further steps, e.g. a formal 
collaborative study under the umbrella of EDQM BSP or WHO.  
5.12.6. EPAA Lead Theme Workshop   
In September 2014, the European Partnership for Alternative Approaches to Animal Testing 
(EPAA) held a workshop with the title "Knowledge sharing to facilitate regulatory decision-
making". The workshop brought together representatives from industry, regulators and 
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scientists (including scientists active in policy advice) to discuss how knowledge sharing 
involving all relevant actors could improve and accelerate the development, validation, 
regulatory acceptance and use of alternative methods to animal testing. Four case studies 
outlined the procedures in place to obtain regulatory acceptance of new test methods in 
different industry sectors and highlighted potential examples of involvement of various 
actors in view of facilitating regulatory use of methods. On the background of these 
examples, the workshop focused on breakout group discussions in view of identifying 
potential issues that need to be addressed to improve the regulatory acceptance of 
alternatives to animal testing. The following topics were identified: (1) Networking and 
communication (including cross-sector collaboration, international cooperation and 
harmonization); (2) involvement of regulatory agencies from the initial stages of test 
method development; and (3) improved communication on the necessary prerequisites for 
test method acceptance including the establishment of specific criteria for regulatory 
acceptance. Finally, the workshop concluded that data sharing and intellectual property 
issues may affect many aspects of test method development, validation and regulatory 
acceptance. The workshop recommended that financial resources are made available to 
boost education and outreach activities aimed at improving the acceptance and use of 
alternatives to animal testing.  
 
5.13. Meeting of the European 3Rs Centres 
On 21 to 22 April 2015, EURL ECVAM hosted the meeting of twelve 3Rs Centres from 
across the EU, including EURL ECVAM. The participants shared information on their 
organisations, presented their activities and explained their views on how to achieve 
impact in the 3Rs. Specific areas discussed included the identification of priorities to 
reduce animal use in biomedical research (including addressing concerns related to the 
increasing use of transgenic animals); communication and dissemination of knowledge and 
information on the 3Rs; education and training at undergraduate, postgraduate and 
professional levels; validation of methods towards their use in regulatory safety 
assessment; and understanding for example how in vitro models (e.g. engineered tissue) 
can be developed and promoted as key enabling biotechnology to stimulate innovation and 
growth in a variety of sectors. Time was also dedicated to exploring how to define novel 
3Rs metrics that could serve to estimate, for example, the impact of 3Rs activities and to 
identify trends. Key provisions in the Directive 2010/63 on the protection of animals used 
for scientific purposes were reviewed including the process of project evaluation. A number 
of opportunities for closer cooperation between centres were identified. 
The 3Rs centres agreed to follow up on the priorities that they identified and to pursue 
their discussions and to meet up again. 
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6. Dissemination of Information on Alternatives41 
6.1. In vitro methods: DB-ALM—EURL ECVAM’s DataBase service on 
ALternative Methods to animal experimentation  
The access to comprehensively described methods is a prerequisite for their use within 
decision making processes by regulators and scientists or any end-user in biomedical 
sciences and toxicology. DB-ALM42 provides standardised descriptions of methods that are 
at all stages of development, validation or regulatory acceptance in the different policy 
areas and for different purposes to enhance the knowledge about and uptake of advanced 
technologies. Information at various level of detail is provided and defined according to 
pre-determined criteria for data content by experts in the field. Current focus is given to in 
vitro methods used for safety assessments of chemicals and/or formulations, but it is not 
limited to it. 
The method descriptions capture all information elements necessary to allow judgments of 
its usefulness, that cover: information on the potential of a method including its intended 
objectives and applications, the scientific principle and need for it, a summary description 
of study results obtained so far including performance and reliability evaluations as 
available and appropriate, discussions on strengths and eventual limitations completed 
with their status of development, validation or regulatory acceptance. Related information 
of studies performed and chemicals tested are provided as they become available. 
6.1.1. Status  
Public launch of the revised DB-ALM 2014: 
The year 2014 has seen the public launch of the revised database presented at the 9th 
World Congress on alternatives to animal use in life sciences and received throughout 
positive comments during online demonstrations. The DB-ALM search interfaces have 
been entirely redesigned to offer more flexibility during data retrieval based on controlled 
scientific vocabularies and/or classifications maintained at the JRC and covering key 
features of advanced and alternative methods. The first release comprised the methods 
data sector. The remaining data sectors will be subject to subsequent releases. 
Contents: 
To date the DB-ALM provides the following information: 
Information Sector Data Sheet Number 
Topic Summaries 5 
                                              
41 The EURL ECVAM databases on alternative methods originate from the Communication of the Commission 
to Council and European Parliament SEC(91)1794, further reinforced by Directive 2010/63. 
42 DB-ALM: http://ecvam-dbalm.jrc.ec.europa.eu 
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Method Summaries 163 
Protocols 152 
Evaluations, EU projects, Validation studies 86 
Test Results (individual investigations) 9231 
Persons & Institutions active in the field of 
alternative methods 
238 
Bibliographic References 7003 
During 2014, the online information content has been enhanced leading to the afore listed 
figures. Priority is placed on methods submitted for validation and on those originating 
from EU Integrated Projects with focus on methods from SEURAT-1, the largest ever 
funded research project to develop computational and in vitro tools and methods that will 
underpin new animal-free approaches to the safety assessment which are under definition 
(see 2.1). The ACuteTox project is still a priority where another eight method summaries 
and protocols are close to finalisation in collaboration with the respective experts, in 
addition to those already published. In total, the DB-ALM continues to provide information 
for 25 topic areas addressing human health and ecotoxicological effects of chemical 
substances, mechanistic information, quality control of biological products, and 
biocompatibility and safety testing of medical devices.  
The over 150 biological endpoints (biological processes, responses or effects) measured by 
the documented methods at various levels of biological organisation comprise: 
 interactions on the molecular level (including biochemistry and biokinetics); 
 basal cytotoxicity testing; 
 functional parameters of organs and tissues; and 
 model organism responses. 
6.1.2. Usage  
The year 2014 has seen a consolidation of the DB-ALM usage maintaining the high level of 
requests for new subscription reached in 2013 that in total now amounts to 4443 
registered users from 82 countries.  
The USA and Italy (approx. 10% each), Germany and France (approx. 9% each) and United 
Kingdom and Spain (approx. 7% each) are the major customers of the DB-ALM, followed by 
Belgium (approx. 5%), India (approx. 4%), the Netherlands and Brazil (approx. 3%), and 
Japan, China and Poland with approx. 2% each covering all main user profiles, such as 
academia, industry, the regulatory community and animal welfare movement. 
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More and more data retrieval procedures are now done on the revised DB-ALM 2014 
version which provides more information, such as methods abstracts, without the need of 
login. Its use is rapidly growing and the number of visits and the number of consultations 
of the Methods data sector has more than doubled during the first three months of online 
access in 2014. 
Link to DB-ALM: http://ecvam-dbalm.jrc.ec.europa.eu 
6.2. In silico Methods: QSAR Model Database 
Although thousands of QSAR models have been developed and published in the scientific 
literature, and some models have been used in regulatory assessment of chemicals in 
some countries for many years, a transparent validation process and objective 
determination of the reliability of QSAR models are crucial to further enhance their 
regulatory acceptance. 
The JRC QSAR Model Database is a freely accessible web application that enables users to 
submit, publish, and search QSAR Model Reporting Formats (QMRF) reports. Developers and 
users of QSAR models can submit to the dedicated mailbox information on QSARs by using 
the QMRF. A downloadable QMRF editor is used for this purpose. The JRC-EURL ECVAM 
then performs a quality control (i.e. adequacy and completeness of the documentation) of 
the QMRF submitted. Properly documented QMRFs are included in the JRC QSAR Model 
Database. Inclusion of the model does not imply acceptance or endorsement by the JRC or 
the European Commission, and responsibility for use of the models lies with the end-users. 
6.2.1. Status  
At the time of writing (September 2015), the JRC QSAR Model Database contains 92 
QMRFs. Three reports for the endpoint Physical Chemical Properties, 16 reports for 
Environmental fate parameters, 32 reports for ecotoxic effects, 39 reports for Human 
Health Effects and two reports for toxicokinetics. Four reports have been published in 2014 
and 18 in 2015.  
6.2.2 Usage  
Overview published reports sorted by endpoint: 
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As an indication of usage, from 1st to 12th September 2015, the JRC QSAR model 
Database had a total of 513 visitors (354 unique), averaging 46.1 per day (31.8 unique).  
Most users in descending order were from Australia, USA, Denmark, China, European Union 
(i.e., users from the EU institutions), South Korea, Netherlands, Mexico, France and India. 
The countries extracting the most data are, in descending order, USA, Australia, Denmark, 
China, European Union, India, South Korea, France, Peru and Spain.  
Link to the QSAR Model Database: http://qsardb.jrc.it 
6.3. Tracking System for Alternative Test Methods towards Regulatory 
acceptance (TSAR) 
TSAR43 serves to track progress of an alternative method, in a transparent manner, from 
proposal for validation through to its final adoption by its inclusion into the regulatory 
framework (EU, OECD and related standards). The currently developed revised TSAR version 
will also cover the needs of the individual partners of EURL ECVAM participating in the 
International Collaboration on Alternative Testing Methods (ICATM). In this way an overall 
view of the methods under evaluation by all international validation centres is provided 
from one access point. In order to be able to best cover all potential needs, more time has 
been invested on the project during 2014, creating a first beta version that is currently 
being tested at the EURL ECVAM premises before opening it to the ICATM partners for trial 
which is planned for the end of this year., After agreement, TSAR will be released to the 
general public. 
                                              
43 TSAR: http://tsar.jrc.ec.europa.eu/index.php?process=1&stage=1 
3 
16 
32 
39 
2 
0 10 20 30 40 50
1. Physical Chemical Properties
2. Environmental fate parameters
3. Ecotoxic effects
4. Human Health Effects
5. Toxicokinetics
Endpoint type 
92 QMRF (September 2015) 
No of QMRFs
70 
 
6.4. Information Retrieval Guidance: EURL ECVAM Search Guide 
The EURL ECVAM Search Guide (first published in 2012 with a re-edition in 2013) 
continues to encounter success in Europe and is also applied in America, with particular 
emphasis on South America, used as a resource for higher education in academic 
institutions and by national authorities for project evaluations. It has now entered the Asian 
market where it was translated and re-published as a handbook and E-book in Korean. 
The EURL ECVAM Search Guide44 has specifically been developed to inform and support 
untrained database users in finding high quality information on relevant alternative 
methods and strategies from the large amount of available information resources in an 
easy, yet systematic, and efficient way during project preparations. 
6.5. Improving Accessibility of Information About Chemicals: 
"ChemAgora" 
People in need of a comprehensive overview of what information is available about a 
certain chemical often struggle with the heterogeneity of that information, scattered 
across numerous locations, in different formats and stored under often conflicting 
identifiers. 
ChemAgora45, the chemical information portal launched by EURL ECVAM in 2014, 
facilitates the online retrieval of available information on a certain chemical substance. 
Chemicals can be searched by their name (or parts of it), CAS Registry number, InChIKey or 
chemical structure in a series of public repositories. Hyperlinks to the exact third party 
pages are provided, where more information about the chemical can be found. The tool 
also provides a list of synonyms the chemical is known under. Using ChemAgora, third 
party data bases can be searched by an identifier originally not available in these 
repositories. Thus, ChemAgora is not only useful for getting an overview of what is 
currently known about a substance, but also adds value to third party systems. 
Making access to information about chemical substances easier across heterogeneous 
platforms will raise the public awareness about chemical knowledge. Stakeholders in the 
chemical community can take more informed decisions when being fully aware of the 
information available about a certain substance, and people using ChemAgora will have a 
head start when it comes to finding out many details about a chemical.  
                                              
44 http://bookshop.europa.eu/en/the-eurl-ecvam-search-guide-pbLBN124391/ 
45 http://chemagora.jrc.ec.europa.eu/chemagora/  
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6.6. Data about Reference Chemicals for Validating Alternative Methods 
made accessible: "Chemical List Information System (CheLIST)" 
A key requirement for the development, characterisation and eventual validation of 
alternative (non-animal) methods for use in biomedical research and regulatory safety 
assessment is the availability of suitable reference or benchmark chemicals for which 
reliable structural, physicochemical and biological property data are available. However, the 
type of information needed to select such reference chemicals is typically scattered across 
a plethora of heterogeneous databases, project websites and peer-reviewed literature. To 
tackle this issue, EURL ECVAM has published the "Chemical Lists Information System" 
(CheLIST46) that provides a means of identifying whether a chemical (or chemical group) 
has been tested in a major EU or international research project and whether the chemical 
appears on a specific regulatory inventory. Information is provided on chemical identifiers 
(e.g. name, CAS number) and chemical structure, and the database can be searched 
according to these types of information. The various datasets and inventories can also be 
compared in order to identify overlaps in chemical membership and to generate 
customised lists. All lists can be downloaded and the references provided for each list 
allow traceability back to the source. 
Using CheLIST, alternative methods can be developed faster as information about 
reference chemicals (for method validation) is available more easily.  
6.7. EURL ECVAM Genotoxicity and Carcinogenicity Database of Ames 
Positive Chemicals  
The EURL ECVAM Genotoxicity and Carcinogenicity Consolidated database47 is a structured 
database that compiles available genotoxicity and carcinogenicity data for 726 Ames 
positive chemicals originating from different sources. By using a harmonised format to 
capture the information, this database represents a powerful resource for data analysis 
that can be used to guide a thorough evaluation of genotoxicity and carcinogenicity. 
The generation of such a consolidated database on genotoxicity and carcinogenicity has 
been demanding in terms of time and effort in order to extract relevant data spread across 
several databases and to compile them in a harmonised format. Moreover, inconsistencies 
(e.g. contradictory data derived from different sources) and poor data quality needed to be 
addressed through rigorous curation which included expert peer review. This investment 
has led to the public release of a powerful resource for developing and evaluating 
alternative approaches to animal testing for genotoxicity and carcinogenicity assessment 
of chemicals. 
                                              
46 https://chelist.jrc.ec.europa.eu  
47 https://eurl-ecvam.jrc.ec.europa.eu/databases/genotoxicity-carcinogenicity-db 
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The database may also serve as a platform for detailed structural characterization of 
specific groups of compounds with or without carcinogenic or genotoxic activity. The 
database is linked to two other JRC databases, ChEList and ChemAgora. 
The database was constructed following a recommendation of an EURL ECVAM Workshop 
on 'How can in vitro mammalian cell genotoxicity tests reduce the need for in vivo follow-
up testing with compounds positive in the Ames test?' (Kirkland et al., 2014a).   
The key question that drove the construction of the database was whether there is a 
combination of in vitro mammalian cell test results that could complement and mitigate 
the implications of a positive Ames test response for the prediction of in vivo genotoxicity 
or carcinogenicity.  The analysis of the data indicates that in the case of an Ames-positive 
chemical, negative results in two mammalian cell tests covering both mutation and 
clastogenicity/aneugenicity endpoints should be considered as indicative of absence of in 
vivo genotoxic or carcinogenic potential (Kirkland et al., 2014b). This analysis has been 
taken up in the context of genotoxicity evaluation of cosmetic substances within the 9th 
revision of SCCS's notes of guidance. 
6.8. Revision of Reference Lists of Genotoxic and Non-Genotoxic 
Chemicals 
Since their publication in 2008 (Kirkland et al., 2008) EURL ECVAM recommended lists of 
genotoxic and non-genotoxic chemicals have become the main reference lists for test 
developers in the area of genotoxicity. Either the whole lists, or parts of them, have been 
used in the evaluation of a large number of newly developed genotoxicity assays (e.g. 
Birrel et al., 2010;  Mizota et al., 2011; Berthelot-Ricou et al., 2011; Hendriks et al., 2012; 
Zwart et al., 2012; Rajakrishna et al., 2014; Ireno et al., 2014; Bryce et al., 2014). 
The lists have also been employed for the selection of chemicals used to assess whether 
modifications to existing protocols led to improvements of the assays in terms of 
performance or served to support the chemical selection of several international inter-
laboratory and validation studies of in vitro and in vivo test methods (Uno et al., 2015; 
Reus et al., 2013; Dertinger et al., 2012; Sakai et al., 2011; Greywe et al., 2012).  
The extensive use of the EURL ECVAM lists of chemicals, as well as the recurring 
recommendation to refer to them for test method design, development and 
implementation, prompted EURL ECVAM to revise and update the lists in light of new 
information (Fowler et al., 2012a, 2014; Kirkland et al., 2014a). 
This revised list of chemicals is foreseen to be published by the end of 2015. 
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6.9. Capturing Adverse Outcome Pathways in a harmonised way: 
"Adverse Outcome Knowledge Base (AOP-KB) – Wiki" 
AOPs are the central element of a toxicological knowledge framework being built to 
support chemical risk assessment based on mechanistic reasoning (see 5.6). Knowledge 
that is relevant in the AOP context is not necessarily new, but might already exist. The 
challenge is that no global effort has yet been undertaken to collect this information. To 
enable the scientific community to share, develop and discuss their AOP-related knowledge 
in one central location and using a harmonised structure, the OECD has – in parallel to the 
instigation of the overall AOP initiative – adopted a first module of its AOP Knowledge 
Base (AOP-KB48), the AOP-KB Wiki. EURL ECVAM and the US EPA jointly developed this tool 
and are also jointly reponsible for managing and executing the AOP-KB project. In 2014, 
the first module of the AOP-KB was launched: The AOP-Wiki is a system that organises, via 
crowd-sourcing, the available knowledge and published research into a verbal description 
of individual pathways, using a user friendly Wiki interface. Controlled-vocabulary drop-
down lists from which to select methods, actions, biological objects, life stages, species etc. 
related to the AOP simplify the entry of ontology-based information. 
The introduction of the AOP concept into the area of chemical risk assessment is a major 
milestone towards the goal of identifying, assessing and ultimately accepting alternatives 
to animal tests for regulatory purposes. Without the AOP-KB tool, the AOP concept would 
remain a theoretical idea without any real-life impact. By facilitating the collection and 
also discussion of AOP-related information, the AOP-KB anchors this novel concept firmly 
in the scientific and regulatory environments, which is a prerequisite for a world with less 
animal testing. 
6.10. Dissemination and Training Activities of EPAA   
In the framework of its collaboration with the Institute for In vitro Sciences (IIVS), the EPAA 
supported several initiatives led by IIVS in China to train regulators and scientists to use 
alternative methods.  
In 2014, sponsored by EPAA, IIVS scientists produced a 13-minute video 49  that 
demonstrates how to perform the Bovine Corneal Opacity and Permeability (BCOP) assay 
according to OECD Test Guideline no. 437. The video focuses on steps that are critical to 
the success of the assay such as handling of the isolated cornea and removal of the test 
material from the cornea at the conclusion of the exposure time. The complete video, with 
English subtitles, is available at no charge50. Translation of subtitles into Chinese and 
Portuguese is underway and new video versions are expected to be available by the end of 
2015.  
                                              
48 https://aopkb.org 
49 http://ec.europa.eu/growth/sectors/chemicals/epaa/index_en.htm 
50 Video on YouTube: https://www.youtube.com/watch?v=TiZbp5KDHI8 
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Other dissemination activities of EPAA comprise the participation in events to raise 
awareness of alternative approaches among policy makers and parliamentarians.  In 
February 2014, MEP Sidonia Jędrzejewska organised a breakfast meeting on the theme 
“Animal Testing – Science or Tradition: what futures to alternatives to animal testing?", to 
which EPAA was invited to give a presentation. In 2014, EPAA was also invited to give a 
briefing on its activities and structure within a session in the 3-day workshop on animal 
welfare organised by Eurogroup for Animals and supported by the Intergroup for Animal 
Welfare of the European Parliament. 
7. International Cooperation on Alternative Test Methods (ICATM) 
7.1. Background to the EURL ECVAM Activities within ICATM 
Regarding the conduct of validation studies, ICATM partners agreed to strengthen their 
collaboration on a voluntary basis and to create guidance on how validation studies should 
be conducted. This includes the establishment of validation management groups (or teams 
VMGs/VMTs) where ICATM members are invited to send experts as liaisons to follow the 
course of such validation studies. EURL ECVAM is involved in ICATM collaborations as 
liaisons in VMTs in the areas of eye irritation, skin sensitisation and reproductive and 
developmental toxicity. 
7.2. Collaboration with Japan (JaCVAM): Hand-1 LUC, Vitrigel Tests, IL-8 
LUC 
Currently, EURL ECVAM activities in VMTs as liaisons include the cooperation in four 
different validation studies led by JaCVAM i.e., the Hand1-Luc Stem cell test, the Vitrigel-
EIT, the Vitrigel-SST and the IL-8 LUC assay for skin sensitisation. 
The Hand1-Luc stem cell based test, designed to evaluate developmental toxicity of 
chemicals is undergoing a JaCVAM-coordinated validation study (LeCoz et al., 2015). 
Currently, between-laboratory reproducibility and predictive capacity of the test method 
are assessed. It is anticipated that the Hand1-Luc validation study will be completed by the 
end of 2015. 
The Vitrigel-Eye Irritancy Test (EIT) method is based on a human corneal epithelial cell line, 
grown on a scaffold of a collagen Vitrigel membrane, containing high-density collagen 
fibrils equivalent to connective tissue as a three-dimensional cell culture model 
(Yamaguchi et al., 2013). Changes in the transepithelial electrical resistance (TEER) in 
response to the exposure of a test chemical, using the barrier function of the epithelium as 
an indicator allows the estimation of its irritancy potential. In an initial study, 30 chemicals 
were tested for their correlation between the GHS classification and Vitrigel EIT. A JaCVAM-
coordinated validation study according to the conceptual framework of the "modular 
approach" was launched in 2013 and is still in the experimental phase. 
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EURL ECVAM is also liaising with JaCVAM on the validation of another Vitrigel-based assay 
(Vitrigel Skin Sensitisation Test, SST), a test method devising the THP-1-cell line using IL-8 
production in response to test chemical incubation for the discrimination between 
sensitisers and non-sensitisers. The Vitrigel SST validation study was launched in June 
2014 and while the experimental phase is still ongoing, the future of this study remains 
unclear. 
EURL ECVAM was also represented, through a nominated expert, on the VMG of the IL-8 
Luc assay for skin sensitisation hazard assessment. The test is based on the analysis of 
the effects of chemicals on the IL-8 promoter activity in THP-1 cells transfected with the 
IL-8 luciferase reporter gene. The test method was evaluated in a multi-phase validation 
study coordinated by JaCVAM. The validation exercise aimed at the characterisation of the 
test method's reliability (transferability, within and between-laboratory reproducibility) and 
predictive capacity. An independent peer review of the validation study is ongoing. The 
OECD considered the inclusion of a project proposal for the development of a test guideline 
on the IL-8 Luc assay method in its work programme in 2015. 
7.3. Collaboration with Brazil (BraCVAM): Validation of the Hen's Egg 
Test on the Chorio-Allantoic Membrane (HET-CAM) for Serious Eye 
Damage/Eye Irritation in Brazil 
The National Institute of Quality Control in Health (INCQS) and the Brazilian Center for 
Validation of Alternative Methods (BraCVAM) have initiated in 2015 the first ever validation 
study of an alternative method in Brazil in view of international regulatory acceptance. The 
study is funded by the Brazilian Ministry of Science, Technology and Innovation (MCTI) and 
it aims first and foremost at building capacity within Brazil and BraCVAM on the conduct of 
validation studies of in vitro methods for use in a regulatory context. The test method 
undergoing prospective validation by BraCVAM is the Hen's Egg Test on the Chorio-Allantoic 
Membrane (HET-CAM) and the main goal of the validation study is to independently assess 
its reliability (reproducibility within and between laboratories) and relevance (predictive 
capacity) to identify chemicals not requiring classification for serious eye damage/eye 
irritation according to UN GHS, combining the experimental results with existing HET-CAM 
data. This validation study follows the recommendations from ICCVAM (ICCVAM, 2007, 
2010) and from the participants of an international workshop on HET-CAM held at the 
Bundesinstitut für Risikobewertung (BfR) in Berlin, Germany on 29 to 30 October 2012. The 
validation and regulatory acceptance of HET-CAM for serious eye damage/eye irritation 
may help further reduce the reliance on animals for this endpoint since HET-CAM has a 
complementary mechanistic coverage of the endpoint not directly addressed by any of the 
other available in vitro alternatives. HET-CAM may thus play an important role in the IATA 
for serious eye damage/eye irritation that the JRC-EURL ECVAM and the US EPA will 
develop for the OECD during the next two years (see 5.3.3.1). 
EURL ECVAM is participating in the study as ICATM liason. A first meeting of the validation 
management group responsible for overseeing and coordinating the validation study was 
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held in Rio de Janeiro, Brazil on 21-22 May 2015, where various aspects of the validation 
study were discussed, including: (i) the study objectives and proposed regulatory use of the 
method, (ii) the study design, (iii) the chemicals selection considering the study objectives 
and the existing data gaps, and (iv) the test method protocol. 
7.4. Collaboration with ICCVAM on ARTAs 
EURL ECVAM participates in the ICCVAM Reference Chemical Working group for Androgen 
Receptor Agonists and Antagonists. This group provides expertise in creating a list of 
reference chemicals for the evaluation of alternative test methods and testing strategies 
to identify chemicals that may act as androgen receptor (AR) agonists or antagonists. 
8. EURL ECVAM strategies 
8.1. EURL ECVAM Strategy to Replace, Reduce and Refine the use of 
Animals in the Assessment of Acute Mammalian Systemic Toxicity 
The EURL ECVAM strategy to replace, reduce and refine the use of animals in the 
assessment of acute mammalian systemic toxicity51 was published in December 2014. The 
strategy underwent consultation with EURL ECVAM's advisory and stakeholder bodies and 
aims to satisfy regulatory requirements within various pieces of EU legislation. One target 
is to minimise the use of animals in the assessment of acute systemic toxicity for 
chemicals subject to the 2018 REACH registration deadline. The strategy will also provide a 
framework for prioritisation of alternative methods submitted to EURL ECVAM for 
validation. The implementation of this strategy will rely on the efforts of EURL ECVAM and 
on the collective and coordinated contribution of a wide range of stakeholders. 
In line with the objectives laid down in the strategy, EURL ECVAM has initiated in-house 
activities aimed at evaluating possibilities to use in silico simulation of metabolism in 
conjunction with the negative result obtained from the 3T3 NRU cytotoxicity assay 
(predicted oral LD50 > 2000 mg/kg b.w.). Results obtained from the metabolism simulation 
strategy used (in silico metabolite formation followed by prediction of LD50 values for 
those metabolites) that could allow the confirmation of a negative result or to flag a false 
negative outcome, are promising. In addition, information regarding the metabolism of the 
compounds has been collected from databases and the literature and has been used to 
confirm/exclude metabolism as a reason for false negative predictions and to challenge 
the outcome of the in silico simulations. 
Attempts have been made to identify frequent chemical groups in toxic compounds (i.e., 
oral LD50 ≤ 2000 mg/kg) using the in-house dataset and the Registry of Cytotoxicity. 
Some chemicals groups were identified as present only and/or mostly in toxic compounds. 
                                              
51https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-acute-mammalian-systemic-
toxicity 
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Although these are preliminary results, it is a first step towards the identification of 
families of chemicals showing acute oral toxicity. 
In addition to the lack of metabolic competence of the cell system (3T3 fibroblast), missing 
toxic effects due to cell-specific toxicity and/or cell-specific functions not captured in these 
cells, could be another reason for under-classifying acutely oral compounds as non-
classified with this in vitro cytotoxicity assay. A literature review was started aimed at 
collecting and organising acute toxic effects by their mechanisms and cell types in eight 
relevant target organs/systems. Hopefully this will help to improve our mechanistic 
understanding of acute systemic toxicity, to identify specific mechanisms of toxicity not 
covered by the 3T3 NRU assay, and to find mechanistic explanations for the identified key 
structural features. The final aim is to evaluate promising components of integrated 
approaches for testing and assessment (IATA), including the better use of alternative (in 
vitro and in silico) methods. 
8.2. EURL ECVAM Strategy to Replace, Reduce and Refine the Use of Fish 
in Aquatic Toxicity and Bioaccumulation Testing 
The assessment of aquatic toxicity and bioaccumulation are important components of the 
environmental hazard and risk assessment of all types of chemicals and are therefore 
included in several pieces of EU and international legislations. Aquatic toxicity refers to the 
effects of chemicals on organisms living in the water and is usually determined by testing 
on organisms representing the three trophic levels, i.e. plants (or algae), invertebrates 
(crustaceans) and vertebrates (fish). Information on bioaccumulation in aquatic organisms 
is important for understanding the behaviour of a compound in the environment. 
Whereas acute aquatic toxicity testing is a basic requirement in most pieces of EU 
chemicals legislation, chronic aquatic toxicity data may be required when the outcome of 
the acute testing indicates a risk or when long term exposure is expected. In addition, 
experimental determination of bioaccumulation may not be necessary if it can be deduced 
by other means (e.g. consideration of physicochemical properties) that a chemical has a 
low potential to bioaccumulate. 
In this document52, EURL ECVAM outlines a strategy based on approaches which will deliver 
an impact on the replacement, reduction and refinement (3Rs) of fish tests used in the 
assessment of aquatic toxicity and bioaccumulation. The strategy is based on an 
assessment of the regulatory needs for these endpoints, the scientific state-of-the art and 
recent activities in these areas. It also intends to provide a framework for the prioritisation 
of alternative test methods submitted to EURL ECVAM for validation. 
                                              
52 https://eurl-ecvam.jrc.ec.europa.eu/eurl-ecvam-strategy-papers/strategy-fish 
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With regard to aquatic toxicity, the strategy proposes the further development of 
mechanistically-based replacement alternatives for acute and chronic fish toxicity, as well 
as the need to revise existing test guidelines to reduce and refine fish testing. Furthermore, 
the development of guidance on the application of integrated approaches is recommended. 
This includes the use of data-driven approaches such as interspecies extrapolations, acute-
to-chronic relationships and the threshold of toxicological concern approach. 
Concerning bioaccumulation, efforts are encouraged for the development and application 
of in silico models such as quantitative structure-activity relationships and physiologically 
based toxicokinetic models, as well as the standardisation of in vitro methods for hepatic 
metabolism in fish. 
EURL ECVAM focuses its own in-house activities on promoting the use of available 
alternative methods for fish acute toxicity testing, on exploring the usefulness of scientific 
approaches to support the waiving of chronic fish tests, and on supporting activities at the 
OECD level.  
The achievement of the objectives in pursuit of the strategic aims presented in the 
strategy document will depend on the proactive and coordinated engagement of multiple 
stakeholders. 
8.3. EURL ECVAM Strategy for achieving 3Rs impact in the assessment of 
toxicokinetics and systemic toxicity 
The EURL ECVAM Strategy document on Toxicokinetics (TK) outlines objectives and 
activities needed to achieve a 3Rs impact in the area of toxicokinetics and systemic 
toxicity, with a view to developing a risk assessment approach that is increasingly based on 
human data53. The importance of physiologically-based kinetic (PBK) modelling is a central 
issue in the strategy document. In order to facilitate the generation, acceptance and use of 
PBK models in regulatory domains, four main objectives are identified. The first concerns 
the development of standards to characterise in vitro and in silico methods that measure 
individual ADME parameters. The second objective aims to establish good kinetic modelling 
practices, including a web portal for PBK modelling approaches. The third objective 
expresses the need for publicly available databases to facilitate access to anatomical and 
physiological (chemical-independent) information to create PBK models, to store in vitro 
ADME data and human in vivo toxicokinetic data. The fourth objective expresses the need 
to develop guidance on how to generate and use these data in a regulatory setting.  
                                              
53 https://ec.europa.eu/jrc/en/publication/eur-scientific-and-technical-research-reports/eurl-ecvam-strategy-
achieving-3rs-impact-assessment-toxicokinetics-and-systemic-toxicity 
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8.4. EURL ECVAM Strategy to Replace, Reduce and Refine the Use of 
Animals in the Assessment of Neurotoxicity  
The EURL ECVAM strategy is based on the assessment of the regulatory needs for 
developmental (DNT) and adult neurotoxicity (ANT) evaluation, as well as the current state 
of the science in this area, including recent ongoing efforts. Currently, only in vivo tests are 
accepted by regulatory bodies since there are no regulatory approved alternative methods 
for this purpose. Within the EU legislation of chemical safety assessment, DNT or ANT 
testing is not a standard requirement, therefore both DNT and ANT evaluation is only 
performed as higher tiered tests triggered based on structure activity relationships or 
evidence of neurotoxicity in systemic adult, developmental or reproduction studies.  
The existing OECD Test Guideline for developmental (TG 426) and adult neurotoxicity (TG 
424) are rarely used due to their complexity, low throughput, high cost and use of a large 
number of animals. Therefore, new reliable and efficient screening and assessment tools 
are needed for better identification, prioritisation, and evaluation of chemicals with 
potential to induce neurotoxicity. 
Based on an analysis of the regulatory requirements for DNT and ANT within the relevant 
pieces of EU legislation, EURL ECVAM has decided to focus efforts on development of an in 
vitro Integrated Testing Strategy (ITS) for neurotoxicity hazard identification. Taking into 
account current knowledge and requirements for a new paradigm for DNT (Bal-Price et al., 
2015a) and ANT testing the proposed ITS will be based on a combination of human cell 
models and endpoints amenable for high throughput and high content (HT/HC) methods. 
Such ITS will be based on the flexible integration of test methods that will require explicit 
specification of context and purpose of use to define confidence required for meeting 
different regulatory applications. To facilitate the interpretation of the obtained results and 
to support scientifically defined fit-for-purpose approaches, the applied in vitro assays will 
be anchored to the key events identified in the Adverse Outcome Pathways (AOPs) recently 
developed for neurotoxicity (Bal-Price et al., 2015b). The AOP concept will be used as a 
basis for ITS establishment, facilitating use of mechanistic understanding of the pathways 
leading to toxicity in regulatory decision making. 
In addition, EURL ECVAM will continue to support activities aimed at the refinement of 
relevant in vivo studies. The strategy is now under an internal EURL ECVAM's reviewing 
process. After its final acceptance, the implementation will rely on the cooperation of EURL 
ECVAM with other related initiatives and the contribution from various stakeholders.  
9. Conclusions 
During 2014 to 2015, EURL ECVAM continued to further advance the 3Rs through the 
development and validation of alternative methods for use in regulatory toxicology and 
through the evaluation, dissemination and promotion of animal-free approaches for use in 
biomedical research. EURL ECVAM worked on a variety of projects and activities from 
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research and development projects, evaluation of submitted test methods, validation of 
alternative methods, promotion of the regulatory acceptance of alternative methods, 
dissemination, database development, collaboration activities with international partners to 
the development of EURL ECVAM strategies in specific areas. 
Many R&D projects led to significant achievements (e.g., DETECTIVE) thanks to the fruitful 
collaboration between EURL ECVAM and its partners. These R&D projects cover a broad 
range of endpoints and adverse effects which are relevant for the protection of human 
health and the environment. R&D projects in which EURL ECVAM is involved, are 
investigating the most recent technologies and promising methods, such as e.g. the use of 
physiologically based toxicokinetics and stem cells technology. 
EURL ECVAM evaluated test method submissions which encompass many diverse areas 
such as fish toxicity, genotoxicity, toxicokinetics, teratogenicity, skin sensitisation, and 
topical toxicity (skin and eye irritation/corrosion). For each of these, EURL ECVAM 
consistently evaluated their relevance in terms of the 3Rs, their scientific value, notably 
considering the mechanistic aspects, performed data analysis, and assessed their possible 
regulatory uses. EURL ECVAM gave the priority to those test methods addressing 
regulatory gaps or being the most innovative from a scientific point of view. 
EURL ECVAM is involved in several validation studies in collaboration with several partners 
(e.g., with Cosmetics Europe for the genotoxicity testing) and coordinates the validation 
study on the AR-CALUX test method that uses EU-NETVAL laboratories for conducting the 
study for the first time.  
EURL ECVAM developed standards for the performance assessment of in vitro and in silico 
methods used for the toxicity testing of chemicals which will form the basis of 
internationally accepted test guidelines and guidance. This also includes the specification 
of regulatory-targeted reporting standards for describing in vitro and in silico methods and 
for recording and communicating data generated with them. 
The ESAC reviewed validation studies and issued opinions on test methods in the fields of 
skin sensitisation, eye and skin irritation and metabolic clearance. Based on these opinions 
and stakeholder input, EURL ECVAM published two new recommendations. 
At the regulatory level, EURL ECVAM developed several (test) guidelines in the frame of its 
collaboration with several organisations (OECD, ECHA, ICH and VICH). Adopted guidelines 
are ultimately translated in the relevant European regulations. EURL ECVAM also developed 
or contributed to the development of several guidance documents related to integrated 
approaches to testing and assessment (IATA) which guide risk assessors in the use of 
combined test methods and in the type of conclusions they may draw from these 
approaches. 
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EURL ECVAM has also increased its dissemination activities, especially through the 
development of new databases or the overhaul of existing ones. These databases make 
available the most recent knowledge on alternative methods to scientists and the public. 
They also serve as a common tool for EURL ECVAM's partners as they contribute to the 
consistent use of reliable data. 
EURL ECVAM furthermore increased its engagement with a variety of key actors and 
stakeholders and the 3Rs community as a whole, with the intention of sustaining the levels 
of commitment and investment on the part of all key players in the field of alternative 
approaches. 
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Annex I—Summary status of the adoption of Test Guidelines based on alternative methods in the OECD TG 
programme (2012-2015) 
Table 1 summarises the status of adoption of OECD test guidelines on alternative methods from 2012 to 2015. It should be noted that beside TGs, also 
Guidance Documents and new projects on alternative methods were respectively adopted and included on the OECD Work programme during that period. 
For additional information, please consult the OECD website of the Test Guideline Programme: 
http://www.oecd.org/env/ehs/testing/oecdguidelinesforthetestingofchemicalsandrelateddocuments.htm 
Table 1. Status of adoption of OECD Test Guidelines based on alternative methods 2012-2015 
Nr. Toxicity area Test method description Acceptance status 
1 Skin corrosion Reconstructed human Epidermis (RhE) test methods as 
included in OECD TG 431/EU TM B.40 bis 
Adopted in 2004; updated version (sub-categorisation, 
inclusion of performance standards, inclusion of SkinEthic™ 
RHE and epiCS®) adopted in 2013. Revised version including 
sub-categorisation with the epiCS® test method adopted in 
2014. 
Updated in 2015 for the deletion of the performance 
standards (published separately on the Series on Testing and 
Assessment No. 219), inclusion of paragraphs referring to the 
IATA for Skin Corrosion and Irritation (OECD GD No. 203) and 
inclusion of the use of HPLC/UPLC-spectrophotometry as an 
alternative procedure to measure tissue viability (increasing 
the applicability domain of the test methods to coloured 
substances interfering with the measurement of MTT-
formazan) 
2 Skin corrosion Transcutaneous Electrical Resistance (TER) test method 
as included in OECD TG 430/EU TM B.40 
 
Adopted in 2004; updated version (inclusion of performance 
standards) adopted in 2013 
Updated in 2015 for the deletion of the performance 
standards (published separately on the Series on Testing and 
Assessment No. 218) and the inclusion of paragraphs 
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Nr. Toxicity area Test method description Acceptance status 
referring to the IATA for Skin Corrosion and Irritation (OECD 
GD No. 203) 
3 Skin corrosion In vitro Membrane Barrier Test Method for Skin 
Corrosion as included in OECD TG 435/EU TM B.40 
 
Adopted in 2006; Updated in 2015 for the inclusion of the 
Corrositex® prediction model, the deletion of the performance 
standards (to be published separately on the Series on 
Testing and Assessment), the inclusion of paragraphs 
referring to the IATA for Skin Corrosion and Irritation and the 
updating of the list of proficiency substances (OECD GD No. 
203) 
4 Skin irritation Reconstructed human Epidermis (RhE) test methods as 
included in OECD TG 439/EU B.46 
Adopted in 2010; updated version (inclusion of LabCyte EPI-
model24 SIT) adopted in 2013 
Updated in 2015 for the deletion of the performance 
standards (published separately on the Series on Testing and 
Assessment No. 220), inclusion of paragraphs referring to the 
IATA for Skin Corrosion and Irritation (OECD GD No. 203) and 
inclusion of the use of HPLC/UPLC-spectrophotometry as an 
alternative procedure to measure tissue viability (increasing 
the applicability domain of the test methods to coloured 
substances interfering with the measurement of MTT-
formazan) 
5 Serious eye 
damage/eye 
irritation  
Fluorescein Leakage (FL) test method as included in 
OECD TG 460 
Adopted in 2012 
6 Serious eye 
damage/eye 
irritation 
Bovine Corneal Opacity and Permeability (BCOP) test 
method as included in OECD TG 437/EU TM B.47 
Adopted in 2009; updated version (revision of positive 
controls, use to identify non-classified chemicals and several 
other revisions) adopted in 2013 
7 Serious eye 
damage/eye 
Isolated Chicken Eye (ICE) test method as included in 
OECD TG 438/EU TM B.48 
Adopted in 2009, updated version (use to identify non-
classified chemicals and several other revisions) adopted in 
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irritation 2013 
8 Serious eye 
damage/eye 
irritation 
Cytosensor Microphysiometer (CM) test method New draft TG discussed at WNT in 2013 but not yet adopted, 
pending further clarification on its use to identify non-
classified chemicals 
9 Serious eye 
damage/eye 
irritation 
Short Time Exposure (STE) test method for the detection 
of chemicals causing serious eye damage and chemicals 
not requiring classification for serious eye damage or 
eye irritation, as included in OECD TG 491 
Adopted as a new TG in 2015 
10 Serious eye 
damage/eye 
irritation 
Reconstructed human Cornea-like Epithelium (RhCE) for 
the detection of chemicals not requiring classification 
and labelling for eye irritation or serious eye damage as 
included in OECD TG 492 
Adopted as a new TG in 2015 
11 Skin sensitisation In chemico skin sensitisation: Direct Peptide Reactivity 
Assay (DPRA), as included in OECD TG 442C 
Adopted as a new TG in 2015 
12 Skin sensitisation In vitro skin sensitisation: ARE-Nrf2 Luciferase test 
method (KeratinoSens™), as included in OECD TG 442D 
Adopted as a new TG in 2015 
13 Skin sensitisation In vitro Skin Sensitisation Test: Human Cell Line 
Activation Test (h-CLAT),  
2nd commenting round at OECD finalised. OECD expert group 
meeting scheduled in October 2015 to discuss final issues. 
14 Carcinogenicity In vitro Syrian Hamster Embryo (SHE) Cell 
Transformation Assay (CTA) as included in OECD GD No. 
214 
Adopted as a new GD in 2015 
15 Carcinogenicity In vitro Bhas 42 Cell Transformation Assay (CTA)  New draft GD underwent two commenting rounds. Draft GD 
will be considered for adoption in April 2016 
 
16 Genotoxicity In vitro Mammalian Chromosome Aberration Assay as 
included in OECD TG 473 
 
 
Updated OECD TG 473 (originally adopted in 1983)  
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17 Genotoxicity In vitro Mammalian Cell Micronucleus Assay as included 
in OECD TG 487  
Updated OECD TG 487 (originally adopted in 2010) adopted 
in 2014 
18 Genotoxicity In vitro Mammalian Cell Gene Mutation Test using Hprt 
and xprt genes as included in OECD TG 476  
 
 
OECD TG 476 (originally adopted in 1984) "In vitro 
Mammalian Cell Gene Mutation Test" has been split up into 
two TGs:  
1. The updated TG 476 now using the Hprt and xprt genes 
was adopted in 2015; 
2. OECD TG 490 using thymidine kinase Gene (see below) 
19 Genotoxicity In vitro Mammalian Cell Gene Mutation Tests Using the 
Thymidine Kinase Gene as included in OECD TG 490 
Adopted as TG 490 in 2015  (see above) 
20 Genotoxicity In vivo Mammalian Alkaline Comet Assay  Adopted as new TG 489 in 2014 
21 Endocrine 
disruption 
Estrogen receptor transactivation assay (BG1Luc ER TA; 
agonist and antagonist protocols) as included in OECD 
TG 457 
Adopted in 2012 
OECD TG 457 was deleted in 2015.  The method was included 
in OECD TG 455 in 2012 (agonist part) and 2015 (antagonist 
part) (see table entry below). 
22 Endocrine 
disruption 
Performance-Based Test Guideline for Stably 
Transfected Transactivation In Vitro Assays to Detect 
Estrogen Receptor Agonists  
OECD 455 adopted in 2009 (STTA assay using the hERα-
HeLa-9903 cell line); updated version (PBTG, inclusion of 
BG1Luc ER TA assay using the BG1Luc-4E2 cell line) adopted 
in 2012; Second updated version was adopted in 2015. 
The latest update includes the antagonist part of both 
methods which led to the deletion of OECD TG 457 in parallel 
as it is no longer needed (see above). 
23 Endocrine 
disruption 
Performance-Based Test Guideline for Human 
Recombinant Estrogen Receptor (hrER) In Vitro Assays to 
Detect Chemicals with ER Binding Affinity as included in 
OECD TG 493 
Adopted as new TG in 2015.. It includes two reference test 
methods: 
 In Vitro Estrogen Receptor (ER) Binding Assay Using a Full 
Length Human Recombinant ERα; 
 In Vitro Estrogen Receptor Binding Assay Using a Human 
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Recombinant Ligand Binding Domain Protein 
24 Acute  fish toxicity  Fish Embryo Acute Toxicity (FET) Test as included in 
OECD TG 236 
Adopted in 2013 
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Annex II—ICATM Alternative Test Methods Validation and Regulatory Acceptance 
Table 2. ICATM Alternative Test Methods Validation and Regulatory Acceptance 
Method Current Status Lead Action 
Organization 
International Acceptance 
Dermal Corrosivity Test Methods 
CORROSITEX Skin Corrosivity Test Completed  OECD TG 435 (2006) 
Updated version (including the 
Corrositex® prediction model, the 
deletion of the performance standards 
(to be published separately in the 
Series on Testing and Assessment), 
including paragraphs referring to the 
IATA for Skin Corrosion and Irritation in 
OECD GD No. 203 and the updating of 
the list of proficiency substances) 
adopted in 2015 
EpiSkin™, EpiDerm™, SkinEthic™, 
epiCS® Skin Corrosivity Tests 
Completed  OECD TG 431 (2004), updated 
version (sub-categorisation, inclusion of 
performance standards, inclusion of 
SkinEthic™ RHE and epiCS™) adopted in 
2013. Revised version including the 
sub-categorization with the epiCS™ test 
method adopted in 2014 
Updated version [deleting the 
performance standards (published 
separately in the Series on Testing and 
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Method Current Status Lead Action 
Organization 
International Acceptance 
Assessment No. 219), including 
paragraphs referring to the IATA for 
Skin Corrosion and Irritation in OECD 
GD No. 203 and including the use of 
HPLC/UPLC-spectrophotometry as an 
alternative procedure to measure 
tissue viability (increasing the 
applicability domain of the test 
methods to coloured substances 
interfering with the measurement of 
MTT-formazan)] adopted in 2015 
Rat TER Skin Corrosivity Test Completed  OECD TG 430 (2004), updated 
version (inclusion of performance 
standards) adopted in 2013 
Updated version (deleting the 
performance standards (published 
separately in the Series on Testing and 
Assessment No. 218) and including 
paragraphs referring to the IATA for 
Skin Corrosion and Irritation in OECD 
GD No. 203) adopted in 2015 
Dermal Irritation Test Methods 
In vitro reconstructed human 
epidermis (RhE) test methods: 
EpiDerm™, EpiSkin™, SkinEthic™ RHE 
Completed 
-  
-  
 OECD TG 439 (2010),  updated 
version (including the LabCyte™ EPI-
model) adopted in 2013 
Updated version [deleting the 
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Method Current Status Lead Action 
Organization 
International Acceptance 
and LabCyte EPI-MODEL24 SIT  performance standards (published 
separately in the Series on Testing and 
Assessment No. 220, including 
paragraphs referring to the IATA for 
Skin Corrosion and Irritation in OECD 
GD No. 203 and including the use of 
HPLC/UPLC-spectrophotometry as an 
alternative procedure to measure 
tissue viability (increasing the 
applicability domain of the test 
methods to coloured substances 
interfering with the measurement of 
MTT-formazan)] adopted in 2015 
In vitro reconstructed human epidermis 
(RhE) test methods: Korean epidermis 
model 
KoCVAM sponsored validation study is 
ongoing 
KoCVAM  
Phototoxicity Test Methods 
3T3 NRU Phototoxicity Test Completed  OECD TG 432 (2004) 
ICH S10 (2014) 
Test method battery to predict 
phototoxicity (yeast growth inhibition 
phototoxicity assay and red blood cell 
photohemolysis assay) 
Japanese Regulatory Acceptance Board 
recommended additional work be 
performed 
JaCVAM  
In vitro test method based on 
reactive oxygen species (ROS) and 
Completed  ICH S10 (2014) 
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Method Current Status Lead Action 
Organization 
International Acceptance 
photostability  
Ocular Toxicity Test Methods 
Bovine Corneal Opacity and 
Permeability (BCOP) Test Method 
Completed 
 
 OECD TG 437 (2009), updated 
version (positive control, use in a 
bottom-up approach to identify non-
classified chemicals and several other 
revisions) adopted in 2013 
Isolated Chicken Eye (ICE) Test 
Method 
Completed  OECD TG 438 (2009), updated 
version (use in a bottom-up approach 
to identify non-classified chemicals 
and several other revisions) adopted at 
WNT in 2013 
Use of Histopathology as an 
additional endpoint in Ocular Safety 
Testing 
Completed    OECD GD 160 (2011) 
Cytotoxicity test: SIRC CVS Peer review coordinated by JaCVAM is 
ongoing 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, 
KoCVAM and Health 
Canada VMT 
 
Cytotoxicity test: three-dimensional 
dermal model (MATREX) 
JaCVAM-sponsored validation study in 
the planning stage 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
 
Cytotoxicity test: Short Time Exposure 
(STE) test 
Completed  OECD TG 491 (2015) 
 
Use of anaesthetics, analgesics, and Completed  OECD updated TG 405 (2012) 
91 
 
Method Current Status Lead Action 
Organization 
International Acceptance 
humane endpoints for routine use in 
TG 405 
 
In vitro approach for categorisation of 
anti-microbial cleaning products: 
recommendations for further studies 
Completed. EPA/OPP has concluded 
from submission and review of 
alternative eye irritation tests 
conducted on antimicrobial pesticide 
products with cleaning claims (AMCPs) 
that the proposed testing approach is 
acceptable for determining the 
appropriate eye hazard classification 
and labelling for AMCPs (see 
http://www.epa.gov/pesticides/regulati
ng/eye-policy.pdf for the details of the 
scope of the policy). 
NICEATM-ICCVAM  
Cytosensor Microphysiometer® (CM) 
Test method 
The draft TG was submitted to OECD 
for comments including a set of 
Performance Standards  
EURL ECVAM; NICEATM-
ICCVAM 
New draft TG discussed at WNT in 
2013 but not yet adopted, pending 
further clarification on its use in a 
bottom-up approach 
Fluorescein Leakage (FL) test 
method 
Completed  OECD TG 460 (2012) 
Human reconstructed tissue models 
for eye irritation 
- EpiOcular™ EIT 
-  
Completed  OECD TG 492 (2015) 
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Method Current Status Lead Action 
Organization 
International Acceptance 
Vitrigel-EIT MAFF-sponsored validation study 
experimental part finalised 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, Health 
Canada and KoCVAM VMT 
liaisons 
 
Human reconstructed tissue models for 
eye irritation 
LabCyte Cornea-model 
Performance Standards-based 
validation study starts in September 
2015 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
KoCVAM liaisons 
 
Immunotoxicity (Allergic Contact Dermatitis) Test Methods 
Murine local lymph node assay 
(LLNA) for skin sensitization 
 
Completed  OECD TG 429 (2002) 
ISO (2002) 
Updated Murine local lymph node 
assay (LLNA) for skin sensitization 
(20% reduction) 
 
Completed  Update to TG 429 OECD (2010) 
 
ISO (2010) 
Reduced LLNA (rLLNA) 
 
Completed  Update to TG 429 OECD (2010) 
Nonradioactive LLNA protocol (LLNA: 
BrdU-ELISA) 
Completed  OECD TG 442B OECD (2010) 
Nonradioactive LLNA protocol, 
LLNA:DA 
Completed   OECD TG 442A OECD (2010) 
Harmonized performance standards 
for the LLNA 
Completed  Update to TG 429 OECD (2010) 
Nonradioactive LLNA protocol (LLNA: - KoCVAM validation study is on-going KoCVAM  
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Method Current Status Lead Action 
Organization 
International Acceptance 
BrdU-Flow Cytometry) 
In vitro skin sensitisation assay 
(DPRA)  
Completed 
 
 OECD TG 442C 
 
In vitro skin sensitisation assay (h-CLAT)  2nd commenting round at OECD 
finalised for h-CLAT. OECD expert 
group meeting scheduled in October 
2015 to discuss final issues.  
EURL ECVAM; JaCVAM 
and NICEATM-ICCVAM 
VMT liaison members 
 
In vitro skin sensitisation assay 
KeratinoSens™ 
Completed   OECD TG 442D 
In vitro skin sensitisation assay 
IL-8 Luc assay 
Peer review coordinated by JaCVAM is 
ongoing 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, 
KoCVAM and Health 
Canada VMT liaisons 
SPSF to develop a TG approved in 2015 
Vitrigel-SST MAFF-sponsored validation study is 
pending 
JaCVAM; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
liaisons 
 
Acute Toxicity Test Methods 
Up and Down Procedure (UDP) Completed  OECD TG 425 (2008) 
In vitro cytotoxicity test methods for 
estimating starting doses for acute 
oral systemic toxicity tests 
Completed  
-  
 OECD GD 129 (2010) 
In vitro cytotoxicity test (3T3 Neutral Red 
Uptake) for identifying substances with 
acute oral LD50 > 2000 mg/kg b.w. 
EURL ECVAM ESAC peer review 
completed, and EURL ECVAM 
Recommendation published in 2013 
EURL ECVAM and ICATM 
organisations 
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Organization 
International Acceptance 
 
Zebrafish Embryo Toxicity test 
(ZFET) 
Completed   OECD TG 236 (2013) 
Toxicokinetic test methods 
In vitro hepatic biotransformation – CYP 
induction: Hepa RG and cryopreserved 
human hepatocytes 
 EURL ECVAM; NICEATM-
ICCVAM, and JaCVAM VMT 
liaisons 
SPSF for a PBTG approved in April 
2013. Draft PBTG underwent a first 
commenting round in 2014. An OECD 
expert meeting was held in March 
2015.  
In vitro Fish Hepatic Metabolism - 
in vitro system for deriving information 
on biotransformation and improving 
reliability of bio-concentration & bio- 
accumulation factors (BCF & BAF) and 
avoiding use of fish bio-concentration 
tests 
Ring trial conducted under the auspices 
of the OECD is ongoing 
United States and 
European Commission 
(through JRC-EURL 
ECVAM) 
SPSF for a TG on in vitro Fish Hepatic 
Metabolism approved in April 2014  
Endocrine Disruptor Test Methods 
Stably transfected human estrogen 
receptor- transcriptional activation 
assay for detection of estrogenic 
agonist-activity of chemicals (STTA 
and BG1-Luc assays )  
Completed  OECD TG 455 (2009), updated 
2012 and 2015, inclusion of the 
antagonist protocols in addition to the 
agonist protocols, deletion of OECD TG 
457 in parallel as it is no longer needed 
BG1Luc® human estrogen receptor 
transcriptional activation assay: 
Completed  OECD TG 457 (2012) 
TG 457 has been deleted in parallel to 
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Method Current Status Lead Action 
Organization 
International Acceptance 
agonist and antagonist protocols TG 455 updates (see previous table 
entry) 
CertiChem MCF-7 cell proliferation assay 
for the detection of human estrogen 
receptor agonists and antagonists 
International validation study 
completed. Protocol must be revised 
for adequate transferability. 
NICEATM-ICCVAM; 
EURL ECVAM, JaCVAM 
and KoCVAM VMT liaisons 
 
Stably transfected CHO Androgen 
receptor-α transcriptional activation 
assay for detection of androgenic agonist 
and antagonist activity of chemicals (AR-
STTA) 
1st commenting round at OECD 
finalised for AR-STTA. OECD VMG-NA 
meeting scheduled in December 2015 
to discuss final issues.  
JaCVAM and VMG NA 
liaisons 
 
MELN® human estrogen receptor 
transcriptional activation assay: agonist 
and antagonist protocols 
Validation stopped   
Stably Transfected Transactivation in 
vitro Assay to detect Androgen Receptor 
Agonists and Antagonists 
Validation study ongoing  EURL ECVAM , NICEATM-
ICCVAM VMT, JaCVAM and 
KoCVAM VMT liaison 
SPSF to develop a PBTG on ARTA 
approved in April 2013 
Transactivation assay for the detection of 
compounds with (anti)androgenic 
potential using 22Rv1/MMTV cells 
Validation study ongoing Ministry of Food and Drug 
Safety (MFDS) South 
Korea, EURL ECVAM and 
JACVAM VMT liaisons 
 
Performance-Based Test Guideline 
for Human Recombinant Estrogen 
Receptor (hrER) In Vitro Assays to 
Detect Chemicals with ER Binding 
Affinity 
Completed  OECD TG 493 
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Method Current Status Lead Action 
Organization 
International Acceptance 
Genetic Toxicity Test Methods 
In vitro mammalian cell 
micronucleus test 
Completed  OECD TG 487 (2010), updated TG  
adopted in 2014 
 
In vitro mammalian cell chromosome 
aberration assay 
Completed  OECD TG 473 (1997), updated TG  
adopted in 2014 
In vivo comet assay Completed  OECD TG 489 (2014) 
In vitro comet assay Validation study for the in vitro comet 
assay stopped 
JaCVAM ; EURL ECVAM, 
NICEATM-ICCVAM VMT 
liaisons 
 
Genotoxicity assays (micronucleus and 
comet) in 3D skin models 
Validation study ongoing Cosmetics Europe  (lead); 
EURL ECVAM support 
 
Carcinogenicity Test Methods 
In vitro Bhas 42 cell transformation 
assay (CTA) 
Peer review coordinated by EURL 
ECVAM completed  
EURL ECVAM Recommendation 
published in 2013 
JaCVAM ; EURL ECVAM, 
NICEATM-ICCVAM, and 
Health Canada VMT 
liaisons 
SPSF approved in 2010. New draft 
OECD GD underwent 2 commenting 
rounds.  
In vitro Syrian hamster embryonic 
cells (SHE) cell transformation 
assays (CTAs) 
Completed  OECD GD 214 (2015) 
Reproductive Test Methods 
Hand-1 Luc assay 
 
METI-sponsored validation is ongoing JaCVAM ; EURL ECVAM, 
NICEATM-ICCVAM, and 
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Organization 
International Acceptance 
Health Canada, and 
KoCVAM VMT liaisons 
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